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Abstract 
Mitochondria are fundamental for cellular metabolism and take center stage in the 
regulation of systemic energy metabolism. They are origin and target of nutrient 
intermediates of converging metabolic pathways. Thus, it is essential to maintain 
mitochondrial homoeostasis. Cells harbor a large set of mitochondrial proteases 
involved in quality control, including the ATP-dependent Clp protease (CLPP). 
However, CLPP not only degrades misfolded or damaged proteins, CLPP is also 
involved in highly regulated proteolytic activities. Many bacterial and mammalian ClpXP 
substrates have been identified in various metabolic pathways. This study analyzes the 
role of CLPP in mammalian metabolism using whole body and tissue-specific Clpp 
knockout mouse models. 
The ubiquitous loss of CLPP under normal dietary conditions leads to a lean phenotype 
with enhanced glucose metabolism. The absence of CLPP further facilitates increased 
energy expenditure in part by WAT browning, despite decreased physical activity. 
Moreover, CLPP was shown to be involved in fatty acid oxidation by the regulation of 
its putative substrate VLCAD. In addition, CLPP has a critical role in BAT homeostasis 
and cold induced thermogenesis. The mild to moderate mitochondrial dysfunction 
caused by the loss of CLPP in various tissues, induced the expression of the mitokine 
FGF21. However, using Clpp/Fgf21 double knockout mice, it could be shown that 
FGF21 is not mediating the metabolic changes observed in CLPP deficient mice. 
The tissue-specific depletion of CLPP in liver or skeletal muscle and heart revealed a 
dispensable role for CLPP with regard to whole body metabolism, although tissue 
restricted mitochondrial dysfunction was present. Finally, ablation of CLPP was 
demonstrated to protect against HFD induced obesity and insulin resistance. 
Remarkably, HFD-feeding impaired hepatic mitochondrial translation in the absence of 
CLPP resulting in decreased complex subunits and decreased supercomplexes levels 
in an alternate mechanism as previously described for the heart. Thus, mitochondrial 
CLPP has a critical role in metabolic stress conditions in particular during cold 
exposure and high fat diet feeding. Therefore, by analyzing CLPP protease function 
and its link to metabolic stress this study may help to understand pathologies with 
deregulated Clpp expression. 
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Zusammenfassung 
Mitochondrien sind für den Zellstoffwechsel von grundlegender Bedeutung und 
nehmen eine zentrale Rolle in der Regulierung des systemischen Energiestoffwechsels 
ein. Sie sind Ursprung und Zielort von Nährstoffzwischenprodukten konvergierender 
Stoffwechselwege. Daher ist es von besonderer Bedeutung, die mitochondriale 
Homöostase aufrechtzuerhalten. Zu diesem Zweck beherbergen Zellen eine Vielzahl 
von mitochondrialen Proteasen, die an der Qualitätskontrolle beteiligt sind, 
einschließlich der ATP-abhängigen Clp-Protease (CLPP). Allerdings ist CLPP nicht nur 
an der Degradierung fehlgefalteter oder beschädigter Proteine, sondern auch an 
regulierten proteolytischen Aktivitäten beteiligt. CLPP Substrate vieler Bakterien und 
Säugetiere spielen eine Rolle in verschiedenen Stoffwechselwegen. In dieser Studie 
sollte daher die Rolle von CLPP im Stoffwechsel mit Hilfe von Ganzkörper und 
Gewebespezifischen Clpp Knockout Mausmodellen analysiert werden. 
Der ubiquitäre Verlust von CLPP unter Bedingungen einer Normaldiät führt zu einem 
schlankeren Phänotyp mit erhöhtem Glukosestoffwechsel. Weiterhin weisen CLPP-
defiziente Mäuse, trotz einer verminderten körperlichen Aktivität, einen erhöhten 
Energieverbrauch auf, was teilweise bedingt ist durch die Bräunung des weißen 
Fettgewebes. Darüber hinaus wurde gezeigt, dass CLPP eine entscheidende Rolle in 
der Homöostase des braunen Fettgewebes und der Kälte induzierten Thermogenese 
spielt und durch die Regulierung seines potentiellen Substrats VLCAD an der 
Fettsäureoxidation beteiligt ist. Die leichte bis mäßige mitochondriale Dysfunktion, die 
durch den Verlust von CLPP in verschiedenen Geweben verursacht wird, induzierte 
dabei die Expression des Mitokins FGF21. Unter Verwendung eines Clpp/Fgf21 
Doppel Knockout Mausmodells konnte jedoch gezeigt werden, dass FGF21 nicht 
ursächlich für die metabolischen Veränderungen ist, die bei CLPP-defizienten Mäusen 
beobachtet wurden. Der spezifische Verlust von CLPP in der Leber oder dem Herz- 
und Skelettmuskel zeigte eine unbedeutende Rolle für CLPP im Hinblick auf den 
Ganzkörper-Stoffwechsel, obwohl eine mitochondriale Dysfunktion in den jeweiligen 
Geweben vorhanden war. Schließlich wurde gezeigt, dass die Ablation von CLPP 
gegen eine hochkalorische Diät induzierte Fettleibigkeit und Insulinresistenz schützt. 
Bemerkenswerterweise führte die Fütterung der fettreichen Diät in Abwesenheit von 
CLPP zu einer Beeinträchtigung der mitochondrialen Translation in der Leber. 
Allerdings liegt dem ein anderer Mechanismus zugrunde, als welcher zuvor für das 
Herz beschrieben wurde. Dabei konnte eine verminderte Anzahl von Untereinheiten 
der Atmungskette und Superkomplexen beobachtet werden. Die mitochondriale CLPP 
Protease hat daher eine entscheidende Rolle in metabolischen Stresskonditionen, 
  
XV 
insbesondere bei Kälteexposition und der Fütterung mit hochkalorischer Diät. Die 
Analyse der Funktion von CLPP und deren Verknüpfung mit metabolischem Stress 
kann somit dazu beitragen, Pathologien mit deregulierter Clpp Expression besser zu 
verstehen. 
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1 Introduction 
 
1.1  Mitochondria 
Two billion years ago, when the oxygen levels in the earth’s atmosphere were 
changing, an α-proteobacterium entered an ancestral host cell to start a symbiotic 
relationship (Kurland and Andersson, 2000). This is known as the endosymbiotic 
theory, which is suggesting the origin of eukaryotic cells from prokaryotes (Margulis, 
1975). Mitochondria are thought to have evolved from these anaerobic bacterial 
endosymbionts, introducing the oxidative respiratory system into the host cell. 
 
1.1.1 Mitochondrial structure and function 
Mitochondria (Greek mitos "thread” and chondrion "granule”) are found in almost all 
eukaryotic cells with the exception of erythrocytes. They form a highly dynamic network 
within the cell undergoing constant fusion and fission and occupying about 20% of its 
volume (McBride et al., 2006). Mitochondria are compartmentalized by two membranes 
composed of phospholipid bilayers, namely the outer (OMM) and the inner 
mitochondrial membrane (IMM) that are separated by the inter membrane space (IMS). 
The inner membrane has several invaginations referred to as cristae and encloses the 
matrix. The matrix harbors the mitochondrial DNA (mtDNA) a unique feature of 
mitochondria denoting its prokaryotic origin. The mtDNA has great similarity to the 
genome of the bacterium Rickettsia prowazekii (Kurland et al., 1998). During the 
course of evolution, the majority of the ancestral bacterial genes have been lost and 
transferred to the nuclear genome, through a process known as endosymbiotic gene 
transfer (Timmis et al., 2004). Mammalian mitochondria therefore maintain a genome 
encoding only for 13 core proteins of the respiratory chain complexes, 2 rRNA and 22 
tRNAs (Chan, 2006; Wallace, 2005). Mitochondria harbor their own replication 
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machinery for the propagation of the mtDNA, as well as separate systems for the 
transcription and translation of the mitochondrial proteins. The vast majority of the 
mitochondrial proteome, roughly 1500 proteins, is encoded in the nucleus and needs to 
be imported into the mitochondria. 
The hallmark ability of mitochondria is the generation of cellular energy, adenosine 
triphosphate (ATP), through the process of oxidative phosphorylation (OXPHOS) (see 
section 1.3.2.3). Moreover, mitochondria are involved in diverse other cellular 
processes, such as iron-sulfur (Fe-S) cluster biogenesis, lipid biosynthesis, Calcium 
homeostasis, apoptosis and generation of reactive oxygen species (ROS) (Chan, 
2006; Lill and Mühlenhoff, 2005; Nunnari and Suomalainen, 2012; Wallace, 2005). 
 
1.1.2 Mitochondrial genetics 
Mitochondria contain their own genome (mtDNA), which is a closed circular, double-
stranded DNA of approx. 16.6 kb in size. Despite the rather small genome size 
compared to the nuclear genome, point mutations or depletion of mtDNA can lead to 
severe pathologies. Mitochondrial DNA comprises a total of 37 genes of which 13 are 
encoding core subunits of the mitochondrial respiratory complexes I, III, IV and V. 
Additionally, mtDNA encompasses genes for 2 ribosomal RNAs (rRNA) and 22 transfer 
RNA (tRNA) that are essential for mitochondrial translation. Only a small portion of the 
mtDNA (about 1100 bp) comprises a non-coding control region encompassing the 
heavy and light strand promoter (HSP, LSP) for transcription and the origin of 
replication of the heavy strand (OH), whereas the origin of replication for the light strand 
(OL) is located in a distant position (Figure 1.1) (Wallace, 2007). 
Transcription of polycistronic transcripts is initiated from the two promoters and they 
are further processed into mature mRNAs, tRNAs and rRNAs. Those transcripts also 
function as primer for mtDNA replication, which is accomplished by “strand 
displacement” (Holt and Reyes, 2012). 
Unlike the nuclear genome, mitochondria contain between 2-10 copies of mtDNA as 
result of relaxed replication.  Although mammalian mitochondria harbor a DNA repair 
system, mutations of mtDNA still occur and can lead to a heterogeneous population of 
mtDNA sequences (Boesch et al., 2009). This condition is termed heteroplasmy, 
whereas the presence of identical mtDNA copies in a cell is described as homoplasmy 
(Larsson, 2010). 
The mtDNA underlies a non-Mendelian inheritance pattern. It is maternally transmitted, 
while the paternal mtDNA is degraded after fertilization and is not passed to the 
offspring (Al Rawi et al., 2011). This implies that also mtDNA molecules carrying 
mutations are transmitted maternally. When the load of mutated mtDNA molecules 
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exceeds a certain threshold in the cell, this can lead to mitochondrial dysfunction 
(Wong, 2007). The threshold effect is different for each mutation and tissue, and 
determines the manifestation and the outcome of a mitochondrial disease. This is also 
important during cell division, since mitochondria are randomly distributed to the 
daughter cells (Stewart and Chinnery, 2015). 
Mitochondrial DNA mutations commonly affect the OXPHOS system, leading to diverse 
and multifactorial mitochondrial pathologies (Wallace, 2013). 
 
  
 
1.2 Mitochondrial quality control 
The maintenance and surveillance of the mitochondrial proteome is crucial for 
mitochondrial function and cellular homeostasis. The dual origin of the mitochondrial 
proteins represents a particular challenge. Most mitochondrial proteins are encoded in 
the nucleus and have to be translocated across one or two membranes, sorted into 
one of the four compartments and properly folded (Neupert and Herrmann, 2007). In 
addition, the mitochondrial-encoded proteins are synthesized in the matrix and are 
subsequently assembled into respiratory chain complex. The timed coordination of the 
two genomes and the arrangement of all proteins and complexes into the respective 
Figure 1.1 Mitochondrial DNA. 
The mitochondrial DNA (mtDNA) encodes 37 genes, including 7 subunits of Complex I (red), 1 subunit of 
Complex III (orange), 3 subunits of Complex IV (purple), 2 subunits of FOF1-ATP synthase (yellow),  
2 ribosomal RNAs (rRNA, green) and 22 transfer RNAs (tRNA, blue) (Schon et al., 2012). 
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compartments requires a stringent quality control system. Additionally, mitochondrial 
protein homeostasis can be perturbed during different stress conditions like nutrient 
starvation or excess, oxidative stress or age dependent pathologies. A hierarchical 
system of quality control mechanisms allows the surveillance of mitochondrial 
proteostasis and the selective removal of proteins or entire organelles (Rugarli and 
Langer, 2012). 
During the import of nuclear-encoded proteins, the mitochondrial targeting sequence is 
cleaved by the mitochondrial processing peptidase (MPP). The translocation and 
folding of the newly imported proteins is facilitated by the molecular chaperone 
mtHSP70. In addition, mtHSP70 prevents the aggregation of misfolded proteins to 
allow proteolysis (Liu et al., 2001; Wagner et al., 1994). Another matrix chaperone, 
HSP60, is also involved in folding activity of unfolded proteins after import and is 
further needed during mitochondrial stress conditions (Bender et al., 2011; Ostermann 
et al., 1989). The proteolytic removal of proteins is required for terminally damaged, 
misfolded and non-assembled proteins to prevent proteotoxic stress. There are four 
different ATP-dependent proteases performing quality control surveillance within the 
mitochondria. The metalloproteases i-AAA and m-AAA are localized in the IMM with 
their catalytic site oriented towards the IMS or the matrix, respectively and they 
execute quality control for the mitochondrial respiratory system (Gerdes et al., 2012). 
The mitochondrial matrix harbors two proteases LONP1 and ClpXP. Whereas LONP1 
is important for the degradation of oxidized proteins, besides other cellular functions 
(Ngo and Davies, 2007), the function of ClpXP is less clear and implicated in the 
degradation of misfolded proteins (Zhao et al., 2002).  At the organelle level, sustained 
stress may lead to mitochondrial hyperfusion or fragmentation, depending on the 
degree of mitochondrial dysfunction (Rugarli and Langer, 2012). Hyperfusion allows 
mitochondria to exchange genetic material and increase ATP production to alleviate 
stress. Mitochondrial fragmentation facilitates the segregation of damaged 
mitochondria and their subsequent degradation through mitophagy (Kusminski et al., 
2014). The failure of this quality control system results in dysfunctional mitochondria 
and ultimately in cell death, which might trigger pathological processes. 
 
1.3 ClpXP protease 
1.3.1 ClpXP- structure and function  
ClpXP is a AAA+ protease (ATPases associated with various cellular activities) that 
utilizes energy of ATP binding and hydrolysis to catalyze the unfolding and degradation 
of proteins and thereby regulate many mitochondrial processes. The ClpXP complex 
consists of two distinct proteins, the AAA+ ATPase CLPX and the peptidase CLPP and 
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is localized within the mitochondrial matrix. Both proteins are highly conserved and are 
found in almost all bacteria, chloroplast and mitochondria of eukaryotic cells, yet 
S.cerevisiae and S.pombe are lacking a ClpXP homolog (Yu and Houry, 2007). 
Most of what is known today about ClpXP structure, substrates and functions was 
revealed from prokaryotic studies, especially E.coli and much less is known about the 
mammalian protease. The crystal structure of ClpXP has been solved in different 
organisms including humans (Glynn et al., 2009; Kang et al., 2004; Wang et al., 1997). 
Bacterial CLPP consist of two homoheptameric rings that are stacked to form a 
spherical degradation chamber with an axial channel. Human CLPP was shown to 
exists as a single heptameric ring and only upon binding CLPX the double ring is 
formed (Kang et al., 2005). Each CLPP subunit harbors a serine-histidine-aspartate 
catalytic triad, a hallmark of serine proteases. The 14 proteolytic active sites are facing 
the inside of the chamber. This allows to control the proteolytic activity of CLPP, since 
the opening of the channel is restricting the access of native proteins resulting in a low 
peptidase activity of CLPP, being able to degrade peptides less than 15 amino acids 
long (Thompson et al., 1994). To obtain proteolytic activity CLPP assembles on one or 
both ends with a hexameric ring of CLPX to form a holoenzyme complex (Kang et al., 
2005). In bacteria, in addition to CLPX, the ATPases CLPA and CLPC associate with 
CLPP (Sauer and Baker, 2011). The CLPX chaperone functions in substrate 
recognition, ATP-dependent protein unfolding and translocation of the substrate into 
the proteolytic chamber of CLPP (Baker and Sauer, 2012). The targeting of substrates 
for degradation and the recognition by CLPX is mediated by recognition motifs called 
degrons at the N- or C-terminus of the target protein (Flynn et al., 2003). Upon binding 
of such a peptide sequence to the axial opening, CLPX is denaturing and translocating 
the native protein into CLPP in a process requiring numerous cycles of ATP hydrolysis 
to catalyze the conformational change of CLPX to excerpt the mechanical pulling 
(Ortega et al., 2000). The actual function of CLPP is to cleave the translocated protein, 
typically resulting in peptides of 3-7 amino acids in length (Choi and Licht, 2005) that 
exit the chamber and are further degraded by exopeptidases (Figure 1.2). 
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1.3.2 Physiological functions of ClpXP 
Protein degradation by ClpXP is a vital process contributing to protein quality control by 
limiting misfolded or damaged proteins, however, ClpXP is also involved in highly 
regulated proteolytic activities thereby sustaining cellular homeostasis. The selective 
degradation of substrates based on substrate recognition represents an important 
mechanism of proteolytic regulation. 
In E.coli several recognition motifs have been identified. In general these peptide 
sequences contain 3-10 amino acids and are located at the N- or C-terminal end of the 
target protein (Flynn et al., 2003; Gottesman et al., 1998). The best-studied recognition 
motif in E.coli is the ssrA tag. When ribosomes stall during protein synthesis, the  
11 amino acid residue is cotranslationally added to the nascent polypeptides by the 
tmRNA system (Keiler et al., 1996). This allows termination of translation and the 
recycling of the ribosome machinery. The ssrA tagged peptide is then degraded by 
ClpXP. Mutagenesis experiments have shown that the last three residues (Leu-Ala-
Ala) are sufficient for CLPX recognition (Flynn et al., 2001), while the other residues 
are bound by the SspB adaptor protein to enhance ClpXP mediated degradation (Flynn 
et al., 2004). So far the recognition motifs of the mammalian CLPX are unknown. 
ClpXP is not only involved in the quality of de novo protein synthesis but also in the 
regulation of specific stress responses of in E.coli. The DNA repair protein RecN 
genetically encodes a ClpXP recognition motif (Leu-Ala-Ala), which constantly targets it 
for degradation by ClpXP. Upon DNA damage RecN is highly induced as part of the 
SOS regulon and accumulates within the cell irrespective of the ClpXP degradation 
(Neher et al., 2006). As soon as the stress condition is solved the transcription slows 
Figure 1.2 Schematic presentation of the ClpXP degradation cycle. 
The CLPX hexamer recognizes the substrate upon binding of the recognition tag to axial pore. The protein 
substrate is then unfolded and translocated into the CLPP chamber for proteolysis (Baker and Sauer, 
2012). 
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down and RecN is efficiently degraded by ClpXP. Similarly, the general stress 
response regulatory protein σS is regulated by ClpXP degradation together with the 
adapter protein RssB (Hengge, 2009; Zhou et al., 2001). During exponential growth 
RssB binds to σS and targets it for degradation, however, in the stationary phase or 
other stress conditions the σS is stabilized due to decreased binding of RssB (Becker et 
al., 2000). Furthermore, CLPP was demonstrated to be important for the stress 
tolerance of many prokaryotes, including Staphylococcus aureus, Streptococcus 
mutants and Haemophilus parasuis (Frees et al., 2003; Hou et al., 2014; Huang et al., 
2016). CLPP also plays an important role in the virulence of the mammalian pathogens 
Salmonella typhimurium and Listeria monocytogenes (Gaillot et al., 2000; Yamamoto 
et al., 2001). Different than in bacteria, in the fungus Podospora anserine ablation of 
CLPP leads to an increase in lifespan and this it is not accompanied by decreased 
health, which is commonly observed for life expanding interventions (Fischer et al., 
2013). 
Moreover, ClpXP dependent degradation of CtrA is required for the cell cycle 
progression in Caulobacter crescentus (Brown et al., 2009). In HEK293 cells, ClpXP 
was suggested to be involved in the regulation of mitophagy through the degradation of 
PINK1 together with MPP, m-AAA protease and LONP1 (Greene et al., 2012). 
In C.elegans, CLPP-1 was implicated in the retrograde signaling of the mitochondrial 
unfolded protein response (UPRmt) (Haynes et al., 2007). In response to an increased 
accumulation of unfolded or unassembled proteins or a mitonuclear imbalance that is 
exceeding the folding capacity of chaperones, the nuclear expression of mitochondrial 
chaperones and proteases is induced (Houtkooper et al., 2013). CLPP-1 has been 
proposed to degrade unfolded proteins to small peptides, which are exported by the 
ABC transporter HAF (Haynes et al., 2010). The efflux of those peptides might serve 
as an initial signal for the activation and nuclear translocation of the bZIP transcription 
factor ATFS-1, which activates expression of hsp-60 and hsp-6 (HSP60 and mtHSP70) 
(Nargund et al., 2012). In mammals far less is known about the signaling of the UPRmt. 
In response to unfolded mitochondrial protein stress, the transcription factor CHOP 
(C/EBP homology protein), the chaperones HSP60 and mtDNAJ, as well as CLPP as a 
protease were shown to be specifically induced in mammalian cells (Zhao et al., 2002). 
However, unlike in C.elegans, in mammals the induction of those UPR responsive 
genes is not dependent on CLPP (Seiferling et al., 2016), suggesting a different 
signaling mechanism or the involvement of another protease for the UPRmt in 
mammals. 
Recently, a novel role for ClpXP in the regulation of mitochondrial translation through 
the degradation of ERAL1 has been proposed (Szczepanowska et al., 2016). ERAL1 
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binds to the small ribosomal subunit and acts as a chaperone for the mitochondrial 12S 
rRNA during ribosome assembly (Dennerlein et al., 2010). In the absence of CLPP, 
ERAL1 cannot be degraded and is not removed from the small ribosomal subunit, 
which leads to an impaired mitoribosomal assembly and in turn impairs mitochondrial 
translation (Szczepanowska et al., 2016). 
In humans, recessive mutations in CLPP were found to cause Perrault Syndrome, 
which is characterized by premature ovarian failure, sensorineural hearing loss and 
growth retardation besides some other symptoms described for the patients with Clpp 
mutations (Jenkinson et al., 2013; Mytinger et al., 2016). The mouse model lacking 
Clpp expression represents a faithful model of the disease with similar pathologies 
(Gispert et al., 2013). 
Although ClpXP has been extensively characterized in prokaryotes, including a 
comprehensive description of ClpXP substrates, the role of mammalian ClpXP is far 
less understood. A recent study identified 48 potential CLPP interaction proteins using 
a proximity based labeling technique in human cells (Cole et al., 2015). Most of these 
proteins were subunits of the mitochondrial respiratory chain and enzymes involved in 
mitochondrial metabolism. Intriguingly, another study reported overlapping candidates 
of ClpXP interaction partners and substrates in mouse heart, using a more 
sophisticated method to distinguish interactors from near neighbors and to additionally 
identify putative substrates (Szczepanowska et al., 2016). Hence, ClpXP seems to be 
involved in the regulation of mitochondrial metabolism and thereby also cellular and 
whole body metabolism. 
 
1.4 Metabolism 
Metabolism is the entity of all essential biochemical reactions taking place in a cell of 
living organisms. These reactions are organized into metabolic pathways, which begin 
with a particular molecule that is altered and converted into another molecule or 
molecules in a series of defined steps. Metabolic pathways can be divided into 
catabolic and anabolic processes. Catabolic pathways produce chemical energy 
through the degradation of organic molecules, whereas anabolic pathways require 
energy for biosynthetic reactions. Depending on the energy condition within the cell, 
some pathways can be either anabolic or catabolic (Berg et al., 2002). The generation 
of energy is essential for all types of cells. However, the metabolic requirement of each 
cell type is determined by the tissue function (see section 1.4.2.1) and environmental 
factors, like the type and availability of nutrients. 
Due to the interconnection and interdependence of all metabolic pathways, their 
activity requires a fine coordination and tight regulation to ensure metabolic 
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homeostasis in a dynamically changing environment. The metabolic regulation is taking 
place at different levels (Metallo and Vander Heiden, 2013). The communication 
between tissues is mediated through hormone signaling and other extracellular factors 
(see section 1.4.2.2). At the cellular level, the abundance of enzymes or regulatory 
factors is regulated tissue- or context-specifically by mRNA transcription, splicing, 
stability or translation (Cairns et al., 2011). Transcriptional regulation for example 
involves transcription factors such as PPARα or PPARγ or transcription coregulators 
like PGC1α. The nuclear receptor peroxisome proliferator-activated receptors (PPARs) 
are activated by ligand binding and control the expression of gene networks involved in 
lipid metabolism, adipogenesis and inflammation (Ahmadian et al., 2013). Additionally, 
these transcription factors are modulated by the peroxisome-proliferator-activated 
receptor coactivator 1α (PGC1α), the master regulator of mitochondrial biogenesis. 
Another means to regulate enzyme activities and functions are posttranslational 
modifications through the covalent addition of a chemical moiety, such as acetate or 
phosphate to amino acid residues, proteolytic cleavage or degradation of the whole 
protein (Zhao et al., 2010). Enzyme activities can be further modulated by allosteric 
effects in the presence of small molecules, which alter the conformation of an enzyme 
either increasing or decreasing the affinity for its substrate (Phillips and Ainsworth, 
1977). Finally, feedback regulation is a mechanism known to modulate the flux through 
the pathway. When a metabolite reaches a certain concentration, the upstream 
enzyme activity is regulated. 
These mechanisms controlling enzyme activities and therefore metabolic flux can act 
separately or in conjunction. An important example for the interplay of two regulatory 
processes is the control of AMP-activated kinase (AMPK) activity. AMPK functions as 
an energy sensor and master regulator of metabolism (Yuan et al., 2013). Cellular 
energy levels are sensed by AMPK through the direct binding of AMP or ADP 
(allosteric regulation), which leads to a conformational change of AMPK. This 
conformational change allows AMPK to be phosphorylated by upstream kinases 
leading to its activation. In turn AMPK coordinates diverse metabolic responses 
through the phosphorylation of its downstream targets to increase catabolic pathways 
for the rapid modulation of ATP production and consumption.  
All these processes aim to regulate metabolic flux according to the requirements of the 
individual cells. 
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1.4.1 Cellular metabolism 
Metabolic pathways in the cell are compartmentalized to the cytosol, nucleus, 
mitochondria, peroxisomes, endoplasmatic reticulum and lysosomes. Here, we focus 
on the main metabolic reactions allocated to the cytosol and the mitochondria. 
 
1.4.1.1 Cytosolic metabolism 
Cytosol is the liquid component of the cytoplasm surrounding the nucleus and the 
cytoplasmic organelles. The biochemical reactions taking place in the cytosol are 
glycolysis, pentose phosphate pathway, fatty acid synthesis, amino acid metabolism 
and glycogen synthesis. The nutrient derived carbohydrates, lipids and proteins are 
taken up by the cell in the form of glucose, fatty acids and amino acids, which is 
facilitated by specialized membrane proteins. Glucose enters the cell through glucose 
transporters (GLUT1-4) and fatty acid uptake is mediated by fatty acid transporters, like 
the fatty acid translocase (FAT/CD36), tissue-specific fatty acid transport proteins 
(FATP) and plasma membrane fatty acid binding protein (FABPpm) (Fillmore et al., 
2014). 
 
Glycolysis 
Glycolysis (Greek glykos „sweet“ and lysis “degradation”) is an ancient catabolic 
pathway derived from times when there was less oxygen in the atmosphere. It is 
conserved in almost all aerobe and anaerobe living organisms (Fothergill-Gilmore, 
1986). In a series of 9 enzymatic steps one molecule of glucose is converted to two 
molecules of pyruvate. The glycolytic pathway can be divided into three stages. In the 
initial three reactions, glucose is converted to fructose-1-6-biphosphate, requiring two 
molecules of ATP. This first stage facilitates the trapping of glucose within the cell and 
its destabilization for the following reactions. The second stage is the cleavage of the 
six-carbon molecule fructose-1-6-biphosphate into two three-carbon molecules 
glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. In the last stage ATP is 
harvested when the two three-carbon molecules are oxidized to pyruvate. This reaction 
sequence yields two molecules of ATP and two molecules of NADH (reduced 
nicotinamide adenine dinucleotide) (Hue and Hers, 1983). NADH is transported into 
mitochondria through the malate-aspartate and glycerol-3-phosphate shuttles for 
subsequent oxidation reactions (Stein and Imai, 2012). The fate of pyruvate depends 
on the cellular conditions. In the absence of oxygen, pyruvate can be reduced to 
lactate by the lactate dehydrogenase, while regenerating NAD+ (oxidized NAD) 
required for upstream reactions of glycolysis, which is important in skeletal muscle 
when the energy demands exceed the oxygen supply or in erythrocytes due to the lack 
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of mitochondria. Although this reaction is energetically unfavorable as compared to the 
entire oxidation of glucose via glycolysis, the tricarboxylic acid cycle (TCA) and 
oxidative phosphorylation, which is strictly dependent on the availability of oxygen. 
Increased blood lactate concentrations can be also evident for mitochondrial 
dysfunction due to an increased reliance on glycolysis and reduced oxidation of 
pyruvate within the mitochondria. 
Glycolysis is regulated at three distinct steps, through feedback inhibition of the 
hexokinase catalyzing the initial step of glucose to glucose-6-phosphate conversion 
and the allosteric regulation of phosphofructokinase and pyruvate kinase by AMP, 
ADP, ATP or citrate depending on the energy state of the cell. 
 
Gluconeogenesis 
Gluconeogenesis is an anabolic pathway generating glucose from non-carbohydrate 
precursors. During prolonged fasting and starvation conditions gluconeogenesis is 
required to prevent hypoglycemia. The major precursors are pyruvate, lactate, 
gluconeogenic amino acids and glycerol. They are either first converted to pyruvate or 
enter the pathway through later intermediates. Gluconeogenesis is often considered 
the reverse reaction of glycolysis, however, the irreversible reactions of glycolysis have 
to be bypassed during gluconeogenesis by four different enzymes. The first reaction of 
gluconeogenesis is located in the mitochondria and requires a distinct enzyme 
pyruvate carboxylase (PC), the second reaction can be carried out within mitochondria 
or the cytosol by phosphoenolpyruvate carboxykinase (PEPCK) for the conversion of 
pyruvate in the cytosol and in the ER. The other distinctive enzymes required for 
gluconeogenesis are fructose 1,6-biphosphatase and glucose 6-phosphatase, which 
catalyze the hydrolysis reactions (Jitrapakdee, 2012). Gluconeogenesis is reciprocally 
regulated with glycolysis, therefore the same key steps are regulated (Berg et al., 
2002). 
 
Glycogen metabolism 
Glycogen is a multi-branched polymer of glucose and functions as storage form of 
glucose within tissues, especially in liver and skeletal muscle. However, glycogen 
serves different functions in both tissues. Hepatic glycogen is required to maintain 
blood glucose levels during fasting conditions, whereas muscle glycogen is expended 
only for muscular activity as during intense exercise. The synthesis of glycogen 
(glycogenesis) requires a primer consisting of a glycogenin protein attached to α-1,4 
linked glucose oligosaccharide. This primer is used by the glycogen synthase for the 
elongation with UDP-glucose molecules, an activated form of glucose generated from 
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glucose-1-phosphate. Additionally, a branching enzyme is required for the formation of 
α-1,6 linked glucose branches to obtain the polysaccharide glycogen. 
The degradation of glycogen (glycogenolysis) is controlled by the glycogen 
phosphorylase. Together with a bifunctional debranching enzyme, the phosphorylase 
mediates the shortening of the oligosaccharide chains to release glucose-1-phosphate. 
The synthesis and degradation of glycogen are reciprocally regulated through the 
activity of glycogen synthase and phosphorylase. Hormone stimulated cyclic AMP 
(cAMP) cascade acting through protein kinase A is facilitating the switch between the 
active and inactive forms of glycogen synthase and phosphorylase (Bollen et al., 
1998). 
 
Fatty acid synthesis 
In a high-energy state, when glycogen stores are already filled, a surplus of glucose 
results in the synthesis of fatty acids and the formation of triglycerides. Fatty acids are 
synthesized from acetyl-CoA, which is exported from the mitochondria as citrate and 
reconverted to acetyl-CoA in the cytosol. Acetyl-CoA is carboxylated by the acetyl-CoA 
carboxylase (ACC) to malonyl CoA. This reaction is the rate-limiting step during fatty 
acid synthesis and is highly regulated at the level of ACC (Hillgartner et al., 1995; Kim, 
1997). The subsequent reaction steps of the de novo lipogenesis are catalyzed by the 
multifunctional enzyme fatty acid synthase (FAS) (Wakil, 1989). Malonyl CoA functions 
as a two-carbon donor for the elongation of acetyl-CoA. This step is repeated six times 
in a cyclic manner resulting in C16.0 palmitic acid. During the reaction nicotinamide 
adenine dinucleotide phosphate (NADPH), derived from the pentose phosphate 
pathway, functions as a reducing agent. The palmitic acid produced by the FAS can be 
further modulated by elongation or desaturation. In order to be stored in the liver or 
adipose tissue, three fatty acids are esterified with glycerol-3-phosphate resulting in the 
formation of triacylglycerol. 
As mentioned earlier fatty acid synthesis and in parallel also fatty acid β-oxidation is 
regulated by ACC activity. Malonyl CoA generated by ACC, acts as an inhibitor of 
CPT1 and is thus controlling fatty acid uptake into mitochondria for β-oxidation. The 
activity of ACC is modulated by phosphorylation, dephosphorylation and also 
allosterically activated by citrate (Brownsey et al., 2006).  The upstream kinase AMPK 
is mediating the inhibiting phosphorylation of ACC in low energy conditions. Hence, 
AMPK and ACC are stringently regulating fatty acid metabolism according to 
physiological needs. 
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1.4.1.2 Mitochondrial metabolism 
Fatty acid β-oxidation 
During fatty acid β-oxidation (FAO) fatty acids originating from the diet or the hydrolysis 
of triglycerides during fasting conditions are degraded to generate energy in the form of 
ATP. Most of the dietary fats are composed of long chain fatty acids, in particular 
palmitic acid (C16:0) (Rustan, 2009). Long chain fatty acids in the cytosol are 
converted and thereby activated in a two-step process with an acyl adenylate 
intermediate to acyl-CoA by acyl-CoA synthases (ACS) (Grevengoed et al., 2014). 
Long chain acyl-CoAs are unable to diffuse through the IMM and are esterified to 
acylcarnitines by the carnitine palmitoyltransferase 1 (CPT1). This permits the transport 
of the acylcarnitines across the IMM by the carnitine acylcarnitine translocase (CACT) 
in exchange for carnitine. Once inside the mitochondria, CPT2 reconverts the 
acylcarnitines to acyl-CoAs, which can finally undergo FAO (Eaton et al., 1996). 
Medium and short chain fatty acids diffuse through the mitochondrial membrane and 
are activated in an ATP-dependent reaction in situ before undergoing FAO. 
The β-oxidation cycle comprises a series of four enzymatic reactions, in which a two-
carbon acetyl-CoA is released from the acyl-CoA ester per cycle. In the first reaction 
acyl-CoAs are oxidized to enoyl-CoA by chain length specific acyl-CoA 
dehydrogenases: short-chain (C4-C6) acyl-CoA dehydrogenase (SCAD), medium-
chain (C6–C12) acyl-CoA dehydrogenase (MCAD), long-chain (C12–C16) acyl-CoA 
dehydrogenase (LCAD) and very long-chain (C14–C20) acyl-CoA dehydrogenase 
(VLCAD) (Ojuka et al., 2016). The three subsequent reactions are a hydration, 
oxidation and thiolation that are catalyzed either by the mitochondrial trifunctional 
protein (MTP) for very long chain fatty acyl-CoAs or three separate enzymes 
(cronotase, medium/short-chain hydroxyacyl-CoA dehydrogenase and medium-chain 
ketoacyl-CoA thiolase) for short-, medium- and long-chain fatty acids. Each cycle 
results in the formation of one FADH2, one NADH, one acetyl-CoA and a 2-carbon 
shortened acyl-CoA, which re-enters the cycle until two acetyl-CoA molecules are 
produced. The reducing equivalents NADH and FADH2 transfer their electrons either 
directly to complex I of the respiratory chain or via the electron transfer flavoprotein 
(ETF) to ubiquinone, respectively. Acetyl-CoA can be further oxidized in the TCA cycle 
or exported from the mitochondria for de novo lipogenesis. Furthermore, it can also be 
converted into ketone bodies during starvation conditions. 
 
TCA cycle 
The TCA cycle, also referred to as citric acid cycle or Krebs cycle, constitutes a central 
metabolic hub. It represents the final oxidation pathway for metabolic fuels derived 
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from carbohydrates, fats and proteins. Under aerobic conditions pyruvate derived from 
glycolysis in the cytosol is converted to acetyl-CoA by the pyruvate dehydrogenase, a 
reaction yielding one molecule of NADH. The acetyl-CoA is then utilized in the TCA 
cycle for its complete oxidation to CO2 thereby producing three NADH, one FADH2 and 
GTP. The electrons of NADH and FADH2 are again allocated to the respiratory chain. 
The enzyme generating the FADH2, succinate dehydrogenase (complex II) takes not 
only part in the TCA cycle, it is also part of the respiratory chain therefore electrons 
from the oxidation of succinate directly reduce FAD+, a prosthetic group of complex II 
(Akram, 2014). 
The TCA cycle additionally provides many precursors and metabolites for biosynthetic 
pathways including gluconeogenesis, amino acid metabolism or porphyrin synthesis 
(Owen et al., 2002). Many of the TCA cycle intermediates are taken from the cycle by 
cataplerotic reactions, like α-ketoglutarate or oxaloacetate to form amino acids. 
However, they can also be placed back by anaplerotic reactions. Oxaloacetate can be 
redirected for gluconeogenesis or replenished by the pyruvate carboxylase converting 
pyruvate to oxaloacetate. Citrate represents an important source of acetyl CoA when 
exported from the mitochondria for fatty acid synthesis and ketone body formation. The 
TCA cycle is also important in providing succinyl-CoA for the initial reaction of the 
heme biosynthesis (Atamna, 2004). 
 
Oxidative phosphorylation 
The oxidative phosphorylation (OXPHOS) is the final biochemical pathway for the 
generation of the largest proportion of the cellular energy. The mitochondrial OXPHOS 
system consists of four electron transferring protein complexes namely complex I 
(NADH: ubiquinone oxidoreductase), complex II (succinate dehydrogenase), complex 
III (ubiquinol:cytochrome c oxidoreductase), complex IV (cytochrome c oxidase, also 
referred to as COX) and the FOF1-ATP synthase, which are embedded in the inner 
mitochondrial membrane (Figure 1.3) (Barrientos et al., 2002; Fontanesi et al., 2006; 
Lazarou et al., 2007; Rutter et al., 2010). The mobile redox carriers ubiquinone 
(coenzyme Q) and cytochrome c transfer electrons between the individual complexes 
(Figure 1.3). Additionally, ubiquinone is an entry point for electrons derived from FAO, 
which are transferred by the ETF. 
In the beginning, electrons are transferred via redox reactions from the electron carrier 
NADH to complex I and from succinate (via FADH2) to complex II and are passed down 
the respiratory chain to the terminal electron acceptor oxygen. These redox reactions 
drive the proton translocation from the matrix to the IMS by complex I, complex III and 
complex IV and are thereby generating an electrochemical proton gradient. The energy 
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stored within this gradient drives the FOF1-ATP synthase to synthesize ATP from ADP 
and inorganic phosphate (Jonckheere et al., 2012). The protons that flow back to the 
matrix through FOF1-ATP synthase are combined with the reduced oxygen to form H2O. 
 
 
 
The mitochondrial OXPHOS complexes are not simply arranged in sequence, 
however, they have a supramolecular organization (Chaban et al., 2014; Schägger and 
Pfeiffer, 2000). Complexes I, III and IV assemble into supercomplexes with different 
stoichiometry CoI0-1+CoIII2+CoIV0−4 (Dudkina et al., 2010; Genova et al., 2008). 
Supercomplexes comprising all three complexes (CoI+CoIII2+CoIV2) are referred to as 
respirasomes (Marques et al., 2007; Wittig and Schägger, 2009). These 
supramolecular structures are proposed to facilitate channeling of the substrates 
ubiquinone and cytochrome c or to catalytically enhance the reactions due to shorter 
diffusion times. These assumptions are strengthened by the finding that OXPHOS 
complexes are predominantly localized to the protein rich mitochondrial cristae, which 
are structurally separated from the inner boundary membrane by cristae junctions 
(Frey et al., 2002; Gilkerson et al., 2003; Lippe et al., 1988; Schägger and Pfeiffer, 
2000; Vogel et al., 2006). Another crucial function of the supercomplex formation is the 
stabilization of complex I by complex III and complex IV (Diaz et al., 2006; Schägger et 
al., 2004). The ATP synthase dimerizes and forms oligomeric chains, which is 
suggested to impose a curvature of the IMM and thereby increasing the local proton 
concentration (Strauss et al., 2008). Complex II is the only complex that has not been 
detected in higher order structures, which might be due to its dual function in the TCA 
cycle and OXPHOS. Noteworthy, it was shown that supercomplex formation is 
Figure 1.3 OXPHOS system. 
The mitochondrial respiratory chain complexes generate an electrochemical gradient across the inner 
mitochondrial membrane. NADH and succinate are oxidized to NAD+ and fumarate by Complex I and 
Complex II, respectively. The electrons (e-) are transferred via coenzyme Q (CoQ) to Complex III and 
further to Complex IV via cytochrome c (Cyt c). At Complex IV electrons are transferred to the final 
electron acceptor oxygen that forms H2O. The proton gradient produced by Complex I, Complex III and 
Complex IV is used by the FOF1-ATP synthase for ATP synthesis. The nuclear-encoded proteins are 
colored in blue and the mitochondrial-encoded subunits in other colors. Reprinted with modifications from 
Schon et al., 2012.  
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important for mitochondrial function and cell physiology (Ikeda et al., 2013; Wittig and 
Schägger, 2009). 
 
1.4.2 Whole body metabolism 
1.4.2.1 Endocrine regulation of metabolism 
Metabolism is tightly regulated through the concerted actions of endocrine hormones 
(Randle, 1963). It involves an extensive interrelation of metabolites and hormones to 
control and direct metabolic pathways. Here the endocrine actions of insulin, glucagon, 
leptin, ghrelin and incretins in the regulation of glucose and lipid metabolism and whole 
body energy expenditure are considered. 
Blood glucose levels are maintained in a narrow range despite alternate fasting and 
feeding cycles. The glucose concentration in the blood is balanced by the absorption 
from the intestine, glucose production and secretion from the liver and to a lesser 
extent from the kidneys and the clearance by peripheral organs (Saltiel and Kahn, 
2001). 
Cellular responses to endocrine hormones are mediated through receptors on the cell 
surface. Hormone binding induces signaling via G protein coupled receptors and 
second messengers like cAMP (glucagon, ghrelin), tyrosine kinase receptors and a 
direct phosphorylation of downstream substrates (insulin) or cytokine receptors with 
bound Janus kinase (JAK) (leptin) (Schwartz et al., 2000). 
Insulin is one of the most important anabolic peptide hormones. In response to 
increased blood glucose levels, insulin is secreted from pancreatic β-cells (Saltiel and 
Kahn, 2001). Insulin is mainly responsible for reducing blood glucose levels by 
increasing peripheral glucose uptake and reducing glucose production in the liver, by 
reducing gluconeogenesis and glycogenolysis (Rizza et al., 1981). Specifically it 
modulates enzyme levels by decreasing transcription of phosphoenolpyruvate 
carboxykinase (PEPCK), glucose-6-phosphatase, and fructose-1,6-biphosphatase and 
increasing transcription of glucokinase and pyruvate kinase (S J Pilkis and Granner, 
1992). The peripheral insulin dependent glucose disposal is stimulated by membrane 
translocation of GLUT4 in skeletal muscle and adipose tissue, whereas skeletal muscle 
is clearing about 75% (Klip and Pâquet, 1990). Moreover, insulin facilitates storage of 
metabolic fuels in liver, skeletal muscle and adipose tissue by stimulating glycogenesis 
and lipogenesis. 
Glucagon is secreted from pancreatic α-cells in order to increase blood glucose 
concentration. It dominates hepatic metabolism during fasting, by increasing 
glycogenolysis and gluconeogenesis (Campbell and Drucker, 2015). Additionally, 
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glucagon induces lipolysis in adipose tissue to provide more substrates for 
gluconeogenesis (glycerol) and FAO (fatty acids) (Slavin et al., 1994). 
Two important hormones implicated in the regulation of whole body energy expenditure 
are leptin and ghrelin. Leptin is commonly known as the satiety hormone. It is secreted 
from adipocytes and acts on the hypothalamus in the central nervous system thereby 
regulating food intake, energy expenditure and body weight (Schwartz et al., 2000). 
Furthermore, leptin stimulates FAO through AMPK activation and is thus regulating 
lipid metabolism (Minokoshi et al., 2002). The loss of leptin leads to obesity and insulin 
resistance in mice (ob/ob) (Pelleymounter et al., 1995). However, circulating leptin 
levels are increased in obesity, since leptin secretion is proportional to adipose tissue 
weight, a condition often referred to as leptin resistance. 
Ghrelin functions as the counter regulatory hormone to leptin. Its circulating levels are 
alternating and peaking pre-prandial, which was suggesting the function as hunger 
signal (Yin et al., 2009). It is secreted from the stomach and acts like leptin on the 
central nervous system (Abizaid et al., 2006). Ghrelin stimulates appetite and thus 
regulates body weight (Tschöp et al., 2000). Additional physiological functions are the 
stimulation of GH secretion and promotion of gastric motility (Yang et al., 2014). 
The incretin hormones GLP-1 and GIP are secreted from the intestinal cells rapidly 
after food ingestion. They facilitate quick disposal of nutrients by facilitating insulin 
secretion from pancreatic β-cells (Baggio and Drucker, 2007). GLP-1 was also shown 
to promote satiety. 
 
1.4.2.2 Organ interrelation in metabolism with regard to mitochondrial function 
Each organ has specific functions in the body and varies widely in energy needs. The 
functional requirements of the mitochondria are reflected in the tissue-specific 
variations of the mitochondrial proteome, mitochondrial morphology, as well as 
differences in mitochondrial number, ranging from a few hundred to a few thousand per 
cell (Pagliarini et al., 2008; Thor Johnson et al., 2007). These differences are even 
apparent within one tissue, as for example in the different skeletal muscle fiber types. 
The liver is the key metabolic organ governing whole body energy metabolism. It 
represents the metabolic hub providing fuels to other tissues and is the central organ in 
the regulation of glucose metabolism. During fasting conditions the liver increases 
glycogenolysis and gluconeogenesis in response to glucagon signaling in order to 
increase blood glucose levels. Additionally, the liver is the main organ generating 
ketone bodies from fatty acids during starvation, which serve as fuel for the brain. In 
the postprandial state, insulin stimulates glycogenesis and de novo lipogenesis in the 
liver (Rui, 2014). Hepatocytes harbor some distinctive enzymes in order to perform 
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these specialized functions. The glucose transporter GLUT2 allows unlimited uptake 
and release of glucose from and to the circulation. Moreover, liver cells possess 
glucokinase instead of hexokinase, which is mediating the first step in glycolysis, but 
the glucokinase is not allosterically inhibited by its product. Pyruvate derived from 
glycolysis in the liver mainly serves catabolic processes as mentioned above. 
Therefore, hepatic mitochondria primarily have biosynthetic functions. This is reflected 
in the hepatic mitochondrial respiratory function, which has a large spare capacity, 
measureable after uncoupling with the proton ionophore FCCP, indicating that liver 
mitochondria respire at a low range for ATP production. 
Skeletal muscle represents the largest organ in the body. The main fuel for muscle 
cells is glucose, fatty acids and ketone bodies. Skeletal muscle has the largest 
glycogen store for direct use within muscle cells. When immediate energy is required 
during muscle contraction, skeletal muscle cells rely almost entirely on glycolysis. A 
distinct feature of muscle cells is the anaerobic metabolism to generate ATP, when 
glucose is oxidized to lactate during intense exercise. In an exchange with the liver, 
lactate is converted to glucose and provided again to the muscle, this exchange is 
known as the Cori cycle (Berg et al., 2002). The resting muscle relies almost entirely 
on FAO for ATP generation. The presence of GLUT4 in skeletal muscle cells allows the 
insulin-stimulated uptake of glucose and the clearance of the largest proportion of 
blood glucose in the fed state. The alternate functions of skeletal muscle are evident in 
the different muscle fiber types harboring morphologically different mitochondria. Type 
1 fibers contain many mitochondria and rely on OXPHOS for ATP generation, yet they 
are able to oxidize fatty acids and ketone bodies. In contrast, type 2a fibers possess 
many small mitochondria with high capacity for ATP generation. Finally, type 2b fibers 
contain only very few mitochondria since they rely on anaerobic glycolysis and contain 
high amounts of glycogen (Forner et al., 2006). Muscle mitochondria have a high ATP 
synthesis capacity and ATP synthesis is tightly coupled to oxygen consumption 
(Marcinek et al., 2004). 
The heart, unlike the skeletal muscle exclusively functions aerobically. This is evident 
by the large density of mitochondria in the heart. Moreover, the heart relies entirely on 
fatty acids for energy generation (Doenst et al., 2013). Thus, heart mitochondria are 
primarily ATP generating and mitochondrial respiration is functioning to almost full 
capacity in the coupled state. The fatty acids required for heart functioning are in part 
provided by adipose tissue. 
Adipose tissue can be divided into two subtypes depending on the morphology and 
thermogenic function: white adipose tissue (WAT) and brown adipose tissue (BAT). 
WAT contains unilocular adipocytes serving as energy storage in the form of 
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triglycerides also named triacylglycerol. Triacylglycerol is hydrolyzed upon fasting into 
fatty acids and glycerol and released for the oxidation by the liver, heart or skeletal 
muscle, whereas insulin stimulates triglyceride storage. Besides the WAT, the liver is 
the major site of de novo lipogenesis and triglycerides are transported to the WAT for 
storage. Next to skeletal muscles cells, white adipocytes harbor GLUT4 for the insulin 
stimulated glucose uptake. Glucose is required for the generation of glycerol-3-
phosphate, which is needed for the esterification of fatty acids to triacylglycerol. 
Although WAT contains very few mitochondria, dysfunction of white adipose tissue 
mitochondria is associated with decreased lipogenesis and increased lipolysis 
(Kusminski and Scherer, 2012). 
BAT contains multilocular adipocytes rich in mitochondria. The main function of BAT is 
the generation of heat via non-shivering thermogenesis. Cold induced β-adrenergic 
stimulation of BAT by norepinephrine, leads to the transcriptional activation of the 
uncoupling protein 1 (UCP1). UCP1 uncouples the mitochondrial proton gradient from 
ATP synthesis and thereby allows robust oxidation of fatty acids to generate heat 
without generating large amounts of ATP (Cannon and Nedergaard, 2004). Thus, BAT 
has a rather catabolic role in metabolism in contrast to WAT. 
 
1.5 Mitochondrial dysfunction and metabolic diseases 
Mitochondrial dysfunction has been reported in various chronic diseases ranging from 
metabolic diseases, including type 2 diabetes mellitus and obesity to cardiovascular 
diseases, cancer and neurodegeneration (Patti and Corvera, 2010). Although these 
pathologies are not directly caused by mutations in mitochondrial proteins, they do 
affect mitochondrial function. 
The metabolic alteration in tumor cells, involving mitochondrial function, is the shift 
from OXPHOS to glycolysis. This metabolic switch has been assigned to mutations in 
mitochondrial proteins to inactivate OXPHOS or alter different metabolic pathways 
(Yan et al., 2009; Zhang et al., 2012a). Accordingly, increased expression or 
abundance of mitochondrial quality control proteins, including Lonp1, Trap1 and CLPP 
have been associated with cancer (Chae et al., 2012; Cheng et al., 2013; Cole et al., 
2015). 
Type 2 diabetes is characterized by increased blood glucose levels due to impaired 
insulin secretion from pancreatic β-cells and insulin resistance in peripheral tissues. 
The decline in mitochondrial function in skeletal muscle has been attributed to 
contribute to development of diabetes with age (Petersen et al., 2003). Moreover, the 
electron transport chain (ETC) capacity in particular complex I was shown to be 
impaired in type 2 diabetic skeletal muscle (Kelley et al., 2002). A proposed 
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mechanism for the development of impaired insulin signaling and reduced glucose 
oxidation related to mitochondrial function is the accumulation of intermediates of fatty 
acid metabolism resulting from incomplete FAO (Koves et al., 2008). Another 
contributing factor to dysfunctional mitochondria during diabetes or obesity are reactive 
oxygen species (ROS) resulting from nutrient excess. High fat high sucrose diet 
feeding results in increased ROS production that caused oxidative damage to the 
mitochondria and their dysfunction, however, insulin resistance was preceding the 
latter one (Bonnard et al., 2008). Therefore, it seems reasonable that the reduction in 
mitochondrial respiratory function might be a protective mechanism counteracting ROS 
induced insulin resistance. Two studies reported an increased insulin sensitivity and a 
protection from diet induced obesity of mice with reduced mitochondrial respiratory 
activity (Wredenberg et al., 2006). While there are no reports about mutations in the 
mitochondrial quality control proteins associated with metabolic diseases, defects in 
this system has a profound influence on metabolism owing to the loss of mitochondrial 
homeostasis. Impaired proteostasis affects the OXPHOS system as well as other 
mitochondrial proteins, triggering alterations in cellular metabolism that might 
contribute to physiological deregulation and metabolic disease. Hence, defects in 
proteins facilitating mitochondrial biogenesis like PGC1α, mitochondrial dynamics 
(MFN2 and OPA1) and the protease PARL have been linked to metabolic diseases 
and obesity (Civitarese et al., 2010; Lin et al., 2004; Quiró S et al., 2012; Sebastián et 
al., 2012). 
 
1.6 Objectives 
Mitochondrial proteases are essential for maintaining mitochondrial function and 
therefore cell homeostasis. This does not only involve protein quality control by 
degrading misfolded or damaged proteins, mitochondrial proteases also take part in 
highly regulated proteolytic activities and thereby influence several metabolic 
pathways. Due to the large complexity of the proteolytic landscape the physiological 
relevance of several proteases remains unknown. Therefore, this study aims to 
decipher the role of the mitochondrial protease CLPP in mammalian metabolism using 
different mouse models. 
Whole body CLPP deficient mice were analyzed when fed normal chow diet (NCD) or 
high fat diet (HFD) to elucidate the function of CLPP under normal and metabolic 
stress conditions and to determine the relevance of CLPP for whole body physiology. 
Furthermore, tissue-specific CLPP deficient mice were exploited to investigate the 
impact of local impaired proteostasis on whole body metabolism. 
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In addition, a mouse model modulating the mitokine stress response induced by the 
absence of CLPP was developed. In order to dissect the contribution of the FGF21 
mitokine induced response to the whole body phenotype of CLPP deficient mice, 
Clpp/Fgf21 double knockout mice were generated. 
The work outlined here will contribute to the understanding of the CLPP protease and 
its possible relevance in different physiological and pathological conditions.
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2 Materials and Methods 
 
2.1 Animal care 
Animals were housed in groups of 3-5 mice per cage at ambient temperature (22-24°C) 
and maintained on a 12 hour light/dark cycle with lights on at 6 am. Mice had ad libitum 
access to either normal chow diet (R/M-H-V1554, ssniff Spezialdiäten GmbH) 
containing 55.1% carbohydrates, 19.3% proteins and 3.3% fat (9% calories from fat) or 
high fat diet (ssniff EF acc. D12492 (I) mod., ssniff Spezialdiäten GmbH) containing 
27.1% carbohydrates, 24.1% protein and 34.0% fat (60% calories from fat) and 
drinking water. Mice were killed by cervical dislocation at the end of the study. The high 
fat diet was fed starting from 8 weeks of age until the termination of the experiment 
with 15 weeks. All experimental procedures were conducted in compliance with 
protocols approved by local government authorities (Bezirksregierung Köln) and were 
in accordance with NIH guidelines. 
 
2.2 Experimental mouse models 
The conditional targeting for the mitochondrial ATP-dependent Clp protease proteolytic 
subunit (Clpp) gene was conducted by Taconic Artemis, Germany in Art B6/3.5 stem 
cell line on a C56BL/6 TacN background. LoxP sites were introduced flanking exons 3 
and 5 and in addition, an Frt flanked puromycin selection marker was inserted into 
intron 5. Upon successful germline transmission, the Clpp+/PuroR-fl mice were mated with 
Flp deletor mice to remove the PuroR selection cassette. Finally, floxed mice (Clppfl/fl) 
were intercrossed with transgenic mice expressing Cre recombinase. To generate full 
body CLPP knockout mice, Clppfl/fl were mated with transgenic mice ubiquitously 
expressing Cre recombinase under control of the β-actin promoter, resulting in Clpp+/- 
mice. Heterozygous Clpp+/- mice were further intercrossed to obtain homozygous  
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Clpp-/- mice. Liver-specific knockout animals were generated by mating Clppfl/fl animals 
with transgenic mice expressing Cre recombinase under control of the albumin 
enhancer and promoter and the α-fetoprotein enhancer (Afp-Cre) (Kellendonk et al., 
2000). Heart and skeletal muscle-specific knockout animals were generated by mating 
Clppfl/fl animals with transgenic mice expressing Cre recombinase under control of the 
muscle creatine kinase promoter (Ckmm-Cre) (Larsson et al., 1998). 
The fibroblast growth factor 21 (Fgf21) gene targeting was carried out in the lab of Prof. 
David Mangelsdorf that was described earlier (Potthoff et al., 2009). For the generation 
of double deficient Clpp and Fgf21 knockout animals, Clppfl/fl Fgf21fl/fl mice were mated 
with transgenic mice ubiquitously expressing Cre recombinase (β-actin Cre). 
 
2.3 Phenotyping 
2.3.1 Body weight 
Body weight was assessed weekly of individual mice in the age from 4-16 weeks fed 
either NCD or HFD. 
 
2.3.2 Body composition 
The body fat content and lean mass was measured using the nuclear magnetic 
resonance (NMR) analyzer minispec mq7.5 (Bruker Optik). 
 
2.3.3 Indirect calorimetry 
Energy expenditure and respiratory exchange ratio (RER) were determined with 
indirect calorimetry using the PhenoMaster (TSE systems). Animals were acclimated in 
metabolic chambers (7.1 liter) for three days prior to data acquisition to adapt them to 
single housing, food and water dispensers. During this time animals were monitored 
daily and the body weight was determined to ensure proper adaption. Calorimetric 
measurements were conducted at 22°C for 72 h assessing oxygen consumption, 
carbon dioxide production and locomotor activity (infrared light beam frame, TSE 
systems). In addition, food and water intake was assessed with automated measuring 
devices (TSE systems). 
 
2.3.4 Blood glucose measurement 
Blood glucose levels were determined from whole venous tail blood using an automatic 
glucose monitor (Contour Next, Bayer) from either random fed or 6 h fasted animals. 
 
Materials and Methods 
 
24 
2.3.5 Serum analyses 
Serum was obtained by collecting blood from the submandibular vein. Blood samples 
were then incubated at room temperature (RT) for 45 min and centrifuged at 1500 g for 
15 min. Resulting serum was stored at -80°C for subsequent analysis. 
Serum hormone levels were measured using the Bio-Plex Pro Mouse Diabetes 8-Plex 
Assay (Bio-Rad) with the Bio-PlexTM 200 system (Bio-Rad). This system allows the 
simultaneous quantification of eight hormones based on antibody-coupled magnetic 
beads. 
Serum non-esterified fatty acids were quantified using an acyl CoA synthase/ acyl-CoA 
oxidase based calorimetric kit (NEFA-HR2, WAKO Chemicals GmbH). 
Serum Fgf21 levels were determined by an enzyme linked immunosorbent assay 
according to manufacturer’s instructions (Mouse/Rat FGF-21 Quantikine ELISA Kit, 
R&D Systems). 
 
2.3.6 Glucose tolerance test and insulin tolerance test 
Glucose tolerance tests were carried out in 15-week-old animals following a 6 h fast. 
After measuring fasted blood glucose levels, mice were injected intraperitoneally (i.p.) 
with 2 mg g-1 body weight glucose (20% glucose solution, Sigma Aldrich). Blood 
glucose levels were determined 15 min, 30 min, 60 min and 90 min post glucose 
injection. 
Insulin tolerance tests were performed with ad libitum fed 16-week-old animals. After 
recording baseline glucose levels each animal was administered i.p. with 0.6 U kg-1 
body weight insulin (Insuman Rapid, Sanofi-Aventis) and blood glucose levels were 
monitored at 15 min, 30 min, 60 min and 90 min after injection. 
 
2.3.7 Insulin signaling 
Following a 2 h fast, mice were injected with 0.6 U kg-1 body weight insulin (Insuman 
Rapid, Sanofi-Aventis) or saline. Mice were then sacrificed 30 min past injection and 
tissues were collected and frozen in liquid nitrogen. 
 
2.3.8 Acute cold exposure and measurement of rectal body temperature 
For acute cold exposure Clpp-/- and control animals were individually housed in home 
cages with bedding material, however, without nesting material and exposed to 5°C. 
Rectal body temperature was measured using a rectal thermometer (Bioseb) prior to 
the experiment at ambient temperature. Afterwards body temperature was measured 
every hour for 7 h or until core body temperature dropped below 26°C. 
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2.3.9 Femur length 
The mouse hind leg was carefully removed and then muscle and ligaments were 
trimmed away to dissect the femur. The femur was cleaned from connective tissue with 
paper cloth. In the end, the length of the femur was measured between femur head 
and the lateral condyle with a sliding caliper. 
 
2.3.10 Micro computed tomography 
The measurement of the bone mineral density was performed with the LaTheta 
microCT Scanner (Aloka) in anaesthetized mice using 2.5% Isoflurane in oxygen. The 
sections were set to 0.6 µm and analysis was done with the LaTheta software. 
 
2.4 Molecular biology 
2.4.1 Isolation of genomic DNA from mouse ear biopsies 
Mouse ear biopsies were taken at weaning age and subsequently incubated in lysis 
buffer containing 100 mM Tris-HCl, pH 8.5, 5 mM EDTA, pH 8.0, 0,2% (w/v) SDS,  
200 mM NaCl and 10 mg/mL Proteinase K (Sigma Aldrich) in a thermoshaker 
(Eppendorf) at 55°C overnight or until dissolved. DNA was precipitated by adding  
1x volume of Isopropanol and subsequent centrifugation at 13.000 rpm for 30 min at 
4°C in a bench top centrifuge (Eppendorf). After decanting the supernatant, the DNA 
pellet was washed with 70% (v/v) Ethanol and centrifuged again at 13,000 rpm for  
20 min. Hereafter, the DNA pellet was dried and dissolved in 75 µL ddH2O. 
 
2.4.2 Isolation of genomic DNA from mouse tissues 
Liver tissue was incubated overnight in lysis buffer (50 mM Tris-HCl pH 8.0, 2.5 mM 
EDTA, 0.5% (w/v) SDS, 0.1 M NaCl, 10 mg/mL Proteinase K) at 55°C. Contaminants 
were removed by adding 75 µL of 8 M Potassium Acetate and 500 µL chloroform and 
centrifuging at 13,000 rpm for 15 min. Resulting upper aqueous phase was transferred 
to a new tube and DNA was precipitated by adding 2x volume of ice-cold 100% 
Ethanol and centrifuging at 13,000 rpm for 15 min. The resulting DNA pellet was 
washed with 70% (v/v) Ethanol and resuspended in 200 µL ddH2O. 
 
2.4.3 Isolation of total RNA 
Total RNA was isolated from mouse tissues using TRIzol reagent (Life Technologies). 
Initially 50-100 mg of fresh or snap frozen tissue was placed in 2 mL tubes (Peqlab) 
together with ceramic beads (Mobio, Dianova GmbH) and 1 mL TRIzol. The tissue was 
homogenized using a Precellys 24 fast-prep machine (Bertin) at 5500 rpm for 2x  
20 sec. For tissues with high fat content (EWAT and IWAT), an additional 
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centrifugation step following homogenization was performed at 12.000 g for 10 min at 
4°C. Homogenates were then transferred to a new tube and it was proceeded with the 
addition chloroform and subsequent phase separation according to the manufacturer’s 
instruction. RNA pellet was resuspended in RNase/DNase free H2O (Gibco). 
 
2.4.4 Quantification of nucleic acids 
Nucleic acid concentration (DNA and RNA) was determined by measuring sample 
absorption with a NanoDrop 8000 Spectrophotometer (Thermo Scientific). The 
absorbance ratio of 260/280 nm was used to assess nucleic acid quality. A ratio of 1.8 
or 2 was considered as pure DNA or RNA, respectively. 
 
2.4.5 Polymerase chain reaction 
Polymerase chain reactions (PCR) (Mullis and Faloona, 1987; Saiki et al., 1988) were 
performed for the determination of mice genotypes with customized primers (Sigma 
Aldrich) listed in Table 2.1. Amplification reactions were carried out in a Veriti 
Thermocycler (Applied Biosystems, Life Technologies). Each PCR reaction was 
performed in a total volume of 20 µL containing approximately 50 ng DNA template,  
1x DreamTaq Buffer (Thermo Scientific), 62.5 µM dNTP mix (Promega), 0.4 µM of 
each primer and 1U DreamTaq Polymerase (Thermo Scientific). PCR products were 
resolved by gel electrophoresis on 2% (w/v) agarose (Sigma Aldrich) gels (0.5x TBE, 
1:50.000 GelRed (Biotium)). 
 
Table 2.1 Oligonucleotides used for genotyping 
Primer sequences are displayed in 5’-3’ order. 
Primer Primer sequence 5’-3’ TAnnealing  [°C] 
Clpp WT forward GTGGATGATGGTCAGTAGAATCC 61 
Clpp WT reverse CCCAGACATGATTCCTAGCAC 61 
Clpp KO forward TGTGCATTCTTACCATAGTCTGC 61 
Cre forward CACGACCAAGTGACAGCAAT 53 
Cre reverse AGAGACGGAAATCCATCGCT 53 
Fgf21 WT forward GGGCTCTGATAAAGCATTCC gradient (65°C -60°C) 
Fgf21 WT reverse CAGCACTAAGGGAGGCAGAG gradient (65°C -60°C) 
Fgf21 KO forward CCTCCAGATTTAGGAGTGCAGA 56 
Fgf21 KO reverse AGGGAGGCAGAGGCAAGTGATT 56 
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PCR cycling conditions for Clpp, Cre and Fgf21 knockout allele 
1. Initial denaturation at 95°C for 5 min 
2. Denaturation at 95°C for 30 sec 
3. Annealing at 61°C Clpp, 53°C Cre, 56°C Fgf21 KO 30 sec       30x 
4. Elongation at 72°C for 1 min 
5. Final extension at 72°C for 10 min 
 
PCR cycling conditions for Fgf21 wildtype allele 
1. Initial denaturation at 94°C for 2 min 
2. Denaturation at 94°C for 20 sec 
3. Annealing at 65°C for 15 sec                10x 
4. Elongation at 68°C for 10 sec 
5. Denaturation at 94°C for 15 sec 
6. Annealing at 60°C for 15 sec          28x 
7. Elongation at 72°C for 10 sec 
1. Final extension at 72°C for 2 min 
 
In Step 3 the annealing temperature was decreased by 0.5°C per cycle. 
 
2.4.6 Northern blot analysis for mitochondrial mRNA levels 
RNA (2 µg) was mixed with RNA Sample Loading Buffer (Sigma-Aldrich) in a ratio of 
1:3 and heated at 65°C for 10 min prior to running it on a 1.2% agarose-formaldehyde 
gel at 130V for 2.5 h. The gel was then washed three times with RNase free water and 
soaked in 20x SSC.  Next, RNA was transferred by alkaline capillary transfer to 
Hybond N+ membrane (GE Healthcare) overnight. The membrane was then cross-
linked at 80°C for 1.5 h. 
Radioactive labeling with 50 µCi α32P-dCTP of 70 ng mitochondrial probes or 18S 
nuclear probe was performed with the Random Primer DNA labeling kit (Invitrogen). 
The membrane was pre-hybridized with rabid-hyb buffer (GE healthcare) for 1 h at 
65°C before adding the labeled probe to hybridize for 2 h. The membrane was then 
washed with increasingly stringent washing solution (2x SSC, 0.1% SDS, 1x SSC, 
0.1% SDS, 0.5x SSC, 0.1% SDS) for 20 min each at 65°C. Radioactive signals were 
detected with Amersham Hyperfilms. Mitochondrial transcript levels were normalized to 
18S rRNA levels. 
 
2.4.7 Reverse transcription and quantitative real-time PCR 
Total RNA was isolated from tissues as described previously. Next, RNA was 
subjected to DNase digestion by incubating 10 µg RNA in 1x DNase buffer and 2U 
DNaseI (NEB) at 37°C for 10 min. Followed by the addition of 10 mM EDTA and heat 
inactivation of the DNase at 75°C for 10 min. RNA (100 ng µL-1 per sample) was 
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reverse transcribed using the High capacity reverse transcription kit (Applied 
Biosystems, Life Technologies). Resulting cDNA was amplified with Brilliant III Ultra-
Fast SYBR QPCR Master Mix (Agilent Technologies, see Table 2.2) with the exception 
of Atf5, which was amplified using Taqman Assay-on-demand kit (Applied Biosystems, 
Life Technologies) (Table 2.3). Real-time PCR was performed on QuantStudio K Flex 
System (Applied Biosystems, Life Technologies). The target gene expression was 
adjusted for total mRNA content of hypoxananthine-guanine phosphoribosyltransferase 
1 (Hprt1) or TATA box binding protein (Tbp). Calculations were performed using a 
comparative method (2-ΔΔCT). 
 
Table 2.2 Primer used for quantitative real-time PCR 
 
 
Table 2.3 Taqman Probes used for quantitative real-time PCR 
Probe  Catalog Number 
Atf5 MM00459515_m1 
Hprt Mm00446968_m1 
Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
Acadvl CTACTGTGCTTCAGGGACAAC CAAAGGACTTCGATTCTGCCC 
Atf4 GCAAGGAGGATGCCTTTTC GTTTCCAGGTCATCCATTCG 
Chop CTGGAAGCCTGGTATGAGGAT  CAGGGTCAAGAGTAGTGAAGGT 
Cidea TGACATTCATGGGATTGCAGAC GGCCAGTTGTGATGACTAAGAC 
Cpt2 CAGCACAGCATCGTACCCA TCCCAATGCCGTTCTCAAAAT 
Dio2 CAGCTTCCTCCTAGATGCCTA CTGATTCAGGATTGGAGACGTG 
Hprt TCAGTCAACGGGGGACATAAA GGGGCTGTACTGCTTAACCAG 
Igf1 AAATCAGCAGCCTTCCAACTC GCACTTCCTCTACTTGTGTTCTT 
Fgf21 GTGTCAAAGCCTCTAGGTTTCTT GGTACACATTGTAACCGTCCTC 
Ndufa9 GGCCAGCTTACCTTTCTGGAA GCCCAATAAGATTGATGACCACG 
Ndufb6 TGGAAGAACATGGTCTTTAAGGC TTCGAGCTAACAATGGTGTATGG 
Ndufs2 TCGTGCTGGAACTGAGTGGA GGCCTGTTCATTACACATCATGG 
Ndufs3 CTGTGGCAGCACGTAAGAAG GCTTGTGGGTCACATCACTCC 
Ndufv2 GGCTACCTATCTCCGCTATGA TCCCAACTGGCTTTCGATTATAC 
Pgc1α TATGGAGTGACATAGAGTGTGCT CCACTTCAATCCACCCAGAAAG 
Pparα AACATCGAGTGTCGAATATGTGG CCGAATAGTTCGCCGAAAGAA 
Pparγ CCTGAAGCTCCAAGAATACCA GCCTGATGCTTTATCCCCACA 
Sdha GAACACTCCAAAAACAGACCTGC TCCACCACTGGGTATTGAGTAG 
Tbp  GGGAGAATCATGGACCAGAA TTGCTGCTGCTGTCTTTGTT 
Ucp1 AGCCATCTGCATGGGATCAAA GGGTCGTCCCTTTCCAAAGTG 
Uqcrc1 AGACCCAGGTCAGCATCTTG GCCGATTCTTTGTTCCCTTGA 
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2.5 Biochemistry 
2.5.1 Protein extraction from mouse tissues 
For protein extraction, 30-50 mg tissue were disrupted in organ lysis buffer (50 mM 
HEPES, pH 7.4, 50 mM NaCl, 1% (v/v) Triton X-100, 0.1 M NaF, 10 mM EDTA, 0.1% 
(w/v) SDS, 10 mM Na-orthovanadat, 2 mM PMSF, 1x protease inhibitor cocktail (Sigma 
Aldrich) and if necessary 1x PhosSTOP phosphatase inhibitor (Roche)) by using a 
Precellys 24 fast-prep machine (Bertin) at 5500 rpm two times for 20 sec. Particulate 
matter was removed by centrifugation at 13.000 rpm for 45 min at 4°C. Afterwards, 
supernatants were transferred to fresh tubes and protein concentration was determined 
using Bradford reagent (Sigma Aldrich) according to the manufacturer’s instructions. 
Protein extracts were either used directly or stored at -80°C until further use. 
 
2.5.2 Isolation of mitochondria from liver and brown adipose tissue 
Mice were sacrificed by cervical dislocation and tissues were dissected and rinsed with 
ice-cold mitochondria isolation buffer (MIB, 100 mM Sucrose, 50 mM KCl, 1 mM EDTA, 
20 mM TES, 0.2% BSA fatty acid free, pH 7.2). Afterwards tissues were homogenized 
in 15 mL or 5 mL MIB for liver or brown adipose tissue (BAT), respectively with a Potter 
S homogenizer (Sartorius) at 1200 rpm with 10 strokes (liver) or 20 strokes (BAT). All 
subsequent procedures were carried out on ice or 4°C. Homogenates were transferred 
to 50 mL falcon tubes (liver) or 2 mL tubes (BAT) and centrifuged at 8400 g for 5 min. 
The supernatant with floating fat was discarded and the pellet containing mitochondria 
was resuspended in 30 mL (liver) or 1 mL (BAT) MIB. Next, cellular debris and cell 
nuclei were removed from homogenates by centrifugation at 800 g for 5 min. Then the 
supernatant comprising the mitochondria was transferred to a new 50 mL tube (liver) or 
2 mL tube (BAT) and mitochondria were pelleted by centrifugation at 8200 g for 5 min. 
After the supernatant was discarded, the mitochondrial pellet was resuspended in  
400 µL (liver) or 50 µL (BAT) MIB without BSA. Protein concentrations were 
determined by Bradford assay (Sigma Aldrich). Mitochondria were subsequently used 
for respiration analysis or snap frozen in liquid nitrogen. 
 
2.5.3 Isolation of mitochondria from skeletal muscle 
Mice were sacrificed by cervical dislocation and skeletal muscle (SkM) was dissected 
and placed in ice-cold PBS containing 10 mM EDTA. Following the removal of fat and 
ligaments, skeletal muscle tissues were cut into small pieces and incubated on ice for  
30 min in PBS containing 10 mM EDTA and 0.05% trypsin. Next, the samples were 
centrifuged at 200 g for 2 min. The supernatant was discarded and the tissue pieces 
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were resuspended in 5 mL MIB1 (67 mM Sucrose, 50 mM Tris-HCl pH 7.4, 50 mM KCl, 
10 mM EDTA pH 8.0, 0.02% BSA fatty acid free). After the homogenization using a  
Potter S homogenizer at 1200 rpm with 10 strokes, the homogenates were centrifuged 
at 700 g for 5 min at 4°C. The supernatant comprising the mitochondria was 
transferred to a new 50 mL tube and subsequently centrifuged at 8000 g for 5 min at 
4°C to pellet mitochondria. The resulting cytosolic supernatant was discarded and the 
mitochondrial pellet was resuspended in MIB2 (250 mM Sucrose, 10 mM Tris-HCl pH 
7.4, 0.3 mM EGTA-Tris). Proteins were quantified using Bradford reagent (Sigma 
Aldrich) according to manufacturer’s instructions. 
 
2.5.4 Blue native polyacrylamide gel electrophoresis 
Blue native polyacrylamide gel electrophoresis (BN-PAGE) was conducted using the 
NativePAGE Novex Bis-Tris Gel System (Life Technologies) according to 
manufacturer’s instructions. Briefly, 20-40 µg mitochondria were lysed with 4% 
digitonin for the analysis of mitochondrial supercomplexes or 1% DDM for the analysis 
of mitochondrial complexes. After incubation on ice for 15 min, mitochondrial debris 
were removed by centrifugation at 13.000 rpm for 30 min. The resulting supernatant 
was run on 4-16% Bis-Tris gradient gels. Proteins were then transferred onto PVDF 
membranes by wet transfer that was followed by immunodetection of mitochondrial 
complexes and supercomplexes. 
 
2.5.5 SDS-PAGE and Western blot 
For Western blot analysis, protein extracts were boiled for 5 min at 95°C in SDS-PAGE 
loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% Glycerol, 1% β-
mercaptoethanol, 12.5 mM EDTA, 0.02% Bromophenol Blue). Proteins were resolved 
on 8-13% SDS polyacrylamide gels (Laemmli, 1970) together with protein marker 
(PageRuler™ Prestained Protein Ladder) and transferred to nitrocellulose membranes 
using wet transfer system (Bio-Rad). Membranes were then incubated for 1 h at RT in 
5% nonfat dried milk in PBS-T or 5% BSA in TBS-T according to the antibodies used. 
Subsequently, membranes were incubated with primary antibodies (Table 2.4) for  
2 h at RT or overnight at 4°C. After washing the membrane three times in PBS-T or 
TBS-T for 5 min each, membranes were incubated for 1 h at RT with the respective 
secondary antibody (diluted 1:2000, Sigma Aldrich). Again membranes were washed 
three times in PBS-T or TBS-T and signals were visualized using ECL solution (GE 
Healthcare) and exposition to X-ray films (Fujifilms). Films were developed in an 
automatic developer (Kodak). Western blots were quantified relative to levels of loading 
control proteins using the ImageJ software as intensity per mm2. 
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      Table 2.4 Primary antibodies used for Western blot analysis 
Antigen Cat. No. Company Dilution 
ACADS sc-365953 Santa Cruz  1:2000 
ACADVL sc-98338 Santa Cruz  1:2000 
ACTIN A5441 Sigma Aldrich 1:5000 
AFG3L2 - Polyclonal antisera made by Prof. 
Dr. Elena I. Rugarli 
1:1000 
AKT 9272 Cell Signaling 1:2000 
AMPK 2532 Cell Signaling  1:1000 
ATP5A1 MS507 Mitosciences  1:1000 
CLPP WH0008192-M1 Sigma Aldrich 1:1000 
CLPX HPA040262 Sigma Aldrich 1:1000 
COX1 459600 Invitrogen 1:2000 
COX4I1 A21348 Invitrogen  1:2000 
CPT1 sc-31128 Santa Cruz  1:1000 
CPT1M CPT1M11-A Alpha Diagnostic  1:1000 
CPT2 ab181114 Abcam 1:1000 
EFTU - Polyclonal antisera made by Prof. 
Dr. Nono Tomita-Takeuchi 
1:1000 
ERAL1 18881 IBL 1:1000 
GFM1 ab6107496 Abcam  1:1000 
GLUT1 sc-7903 Santa Cruz  1:300 
GLUT4 07-1404 Millipore  1:1000 
HADHA ab54477 Abcam  1:1000 
HSC70 sc-7298 Santa Cruz 1:5000 
HSP60 611562 BD 1:10000 
MTIF2 - Polyclonal antisera made by Prof. 
Dr. Aleksandra Filipovska 
1:1000 
MTIF3 - Polyclonal antisera made by Prof. 
Dr. Aleksandra Filipovska 
1:1000 
LONP1 ab103809 Abcam  1:400 
MCAD sc-49047 Santa Cruz  1:2000 
MFN1 LSC154487 LSBio 1:1000 
MFN2 ab50838 Abcam  1:1000 
MnSOD 06-984 Millipore  1:500 
MRPL37 HPA025826 Sigma 1:1000 
MRPS18B 16139-1-AP Proteintech 1:1000 
MRPS35 16457-1-AP Proteintech 1:1000 
mtHSP70 ab82591 Abcam  1:1000 
NDUFA9 459100 Invitrogen  1:5000 
NDUFB6 A21359 Invitrogen  1:5000 
NDUFS2 ab96160 Abcam  1:2000 
NDUFS3 MS112 Mitosciences  1:1000 
NDUFV2 15301-1-AP Proteintech 1:2000 
OPA1 BD612606 BD 1:500 
pAKT 
(Ser473) 
4060 Cell Signaling 1:1000 
pAMPK 
(Thr172) 
2535 Cell Signaling  1:1000 
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Antigen Cat. No. Company Dilution 
PGC-1α sc-13067 Santa Cruz  1:1000 
SDHA 459200 Invitrogen  1:10000 
TFAM - Polyclonal antisera made by Prof. 
Dr. Nils-Göran Larsson 1:1000 
TOMM20 sc-11415 Santa Cruz Biotechnology 1:1000 
UCP1 - Polyclonal antisera made by Prof. 
Dr. Nils-Göran Larsson 
1:1000 
UQCRC1 459140 Invitrogen  1:5000 
UQCRFS1 MS305 Mitosciences  1:1000 
VDAC 4661 Cell Signaling  1:1000 
 
 
2.5.6 Mitochondrial respiration 
Oxygen consumption of isolated liver mitochondria was assessed with high-resolution 
respirometry (Oxygraph-2k, OROBOROS Instruments). Two different substrate 
uncoupler inhibitor titration (SUIT) protocols were applied. After air equilibration of the 
mitochondrial respiration buffer (120 mM Sucrose, 50 mM KCl, 20 mM Tris-HCl, 1 mM 
EGTA, 4 mM potassium dihydrogen phosphate, 2 mM magnesium chloride, 0.1% BSA) 
200 µg liver mitochondria were added. For the carbohydrate SUIT protocol, first the 
OXPHOS state for complex I was determined by adding 5 mM pyruvate, 2 mM malate, 
20 mM glutamate and 2 mM ADP. The convergent electron flow through complex I and 
II was measured by adding 10 mM succinate. Next, LEAK respiration was assessed by 
the inhibition of the ATP synthase with oligomycin (1.5 µg/mL). Titration of 
carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP, 0.5 µM) was performed to 
determine the maximal electron transfer system (ETS) capacity. Subsequently,  
complex I was inhibited by 0.5 µL Rotenone to determine the maximal ETS capacity 
with electron flow through complex II only. Finally, residual oxygen consumption (ROX) 
was measured upon inhibition of complex III by 2.5 µM Antimycin A. 
For the fatty acid SUIT protocol, respiration was measured with 50 µM 
palmitoylcarnitine, 5 mM malate and 2 mM ADP (OXPHOS state), proceeding with the 
addition of atractyloside (LEAK state) to inhibit the ATP synthase. Next, respiration was 
uncoupled by titrations of FCCP to determine maximal ETS capacity. 
 
2.5.7 Palmitate oxidation rate ex vivo 
Fatty acid β-oxidation in isolated mitochondria was performed as described previously 
(Huynh et al., 2014). Briefly, crude mitochondria were isolated from 200 µg liver,  
100 µg SkM and 80 µg BAT in STE buffer (0.25 M sucrose, 10 mM Tris-HCl pH 7.4,  
1 mM EDTA). Isolated mitochondria were then incubated in oxidation reaction mixture 
containing 0.4 µCi BSA conjugated [1-14C]-palmitate for 1 h at 37°C. After the 
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incubation, the reaction mixture is transferred to a tube with 200 µL of 1 M perchloric 
acid and piece of Whatman paper disc in the cap soaked with 20 µL 1 M NaOH. After  
1 h incubation at RT the paper disc was transferred to a scintillation vial for the 
determination of 14CO2. The acid solution was centrifuged and the supernatant 
afterwards transferred to a scintillation vial for the measurement of the acid soluble 
metabolites using a liquid scintillation counter (Beckmann Coulter). 
 
2.5.8 Sucrose gradient fractionation of mitochondrial ribosomes 
The analysis of mitoribosomes via sucrose gradient fractionation was performed as 
described elsewhere (Szczepanowska et al., 2016). 
 
2.5.9 In organello translation 
For the analysis of de novo mitochondrial translation, 2 mg of isolated mitochondria 
were incubated in ‘hot’ translation buffer (100 mM mannitol, 10 mM sodium succinate, 
80 mM KCl, 5 mM MgCl2, 1 mM KPi, 25 mM HEPES, pH 7.4 supplemented with 35S-
methionine, all other amino acids (60 µg/mL), 5 mM ATP, 20 µM GTP, 6 mM creatine 
phosphate and 60 µg/mL creatine kinase) at 37°C with constant rotation (pulse). 
Following the 1 h incubation, half of the mitochondria were lysed in SDS-PAGE loading 
buffer, while the other half was washed and incubated for additional 3 h in ‘cold’ 
translation buffer containing non-radioactive methionine (chase). Afterwards 
mitochondria were also lysed and both pulse and chase labeled fractions were 
separated by SDS-PAGE. Subsequently, gels were stained with Coomassie staining 
solution, dried at 80°C for 2 h and newly synthesized proteins were detected by 
autoradiography. 
 
2.6 Histological analysis 
2.6.1 Embedding of tissues in paraffin 
After dissection tissues were placed in tissue cassettes (Roth) and immersed in 5% 
(w/v) paraformaldehyde overnight at 4°C for fixation. Next day tissues were dehydrated 
by passing them through increasing concentrations of ethanol for 2 h each (30% (v/v), 
50% (v/v), 70% (v/v), 96% (v/v) and two times in 100% (v/v) ethanol). Afterwards they 
were incubated in xylol for two times 2 h and then transferred to paraffin, for the 
embedding in paraffin blocks. The fixed tissues (liver, SkM, BAT, EWAT and IWAT) 
were sectioned with a microtome (Leica) at 5 µm thickness and transferred onto poly-L-
lysine glass slides (VWR). 
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2.6.2 Cryostat sections 
For cryostat sections, liver tissues were embedded in Tissue-Tek (Sakura) and tissue 
trays were placed on dry ice until the complete hardening of the Tissue-Tek. The 
embedded tissues were then stored at -80°C. Using a Cryostat (Leica) liver or BAT 
tissue was sectioned at a thickness of 7 µm (COX SDH staining) or 12 µm (Oil red O 
staining) and transferred onto poly-L-lysine glass slides. For short term storage, slides 
were kept at -20°C until use. 
 
2.6.3 Hematoxylin and Eosin staining 
Deparaffinized (20 min xylol) and rehydrated tissue sections (2 min each in 100% (v/v) 
EtOH, 96% (v/v) EtOH, 75% (v/v) EtOH and 1 min tap water) were stained with Mayer’s 
Hematoxylin for 4 min and blued in tepid tap water for 1 min. Afterwards sections were 
washed for 15 min in tap water and shortly rinsed with ddH2O. For counterstaining, the 
samples were stained with Eosin for 1 min and then washed with tap water six times. 
Next, the sections were dehydrated for 1 min each in 75% (v/v), 95% (v/v) and 100% 
(v/v) EtOH and cleared with xylol. Coverslips were mounted using Entellan. 
 
2.6.4 Periodic acid Schiff’s reaction 
Deparaffinization and rehydration of tissue slides was done as described above. Next, 
slides were incubated in periodic acid for 5 min and washed with ddH2O two times for  
5 min. The staining time with Schiff’s reagent is tissue dependent and accounted for 
liver 1:20 min and for SkM 10 min. After washing the slides under running tap water for  
10 min, sections were dehydrated for 1 min each in 75% (v/v), 95% (v/v) and 100% 
(v/v) EtOH and cleared with xylol. Finally, they were mounted with Entellan. 
 
2.6.5 Oil red O staining 
Oil red O (ORO) staining was performed on cryosections. The sections were air dried 
for 10 min and surrounded with a PAP pen (Sigma-Aldrich). Subsequently, sections 
were covered with ORO solution for 5 min and counterstained with Mayer’s 
Hematoxylin for 30 sec. The slides were then rinsed under running tap water before 
they were mounted with FluorSave Reagent (Calbiochem). 
 
2.6.6 COX-SDH staining 
Enzyme histochemical staining for COX-SDH was performed on cryosections, after 
drying them for 10 min at RT. Next sections were surround with a PAP pen and 
incubated in COX solution (0.8 ml 3,3 diaminobenzidine tetrahydrochloride, 0.2 ml  
500 μM cytochrome c, a few grains of catalase) at 37 °C for 40 min in a humidified 
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chamber to prevent drying of the sections. After a washing step in PBS, the sections 
were incubated in SDH solution 0.8 ml 1.875 mM nitroblue tetrazolium, 0.1 ml 1.3 M 
sodium succinate, 0.1 ml 2 mM phenazine methosulphate, 0.01 ml 100 mM sodium 
azide) for 60 min at 37 °C. Subsequently slides were washed in PBS and dehydrated 
for 1 min each in 75% (v/v), 95% (v/v) and 100% (v/v) EtOH before mounting the slides 
with Entellan. 
 
2.6.7 Transmission electron microscopy 
For ultrastructural analysis, very thin liver tissue slices were fixed for 24 h in 2% 
paraformaldehyde and 2% glutaraldehyde in 0.1 M cacodylat buffer. Tissues were then 
embedded in epoxy resin and ultrathin sections (70 nm) were cut and transferred to  
100 mesh copper grids. Next, sections were stained with 1.5% uranyl acetate solution 
and lead nitrate. Electron micrographs were taken with the Zeiss 109. All consecutive 
steps after tissue fixation were performed by Beatrix Martiny (CECAD imaging facility). 
 
2.7 Cell Culture 
Mouse embryonic fibroblasts (MEFs) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (4.5 g L-1 glucose, with L-Glutamine and sodium pyruvate; Gibco, 
Thermo Fisher Scientific) supplemented with 10% FBS (Biochrom AG) and  
100 units ml-1 penicillin and 100 μg of Streptomycin. 
For protein extraction cells were trypsinized and the cell pellet was subsequently lysed 
in RIPA buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Na-
deoxycholate, 0.1% SDS, 2 mM EDTA, 10 mM NaF and 1x protease inhibitor cocktail 
(Sigma Aldrich). Following 30 min incubation on ice, suspensions were sonified in a 
water bath for 3 min. Afterwards cell lysates were centrifuged at full speed for 20 min to 
remove cellular debris. The cleared lysates were then directly used or kept at -80°C for 
later use. 
 
2.8 Label-free quantification of the liver proteome 
2.8.1 In-solution digest 
Liver tissue was disrupted in Urea buffer (8 M Urea, 50 mM Triethylammonium-
bicarbonate, 1x protease inhibitor cocktail) using a Precellys 24 fast-prep machine 
(Bertin) at 5500 rpm two times for 20 sec. Cell debris were then removed by 
centrifugation at 20.000 g for 15 min. Thereafter, proteins were reduced by incubation 
with 5 mM dithiothreitol at 37°C for 1 h and thiols were carboxymethylated with 10 mM 
iodoacetamide for 30 min. This step was followed by the protein digestion with 
endoproteinase Lys-C at 37°C for 4h and trypsin at 37°C overnight. Next day, the 
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digestion was terminated by acidification of the solution with formic acid (final 
concentration 1%). Purification of peptides was achieved using the StageTip technique 
before LC-MS/MS analysis was conducted (Rappsilber et al., 2002) 
 
2.8.2 Liquid chromatography and mass spectrometry 
The liquid chromatography and mass spectrometry (LC-MS/MS) device was made up 
of an EASY n-LC1000 (Thermo Scientific) linked via a nano-electrospray ionization 
source (Thermo Scientific) to an ion-trap based bench top Q-Executive Plus (Thermo 
Scientific). The experiment and data analysis was performed by the CECAD 
proteomics facility. 
 
2.9 Computer analyses 
2.9.1 Software 
Statistical analysis was conducted using Microsoft Excel and Graphpad Prism 6 
(Graphpad Software). Figures and Illustrations were prepared with Adobe Illustrator 
CS4 (Adobe Systems). 
 
2.9.2 Statistical analyses 
Data sets with two independent groups were analyzed for statistical significance using 
two-tailed unpaired Student’s t-test. With one exception, respirometry data were 
analyzed using two-tailed paired Student’s t-test. Data sets with more than two groups 
were analyzed using one way analysis of variance (ANOVA) followed by Tukey’s post 
hoc test. All p-values below 0.05 were considered statistically significant; *p <0.05,  
** p< 0.01, ***p< 0.001. All data are presented as mean ± SD. 
 
2.10 Chemicals 
 
Table 2.5 Chemicals 
Name Supplier 
[1-14C]-palmitic acid Hartmann Analytic 
32P-dCTP Hartmann Analytic 
35S-methionine Hartmann Analytic 
β-mercaptoethanol Sigma Aldrich 
Acetic acid AppliChem 
Catalase, bovine liver Sigma Aldrich 
Acetonitrile Sigma Aldrich 
Acryamide-Bisacrylamide 40 Carl Roth 
Adenosine 5’-diphosphate sodium salt Sigma Aldrich 
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Name Supplier 
Adenosine 5’-triphosphate disodium salt (ATP) Sigma Aldrich 
Agarose LE Ambion 
Albumin from bovine serum fatty acid free 
(BSA) 
Sigma Aldrich 
Ammonium bicarbonate Sigma Aldrich 
Ammonium persulfate (APS) Sigma Aldrich 
Antimycin A Sigma Aldrich 
Boric Acid Sigma Aldrich 
Bromophenol blue Merck 
carbonylcyanide  
p-trifluoromethoxyphenylhydrazone (FCCP) 
Sigma Aldrich 
Creatine Phosphokinase Type III, bovine Sigma Aldrich 
Chloramphenicol Sigma Aldrich 
Coenzyme A Sigma Aldrich 
Coomassie Brilliant Blue R-250 Merck 
Cytochrome C, bovine heart Sigma Aldrich 
Diaminobenzidine tetrahydrochloride (DAB) Sigma Aldrich 
Diethyl Malate Sigma Aldrich 
Dimethylsulfoxide (DMSO) Sigma Aldrich 
Disodium phosphate (Na2HPO4) Sigma Aldrich 
Dithiothreitol (DTT) Sigma Aldrich 
Doxycycline monohydrate Sigma Aldrich 
Ethanol AppliChem 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich 
Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA) 
Sigma Aldrich 
Glucose Merck 
Glycerol Sigma Aldrich 
Glycine AppliChem 
Guanosine 5’triphosphate sodium salt hydra Sigma Aldrich 
HEPES AppliChem 
Hydrochloric acid (HCl) VWR 
Isopropanol AppliChem 
L-Carnitine Sigma Aldrich 
L-Glutamic Acid Sigma Aldrich 
Magnesium chloride hexahydrate Sigma Aldrich 
Magnesium sulfate (MgSO4) Merck 
Mannitol AppliChem 
Methanol AppliChem 
Milk powder AppliChem 
Monopotassium phosphate (KH2PO4) Sigma Aldrich 
Nicotinamide adenine dinucleotide reduced 
sodium salt (NADH) 
Sigma Aldrich 
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Name Supplier 
Nitrotetrazolium blue (NTB) Sigma Aldrich 
Oligomycin Sigma Aldrich 
Paraformaldehyde Sigma Aldrich 
Phenazine methosulphate (PMS) Sigma Aldrich 
Perchloric acid Sigma Aldrich 
Periodic acid Sigma Aldrich 
Phosphocreatine disodium salt hydrate 
enzymatic 
Sigma Aldrich 
Polyethylenglycol  Sigma Aldrich 
PonceauS Sigma Aldrich 
Potassium chloride (KCl) AppliChem 
Potassoium hydroxide (KOH) AppliChem 
Rotenone Sigma Aldrich 
Sodium azide Sigma Aldrich 
Sodium chloride (NaCl) Sigma Aldrich 
Sodium deoxycholate Sigma Aldrich 
Sodium dodecyl sulfate (SDS) AppliChem 
Sodium fluoride (NaF) AppliChem 
Sodium hydroxide (NaOH) Sigma Aldrich 
Sodium orthovanadat AppliChem 
Sodium pyruvate Sigma Aldrich 
Sodium succinate dibasic hexahydrate Sigma Aldrich 
Sucrose Sigma Aldrich 
Tetramethylethylenediamine (TEMED) Sigma Aldrich 
Tris Sigma Aldrich 
Triton X-100 Sigma Aldrich 
Trizma Base Sigma Aldrich 
Tween-20 VWR 
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3 Results 
 
3.1 Phenotypic analysis of whole body CLPP deficient mice 
3.1.1 Loss of CLPP does not affect lifespan 
To unravel the in vivo function of mitochondrial CLPP and elucidate the consequences 
of CLPP deficiency on whole body metabolism, CLPP was ubiquitously deleted using a 
β-actin promoter driven Cre recombinase. Deletion of the loxP flanked exon 3 to 5 
results in the loss of the protease domain as well as a frame shift from exon 2 to 6, 
causing a premature translational stop signal (Szczepanowska et al., 2016). The 
remaining Clpp mRNA is likely to be degraded via nonsense-mediated decay 
mechanisms. To verify the loss of CLPP, Western blot analysis was performed in liver, 
skeletal muscle (quadriceps, SkM), brown adipose tissue (BAT), epididymal white 
adipose tissue (EWAT) and inguinal white adipose tissue (IWAT). CLPP protein was 
completely absent in all analyzed tissues, thus confirming efficient targeting of the Clpp 
gene (Figure 3.1). To decipher the metabolic phenotype of Clpp-/- mice all experiments 
were performed with male mice at the age of 15 weeks unless otherwise indicated. 
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Interestingly, CLPP deficiency did not result in embryonic lethality as it was observed 
for other mitochondrial proteases, such as LONP1, YME1L (Quirós et al., 2014; Wai et 
al., 2015). However, CLPP deficient mice (Clpp-/-) were not born in Mendelian ratios. 
Only about 60% of Clpp-/- mice were born, whereas the other genotypes (Clpp+/+,  
Clpp+/-) were recovered at the expected Mendelian ratios (Szczepanowska et al., 
2016). Although CLPP seems to be essential during embryonic development under 
certain conditions, the lack of CLPP does not have an impact on the postnatal lifespan. 
No significant differences were observed for the median and maximal survival for both 
males and females (Figure 3.2 A, B). 
To determine the effect of CLPP deficiency on body weight, control and Clpp-/- mice fed 
normal chow diet (NCD) were monitored upon weaning for a period of 12 weeks. 
Already at three weeks of age CLPP deficient animals displayed a reduced body 
weight as compared to control mice. The weight reduction of approximately 25-30% 
persisted throughout the analyzed time period in both genders (Figure 3.2 C, D). 
Whether CLPP deficient mice are already born with a reduced body weight or if they 
develop differently upon birth, still needs to be investigated. 
Furthermore, body composition was analyzed using magnetic resonance imaging. The 
fat mass of Clpp-/- mice was significantly reduced by 51% and 53% in males and 
females as compared to control (Figure 3.2 E). Although the lean mass was also 
reduced in these animals, it was affected to a lesser extent than the fat mass, i.e. 33% 
and 25% in males and females, respectively (Figure 3.2 F). Thus, it can be concluded 
that the body weight of CLPP deficient mice is mainly reduced due to decreased fat 
mass. 
 
Figure 3.1 Validation of ubiquitous CLPP deletion. 
Western blot analysis of CLPP levels in liver, skeletal muscle, heart, brown adipose tissue, epididymal 
white adipose tissue and inguinal white adipose tissue in control (Clpp+/+) and CLPP deficient mice (Clpp-/-
). CALNEXIN, SDHA or VDAC serve as loading control (Ctrl). 
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As well as a significant reduction in body weight, also reduced body length was 
observed for Clpp-/- mice (Figure 3.3 A). The overall decrease in body length correlated 
with a decrease of femur length in these mice at 15 weeks of age (Figure 3.3 B). 
Moreover, the bone morphology was altered due to the lack of CLPP.  Micro computed 
tomography (microCT) analysis revealed a significant decrease of total bone mineral 
density (BMD) by 8% in males and 14% in females (Figure 3.3 C). 
Figure 3.2 Phenotypic characterization of Clpp-/- mice. 
(A) Kaplan-Meyer survival curves for male Clpp-/- mice (n=14) and control mice (n=9). (B) Lifespan 
analysis of female Clpp-/- mice (n=4) and control mice (n=7). (C) Body weight of male Clpp-/- mice (n=10) 
and control mice (n=9) was monitored till 15 weeks of age on normal chow diet (NCD). (D) Body weight of 
female Clpp-/- mice (n=8) and control mice (n=9) was monitored till 15 weeks of age on normal chow diet 
(NCD). (E) Body fat mass of Clpp-/- mice and control mice fed NCD determined by NMR at 15 weeks of 
age (male n=8 and female n=7). (F) Lean body mass of Clpp-/- mice and control mice fed NCD determined 
by NMR at 15 weeks of age (male n=8 and female n=7). Data are presented as mean ± SD (*P<0.05, 
**P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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To determine whether alterations in the growth hormone (GH)/ insulin like growth  
factor 1 (IGF1) axis are contributing to the growth defect in Clpp-/- mice, Igf1 transcript 
levels were analyzed in liver of 5- and 15-week-old mice. The liver is the main source 
of circulating IGF1, which is acting as an endocrine hormone and promoting the linear 
growth effect of pituitary GH (Laron, 2001; Yakar et al., 2002). However, no change in 
Igf1 transcript levels was observed in Clpp-/- mice at 5 and 15 weeks of age (Figure 3.3 
D). One reason for this unexpected result could be the selected time points, since the 
growth defect is already present at an earlier age or the experimental assessment. 
 
 
 
3.1.2 Clpp-/- mice have increased energy expenditure and improved glucose 
homeostasis despite lower locomotor activity 
To further investigate the energy homeostasis of Clpp-/- mice, indirect calorimetry was 
performed in metabolic cages. The results of all parameters represent mean values 
obtained during the light (6:00 am to 6:00 pm) and the dark phase (6:00 pm to 6:00 
am) and clearly show the diurnal rhythm in all groups. The highest values were 
obtained in the dark phase, corresponding to the period with the major activity of the 
Figure 3.3 Clpp-/- mice exhibit growth defect. 
(A) Representative image of male control and Clpp-/- mouse revealing the difference in body size. (B) 
Femur length of Clpp-/- mice and control mice measured between femur head and lateral condyle (male 
n=6-7, female n=6). (C) Total bone marrow density of control and CLPP deficient animals (n=6-7). (D) Igf1 
transcript levels in liver of Clpp-/- mice and control mice at 5 and 15 weeks (n=4). Data are presented as 
mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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animals.  No significant difference in food and water intake was observed between 
control mice and Clpp-/- mice (Figure 3.4 A, B), ruling out decreased caloric intake as 
reason for the lean phenotype of Clpp-/- mice. The respiratory exchange ratio (RER) is 
the ratio of CO2 produced / O2 consumed and indicates the primary type of fuel 
utilization. An RER of 1.0 indicates use of carbohydrates and a value of 0.7 is 
indicative for fat as primary fuel source.  No significant difference in the RER during the 
light and the dark phase was observed between control and Clpp-/- mice (Figure 3.4 C), 
indicating no major alteration in metabolic fuel preference. However, consistent with 
the lean phenotype, energy expenditure in the dark phase, normalized for the lean 
body weight, was increased in Clpp-/- mice (Figure 3.4 D). 
 
 
 
To investigate whether increased physical activity contributes to the increased energy 
expenditure in CLPP deficient mice, locomotor activity was monitored. Surprisingly,  
Clpp-/- mice displayed decreased locomotor and rearing activity as compared to 
controls primarily during the dark phase (Figure 3.5 A, B). Hence, physical activity is 
not enhanced and thus is not contributing to the increased energy expenditure in CLPP 
Figure 3.4 Loss of CLPP increases energy expenditure. 
(A) Water intake of male Clpp-/- mice and control mice during the light and dark phase (n=7). (B) Food 
intake normalized to lean body mass of control and Clpp-/- mice during the dark and light phase (n=7).  
(C) Respiratory exchange ratio over period of 24 h of control and Clpp-/- mice (n=7). (D) Energy 
expenditure corrected for lean body mass of control and Clpp-/- mice during the dark and light phase (n=7). 
Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
Phenomaster experiments were performed by Steffen Hermans. 
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deficient mice. 
 
 
 
Since Clpp-/- mice exhibit increased energy expenditure during the dark (active) phase, 
when mainly carbohydrates are metabolized, their glucose metabolism was further 
examined. When subjected to insulin tolerance tests, Clpp-/- mice displayed an 
increased insulin sensitivity as compared to control mice (Figure 3.6 A). Notably, the 
insulin concentration had to be reduced to 0.6 U kg-1 body weight (standard 0.75 U kg-1 
BW) due to the hyper responsiveness of CLPP deficient mice. Clpp-/- mice further 
exhibited an improved glucose tolerance (Figure 3.6 B). Hence, both the ability of 
insulin to decrease blood glucose levels and the insulin mediated counter response to 
elevated glucose levels are enhanced in CLPP deficient mice. To further elucidate the 
reason for the enhanced glucose metabolism in Clpp-/- mice, expression levels of the 
insulin dependent glucose transporter 4 (GLUT4) were determined in insulin target 
tissues. GLUT4 was strongly increased in SkM and EWAT of Clpp-/- mice as compared 
to control mice, whereas no change in was observed in BAT (Figure 3.6 C, D). In 
contrast, the abundance of the insulin independent glucose transporter 1 (GLUT1) was 
not changed in liver and SkM tissue (Figure 3.6 E, F). Taken together, CLPP deficient 
mice display an enhanced glucose homeostasis facilitated by increased peripheral 
glucose uptake. 
Figure 3.5 Reduced locomotor and rearing activities in Clpp-/- mice. 
(A) Average activity of Clpp-/- and control mice per hour during light and dark phase (n=7). (B) Rearing 
activity of Clpp-/- and control mice per hour during light and dark phase (n=7). Data are presented as mean 
± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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3.1.3 CLPP deficiency causes a fasting-like phenotype 
To further assess the basal metabolic state in CLPP deficient mice, blood and serum 
parameters were analyzed. Blood glucose levels were measured under fed and fasted 
conditions. In line with previous results, blood glucose levels were significantly reduced 
in Clpp-/- mice as compared to controls in both conditions. Conversely, levels of free 
fatty acids, also called non-esterified fatty acids (NEFA) were not significantly changed 
in male Clpp-/- mice and seem to be increased in female Clpp-/- mice as compared to 
control mice (Figure 3.7 A, B), indicating an increased lipolysis in female Clpp-/- mice. 
Figure 3.6 Improved glucose homeostasis in Clpp-/- mice due to increased peripheral glucose 
uptake. 
(A) Insulin tolerance test was performed on male control and Clpp-/- mice fed NCD (n=10). (B) Glucose 
tolerance test was performed after 6 h fast on male control and Clpp-/- mice fed NCD (n=10). (C) Western 
blot analyses for GLUT4 in CLPP deficient and control SkM, BAT and EWAT tissue lysates (n=4). 
CALNEXIN serves as loading control. (D) Quantification of GLUT4 Western blot analysis. (E) Western blot 
analysis for GLUT1 in CLPP deficient and control liver and SkM tissue lysates. CALNEXIN serves as 
loading control (n=4). (F) Quantification of GLUT1 Western blot analysis. Data are presented as mean ± 
SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). GTTs and ITTs were performed together 
with Katharina Senft. 
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Analysis of further metabolic markers revealed no changes in serum insulin, ghrelin, 
glucagon-like-peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) 
and resistin levels in Clpp-/- mice as compared to control mice in the fed state (Figure 
3.7 C, E, G-I). GIP and GLP-1 are secreted from the intestine upon food ingestion to 
stimulate pancreatic insulin secretion (Baggio and Drucker, 2007). The absence of 
changes in GLP-1 and GIP levels is thus in line with comparable insulin levels in 
control and Clpp-/- mice and further suggests a functional intestinal nutrient absorption. 
Moreover, a significant decrease in leptin levels was observed upon loss of CLPP 
corresponding to the decreased fat mass in Clpp-/- mice (Figure 3.7 D). Leptin is a 
central hormone in the hypothalamic regulation of satiety. Glucagon instead is secreted 
upon fasting to increase blood glucose levels by decreasing glycogen synthesis and 
increasing gluconeogenesis. Accordingly, glucagon levels were increased in Clpp-/- 
mice as compared to controls (Figure 3.7 F). Taken together, these data suggest that 
loss of CLPP leads to a fasting-like phenotype with lower blood glucose levels and 
altered hormone signature. 
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At the tissue level, energy deficiency is sensed by the AMP-activated protein kinase 
(AMPK). AMPK plays a key role in the regulation of glucose and lipid metabolism in 
response to various stimuli as nutrient deprivation. To investigate the energy state at 
the tissue level of Clpp-/- mice, phosphorylation of threonine-172 of AMPKα subunit in 
liver, SkM and EWAT was analyzed. The pAMPK/AMPK ratio was significantly 
increased in SkM of Clpp-/- mice (Figure 3.8 A, B), indicating an energy deficient state 
with increased AMP/ATP ratio. In contrast, no difference was observed for liver and 
EWAT (Figure 3.8 A, B). Thus, the fasting-like phenotype of Clpp-/- mice is also 
associated with AMPK activation in SkM. 
Figure 3.7 Serum parameters of control and CLPP deficient mice. 
(A) Fed and fasted blood glucose levels of control and Clpp-/- mice at 15 weeks of age. (B) Serum non-
esterified fatty acid (NEFA) levels (male n=12, female n=5-6). (C-J) Analysis of serum metabolic markers 
in Clpp-/- and control mice at 16 weeks of age (n=10) (C) Insulin (D) Leptin (E) Ghrelin (F) Glucagon  
(G) Glucose-dependent insulinotropic polypeptide (GIP) (H) Glucagon-like peptide 1 (GLP-1) (I) Resistin  
(J) Plasminogen activator inhibitor-1 (PAI-1). Data are presented as mean ± SD (*P<0.05, **P<0.01, 
***P<0.001; unpaired two-tailed t-test). 
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3.1.4 Lack of CLPP decreases glycogen content in liver and skeletal muscle 
Hepatic and muscle glycogen metabolism are essential for glucose homeostasis and 
represent important energy sources during early starvation and physical exercise. 
Since CLPP deficient mice exhibit increased serum glucagon levels, which is known to 
decrease glycogen synthesis and enhance glucose metabolism, glycogen 
utilization/storage was investigated in CLPP deficient mice in liver and SkM. Notably, 
the glycogen content in liver and SkM was reduced in Clpp-/- mice in comparison to 
control mice as shown by PAS reaction (Figure 3.9). No difference was observed for 
the general morphology of liver and SkM of Clpp-/- mice as revealed by H&E staining of 
histological sections (Figure 3.9). 
 
Figure 3.8 AMPK activation in SkM of CLPP deficient mice. 
(A) Western blot analysis of phosphorylated Thr172 AMPK (pAMPK) and AMPK in liver, SkM and EWAT of 
Clpp-/- mice. CALNEXIN serves as loading control (n=4). (B) Quantification of Western blots in (A) 
presented as ratio of pAMPK and AMPK. Data are presented as mean ± SD (*P<0.05, **P<0.01, 
***P<0.001; unpaired two-tailed t-test). 
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3.1.5 Effect of CLPP deficiency on fatty acid β-oxidation 
Mitochondria are central to fatty acid β-oxidation (FAO). Since CLPP deficient mice 
display decreased fat mass, it was examined whether loss of CLPP affects fatty acid  
β-oxidation. First, β-oxidation was analyzed using [1-14C]-palmitate and measuring the 
incorporation into CO2 and acid soluble metabolites (ASM) in liver, SkM and BAT 
mitochondria. Different than expected the β-oxidation rate was significantly reduced by 
about 25% in liver and SkM of CLPP deficient mice and no significant difference was 
observed for BAT (Figure 3.10 A). 
Second, mitochondrial β-oxidation was analyzed exploiting high-resolution respirometry 
in isolated liver mitochondria in the presence of long chain palmitoylcarnitine (C16) and 
malate. The electrons from β-oxidation are supplied by the electron transferring 
flavoprotein (ETF) to Coenzyme Q. Malate is required to prevent the accumulation of 
acetyl-CoA and replenish CoA (Ojuka et al., 2016). In compliance with the previous 
result of the ex vivo FAO the ADP stimulated respiration on long chain 
palmitoylcarnitine (OXPHOS ETF + CoI) was significantly reduced in CLPP deficient 
mice. However, mitochondria from control and Clpp-/- mice were equally coupled 
(LEAK) and also the maximal capacity of the electron transfer system (ETS) was not 
Figure 3.9 Loss of CLPP decreases glycogen content in liver and SkM. 
Histological analysis of liver and SkM tissue sections. H&E - hematoxylin and eosin staining; PAS - 
periodic acid Schiff’s reaction, assessment of glycogen content; ORO - oil red O staining, assessment of 
neutral lipids (n=4). Scale bar 50 µm. 
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changed (Figure 3.10 B). Remarkably, when substrates feeding electrons to complex I 
and complex II were applied, all respiratory states were unchanged in mitochondria 
from control and Clpp-/- mice, (Figure 3.10 C). Thus, CLPP deficiency leads to 
decreased β-oxidation in liver and SkM, however, mitochondrial respiration is not 
affected in liver mitochondria. 
 
 
 
To gain further insights into the deregulated fatty acid β-oxidation in Clpp-/- mice, 
expression of major enzymes involved in the catabolism of fatty acids were analyzed in 
various metabolic tissues. Mitochondrial fatty acid β-oxidation comprises different steps 
and requires uptake of long chain acyl-CoAs via the carnitine palmitoyltransferase 
system (CPT1, CACT and CPT2) before the β-oxidation involving four mayor enzymes 
acyl-CoA dehydrogenase, enoyl-CoA hydratase, hydroxyacyl-CoA dehydrogenase and 
ketoacyl-CoA thiolase can take place. The acyl-CoA dehydrogenases differ in their 
specificity for very long-, long-, medium- and short-chain acyl-CoAs. 
Comparing the expression profiles of liver, SkM and BAT, the specific downregulation 
Figure 3.10 CLPP deficient mice exhibit decreased FAO in liver and SkM. 
(A) Ex vivo fatty acid oxidation of long chain [1-14C]-palmitate in liver (n=6), SkM (n=6) and BAT (n=5) of 
control and Clpp-/- mice. Data are presented as mean ± SD (*P<0.05; unpaired two-tailed t-test).  
(B-C) Respiratory flux of isolated liver mitochondria in the presence of (B) fatty acid oxidation substrates 
(palmitoylcarnitine and malate) or (C) CoI and CoII substrates (pyruvate, malate, glutamate and succinate) 
OXPHOS - ADP stimulated respiration, LEAK - upon addition of oligomycin and ETS - maximal respiration 
after FCCP titration (n=4). Data are presented as mean ± SD (*P<0.05; paired two-tailed t-test). Ex vivo 
FAO experiments were performed together with Dr. Alexandra Kukat. 
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of the carnitine palmitoyltransferase 2 (CPT2) and striking upregulation of the very long 
chain acyl CoA dehydrogenase (VLCAD) was observed in CLPP deficient mice (Figure 
3.11 A-F), whereas no difference was detected for CPT1A (liver isoform), CPT1M 
(muscle and adipose tissue isoform), MCAD, SCAD and HADHA. In BAT, next to CPT2 
also MCAD was downregulated. Since the liver, SkM and BAT are tissues highly 
dependent on fatty acid oxidation, also WAT depots were examined. WAT contains far 
less mitochondria and the role of fatty acid β-oxidation in this tissue is not very well 
understood, yet it was shown that fasting increases fatty acid oxidation in WAT of 
broiler chicken (Torchon et al., 2017). In both EWAT and IWAT strong upregulation of 
VLCAD was observed, consistent with the data from liver, SkM and BAT, while CPT2 
levels were not altered (Figure 3.12 A-D). Taken together, the changes in proteins 
involved in FAO manifest in decreased rates of fatty acid oxidation in liver and SkM of 
CLPP deficient mice. Furthermore, there are tissue-specific differences in the 
adaptions to the CLPP dependent increase in VLCAD. 
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 Figure 3.11 Profile of FAO enzymes in Clpp-/- mice (1). 
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Figure 3.11 Profile of FAO enzymes in Clpp-/- mice (1). 
Loss of CLPP increases VLCAD steady state levels and decreases CPT2. (A, C, E) Western blot analysis 
of enzymes involved in FAO in (A) liver (C) SkM and (E) BAT lysates. CALNEXIN and ACTIN serve as 
loading controls. (B, D, F) Quantification of Western blots shown in (A, C, E). Data are presented as mean 
± SD (*P<0.05; paired two-tailed t-test). Western Blots were performed together with Katharina Senft. 
 
 
 
 
Since CLPP is a mitochondrial matrix protease, upregulation of a matrix protein in a 
CLPP deficient background is an indication for possible substrate. 
The universal upregulation of VLCAD proposes it as a novel CLPP substrate. To test 
this hypothesis, mRNA levels of Acadvl (gene encoding VLCAD) were analyzed. No 
significant difference at the transcript level, further supports VLCAD as a possible 
Figure 3.12 Profile of FAO enzymes in Clpp-/- mice (2). 
In adipose tissue loss of CLPP increases VLCAD steady state levels (A, C) Western blot analysis of 
enzymes involved in FAO in (A) EWAT and (C) IWAT lysates. CALNEXIN serves as loading control. (B, D) 
Quantification of Western blots shown in (A, C). Data are presented as mean ± SD (*P<0.05; paired two-
tailed t-test).  
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CLPP substrate, indicating that increased VLCAD levels are not due increased gene 
expression, but rather due to increased stability of the protein (Figure 3.13 A). 
Moreover, transcript level analysis of Cpt2 also revealed no significant difference 
(Figure 3.13 A), suggesting that the decreased abundance of CPT2 is not mediated by 
transcriptional repression, rather due to post-transcriptional modification or increased 
protein turnover. 
To further assess whether VLCAD is a putative CLPP substrate, its expression was 
analyzed in immortalized Clpp knockout mouse embryonic fibroblasts (MEFs). CLPP 
dependent upregulation of VLCAD was detected, whereas the counter regulatory 
response of CPT2 downregulation was absent (Figure 3.13 B). 
Clpp knockout MEFs were further used to assess the stability of VLCAD during a 
cycloheximide chase (CHX) experiment. While blocking the cytoplasmic translation 
with cycloheximide and following the turnover, no difference was observed regarding 
the steady state levels of VLCAD in the wildtype or CLPP deficient cells, due to long 
half-life (>12 h) of VLCAD (Figure 3.13 C). Therefore, this method is not sufficient to 
confirm the increased stability of VLCAD in Clpp knockout MEFs. A different approach 
could be the 35S-methionine labeling of proteins and to follow the protein stability after 
immunoprecipitation of VLCAD. These results identify VLCAD as putative CLPP 
substrate and thus propose a role for CLPP in the regulation of fatty acid β-oxidation. 
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3.1.6 Loss of CLPP severely impairs cold tolerance 
Brown adipose tissue is an organ actively contributing to whole body energy 
expenditure. Increased energy expenditure, as observed for Clpp-/- mice, can be 
caused by increased mitochondrial uncoupling due to enhanced adaptive 
thermogenesis. To examine the significance of CLPP deficiency for BAT function, first 
BAT morphology was analyzed. Upon dissection, CLPP deficient interscapular BAT 
was more lipid laden, having a much lighter appearance in contrast to the brown color 
of control BAT (Figure 3.14 A). Histological analysis of H&E stained BAT tissue slides 
confirmed the alterations by the presence of large unilocular lipid droplets in the BAT of 
Clpp-/- mice instead of the classic multilocular lipid droplets as seen in control mice. In 
accordance with these findings ORO staining of neutral lipids showed a slight increase 
and more dense appearance of lipid droplets in BAT of CLPP deficient mice in 
comparison to control mice (Figure 3.14 B). Finally, COX-SDH staining of BAT 
revealed no difference in mitochondrial function of control and Clpp-/- mice. 
Next, thermogenic protein abundance was analyzed in BAT whole tissue lysates. 
Interestingly, gender specific differences could be observed for Clpp-/- mice. While 
UCP1 and TOMM20 levels were not changed in male Clpp-/- mice and only PGC1α 
Figure 3.13 VLCAD is a putative substrate of CLPP. 
(A) Relative expression levels of Acadvl and Cpt2 in liver of control and Clpp-/- mice (n=4). (B) CLPP 
deficient MEFs were cultured and cell lysates were analyzed by Western blot for VLCAD and CPT2 
expression (n=3). CALNEXIN serves as loading control. (C) Cycloheximide (CHX) chase experiment for 
the determination of the stability of VLCAD in the absence of CLPP. Cells were harvested 0, 2, 4, 6, 8, 10 
and 12 h after starting the treatment with CHX and lysed for subsequent Western blot analysis (n=3). 
ACTIN serves as loading control. Data are presented as mean ± SD. Cycloheximide chase assay was 
performed by Dr. Karolina Szczepanowska. 
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levels were increased, an increase in TOMM20, a consistent increase in PGC1α and 
decreased levels of UCP1 were detected in female Clpp-/- mice (Figure 3.14 C, D). 
TOMM20 is an outer mitochondrial membrane protein and can thus not be directly 
linked to mitochondrial mass, since an increase in mitochondrial mass is often 
associated with an increase in mitochondrial size not in number. Whether the reduction 
in UCP1 protein in BAT of female Clpp-/- mice results from a decrease in mitochondrial 
mass in a CLPP dependent manner or from the influence of sex hormones needs to be 
further investigated. It was previously reported about gender related differences in BAT 
thermogenesis in rats in response to cold or diet induced obesity (Rodriguez-Cuenca et 
al., 2002; Rodríguez et al., 2001). 
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To analyze whether the lipid accumulation in combination without altered UCP1 
abundance in BAT of male Clpp-/- mice has an impact on adaptive thermogenesis, 
control and Clpp-/- mice were exposed to 5°C. Basal body temperature at room 
temperature (22°C) was not different between control and CLPP deficient mice (Figure 
3.15 A), indicating functional maintenance of body temperature in Clpp-/- mice. 
Intriguingly, cold exposure induced severe hypothermia in Clpp-/- mice with a body 
temperature drop from 36°C to 27°C within 2 h, whereas the body temperature of 
control mice was only lowered by 2°C to 34°C (Figure 3.15 A). Based on the 
observation that UCP1 levels are not changed in male Clpp-/- mice, yet these mice are 
Figure 3.14 Lipid accumulation in BAT of Clpp-/- mice. 
(A) Gross morphology of BAT of control and Clpp-/- mice. (B) Histological analysis of BAT, H&E - 
hematoxylin and eosin staining; ORO - oil red O staining, assessment of neutral lipids; COX-SDH - 
enzyme histochemical double staining for COX and SDH activities (n=4). Scale bar 50 µm. (C) Western 
blot analysis of thermogenic proteins and mitochondrial mass (TOMM20) in BAT lysates of male and 
female control and Clpp-/- mice. CALNEXIN serves as loading control. (D) Quantification of blots shown in 
(C). Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
Cryosections were done by Steffen Hermans. 
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severely impaired in maintaining body temperature upon cold exposure, it was 
investigated whether UCP1 induction or mitochondrial function is impaired upon cold 
exposure. UCP1 levels examined in isolated BAT mitochondria showed a significant 
reduction in Clpp-/- mice upon cold exposure (Figure 3.15 B). Next, mitochondrial 
complex and supercomplex levels were assessed in cold exposed Clpp-/- mice by BN-
PAGE and subsequent Western blot analysis. At complex level, Clpp-/- mice exhibited a 
severe reduction for CoI, while CoIII and CoIV were less affected. No difference was 
observed for the entirely nuclear-encoded CoII and the levels of CoV were even 
increased in cold exposed Clpp-/- mice as compared to control mice (Figure 3.15 C). 
Similar changes were observed for assembled mitochondrial supercomplexes (Figure 
3.15 D). 
Taken together, loss of CLPP leads to an aberrant BAT morphology due to lipid 
accumulation and leads to an impaired thermogenesis due to decreased UCP1 
induction and severe mitochondrial dysfunction upon cold exposure. The severe 
decrease in mitochondrial complexes especially CoI in BAT of CLPP deficient mice 
does most likely not exclusively result from the short cold exposure (2 h), but rather 
from a further stress induced deterioration of a previous defect. However, whether a 
general reduction of mitochondrial complexes in BAT of Clpp-/- mice is present needs to 
be further investigated.
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3.1.7 Loss of CLPP leads to enhanced browning of WAT 
Another often-disregarded tissue related to energy expenditure is the WAT, since it 
usually exhibits energy storage function. Particularly in mouse models of mitochondrial 
dysfunction it was shown that “browning” of white adipose tissue increases energy 
expenditure (Vernochet et al., 2012). Browning is the emergence of adipocytes with 
brown properties, referred to as beige or brite adipocytes within classical WAT depots 
(Kishida et al., 2015). Therefore, different WAT depots were analyzed from Clpp-/- mice. 
Consistent with the decreased body fat mass, EWAT (visceral) and IWAT 
Figure 3.15 CLPP is essential for cold induced thermogenesis. 
(A) Body temperature of control and Clpp-/- mice exposed to 4°C for 2 h (n=3-4). (B) Western blot analysis 
of thermogenic proteins in mitochondrial lysates from BAT of Clpp-/- and control mice exposed to 4°C for  
2 h. (C-D) BN-PAGE and subsequent Western blot analysis of mitochondrial respiratory chain complexes 
(n=3) (C) and supercomplexes (D) of BAT mitochondria from control and Clpp-/- mice exposed to 4°C for  
2 h. Antibodies against individual complex subunits (indicated in parenthesis) were used for the detection 
of assembled complexes. Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired 
two-tailed t-test). 
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(subcutaneous) depots were smaller in Clpp-/- mice as compared to control  
(Figure 3.16 A) and especially the EWAT displayed more brown-like appearance. This 
was further confirmed upon histological analysis of the fat depots. Adipocyte size of 
EWAT and IWAT was not different between control and Clpp-/- mice, however, in 
EWAT of Clpp-/- mice occasionally regions with brown like morphology were detected 
(Figure 3.16 B). A hallmark of white adipose tissue browning is the increase in 
transcript levels of thermogenic genes, which was also present in EWAT of Clpp-/- 
mice, as shown by increased Ucp1, Dio2 and Cidea mRNA levels (Figure 3.16 C). In 
IWAT of Clpp-/- mice only the increase in Cidea mRNA levels was significantly different 
from control mice. In contrast, corresponding transcript levels in BAT of Clpp-/- mice 
were decreased or not changed (Figure 3.16 C right panel), indicating a whitening of 
the BAT in the absence of CLPP (Shimizu and Walsh, 2015). Thus, it can be 
concluded that Clpp-/- EWAT acquired thermogenic capacity, which might contribute to 
increased energy expenditure of Clpp-/- mice. This effect is not as strong in IWAT of 
Clpp-/- mice and almost reversed for BAT, again indicating tissue-specific differences in 
the consequences of CLPP deficiency. 
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Fibroblast growth factor 21 (FGF21) is an important metabolic hormone secreted upon 
fasting from the liver (Badman et al., 2007; Inagaki et al., 2007). Moreover, FGF21 was 
suggested as a marker for mitochondrial dysfunction that functions as mitokine and 
elicits a global response (Tyynismaa et al., 2010). Given that many of the observed 
phenotypes in Clpp-/- mice resemble those reported for FGF21 transgenic mice with 
hepatic overexpression of FGF21 like reduced body weight, reduced body size, 
enhanced insulin sensitivity, it was investigated whether FGF21 could be mediating the 
phenotype of CLPP deficient mice (Zhang et al., 2012b). Therefore, Fgf21 induction 
was explored at the transcript level in metabolically important tissues. Remarkably, in 
all observed tissues Fgf21 levels were increased at least 3-fold (Figure 3.17 A), 
whereas the strongest increase was found in the heart of Clpp-/- mice. This is in line 
with the highest degree of mitochondrial dysfunction observed in heart of Clpp-/- mice 
Figure 3.16 Browning of WAT in Clpp-/- mice. 
(A) Gross morphology of EWAT and IWAT of control and Clpp-/- mice. (B) Hematoxylin and eosin staining 
of EWAT and IWAT tissue sections (n=7). Scale bar 50 µm. (C) Relative expression of thermogenic genes 
(Ucp1, Cidea, Dio2) in EWAT, IWAT and BAT of control and Clpp-/- mice (n=3). Data are presented as 
mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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(Szczepanowska et al., 2016). The transcriptional increase in Fgf21 was associated 
with 2-fold increase in circulating serum FGF21 (Figure 3.17 B). Hence, increased 
serum FGF21 could facilitate some of the phenotypes observed for CLPP deficient 
mice. 
Transcriptional activation of Fgf21 expression is regulated by ATF4 and PPARα. The 
Fgf21 promoter harbors two PPARα response elements (PPRE) as well as three amino 
acid response elements (AARE) and is directly bound by PPARα and ATF4 (Inagaki et 
al., 2008; Maruyama et al., 2016). Besides an increased Atf4 expression in heart no 
difference in Atf4 and Pparα expression was observed in the other analyzed tissues of 
Clpp-/- mice. In addition, transcript levels of the bZIP transcription factors CHOP and 
ATF5 were assessed. Chop was again only elevated in heart, whereas in all analyzed 
tissues Atf5 was upregulated. Although ATF5 was not reported to induce Fgf21 
expression so far, a recent study analyzing Fgf21 induction in liver in response to 
different diet combinations using microarray data, found the closest correlation of Atf5 
and Fgf21 expression (Solon-Biet et al., 2016). 
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3.2 Phenotype of Clpp-/- mice is independent of FGF21 
To analyze the functional relevance of FGF21 in mediating the phenotype of Clpp-/- 
mice, double deficient mice lacking CLPP and FGF21 (DKO) were generated and as 
control homozygous Clpp (Clpp-/-) and Fgf21 (Fgf21-/-) knockout mice. Many of the 
observed phenotypes for Clpp-/- mice are in accordance with Fgf21 overexpression or 
pharmacological effects of FGF21 treatment. Unexpectedly, despite the loss of Fgf21 
(Figure 3.18 B) the phenotype of DKO mice was almost identical to Clpp-/- mice. The 
body weight gain of DKO mice was similar to Clpp-/- mice till 15 weeks of age (Figure 
3.18 A) and Fgf21-/- mice only slightly deviate from the weight curve of the wildtype 
control animals. Furthermore, FGF21 is not involved in the regulation of the fat 
metabolism in Clpp-/- mice. Both genotypes, Clpp-/- and DKO mice had a similar body 
Figure 3.17 Systemic induction of Fgf21 and increased circulating levels in Clpp-/- mice. 
(A) Relative expression of Fgf21 in liver, SkM, heart, BAT, EWAT and IWAT (n=4). (B) Circulating serum 
levels of FGF21 in control and CLPP deficient mice (male n=10, female n=4). (C) Atf4, Atf5 and Chop 
expression levels in liver, SkM, Heart and for BAT only Atf5 (n=4). (D) Relative expression of Pparα and 
Pparγ in all metabolically relevant tissues (n=4). Data are presented as mean ± SD (*P<0.05, **P<0.01, 
***P<0.001; unpaired two-tailed t-test). 
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fat mass, although fat mass of FGF21 deficient mice was significantly increased as 
compared to control mice (Figure 3.18 C). Thus, endogenous FGF21 only has a 
negligible role in regulating body weight and fat mass in Clpp-/- mice. 
Since FGF21 was further shown to blunt growth hormone action and thereby reduce 
longitudinal growth (Inagaki et al., 2008; Wu et al., 2013), femur lengths were 
measured to determine whether endogenous FGF21 in Clpp-/- mice is responsible for 
the growth retardation. From visible inspection of the DKO mice it was already 
apparent that despite loss of FGF21 action, these mice are indistinguishable from Clpp-
/- mice. This relates well with equivalent femur lengths of Clpp-/- and DKO mice (Figure 
3.18 D). Hence, the growth defect in Clpp-/- mice is independent of FGF21. To decipher 
whether FGF21 serves as a cell autonomous stress response to enhance 
mitochondrial function (Ji et al., 2015), mitochondrial complex levels were examined in 
liver tissue. However, mitochondrial complex as well as supercomplex levels did not 
differ between all four groups (Figure 3.18 E, F). Albeit of similar mitochondrial complex 
levels, increased levels of LONP1 and TFAM were observed in DKO mice, indicating a 
possible induction of UPRmt and increased mitochondrial mass (Figure 3.19). To 
conclude, FGF21 has a dispensable function for the systemic metabolic adaptions of 
Clpp-/- mice. 
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Figure 3.18 Loss of FGF21 in CLPP deficient mice does not normalize whole body physiology. 
(A) Body weight of male control mice, Clpp-/-, Fgf21-/-, and DKO mice (n=6-10) was monitored till 15 weeks 
of age on normal chow diet (NCD). (B) Relative Fgf21 transcript levels in liver of control, Clpp-/-, Fgf21-/- 
and DKO mice (n=4). (C) Body fat mass of control, Clpp-/-, Fgf21-/- and DKO mice fed NCD determined by 
NMR (n=8). (D) Femur length of control, Clpp-/-, Fgf21-/- and DKO mice (n=5-7). (E, F) BN-PAGE and 
subsequent Western blot analysis of mitochondrial complexes (E) and mitochondrial respiratory 
supercomplexes (F) of liver mitochondria from control, Clpp-/-, Fgf21-/- and DKO mice (n=3). Antibodies 
against individual complex subunits (indicated in parenthesis) were used for the detection of assembled 
complexes. Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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3.3 Tissue-specific disruption of Clpp 
In order to dissect the role of CLPP in different tissues and to elucidate the contribution 
of CLPP deficiency in individual organs to the whole body metabolism, two tissue-
specific mouse models were generated: 
(I) by ablating Clpp expression in liver using transgenic mice expressing Cre 
recombinase under control of the albumin enhancer and promoter and the  
α-fetoprotein enhancer (Afp-Cre) and 
(II) by disrupting the Clpp gene in heart and skeletal muscle by mating Clppfl/fl 
mice with mice expressing Cre from the muscle creatine kinase promoter 
(Ckmm-Cre). 
 
3.3.1 Liver restricted loss of CLPP does not affect body weight and glucose 
homeostasis 
CLPP ablation in liver was mediated by Cre recombinase under control of the albumin 
promoter and enhancer and the α-fetoprotein enhancer to produce Clppflox/flox, +/Afp-Cre 
mice, denoted as ClppLKO. The liver is composed of different cell types; hepatocytes 
are the most abundant cells with about 80%, Kupffer cells, Ito cells, endothelial cells 
and biliary duct cells. The albumin promoter is fully active before embryonic day 10.5 
(E10.5) in hepatocytes and biliary duct cells (Kellendonk et al., 2000). First, the 
complete loss of CLPP in the target tissue was confirmed at 15 weeks of age. Although 
not all liver cell types were targeted, no residual CLPP was observed (Figure 3.20 A). 
CLPP abundance in peripheral tissue (SkM) was not affected (Figure 3.20 A). In 
contrast to full body Clpp-/- mice, ClppLKO and respective control mice were born at the 
expected Mendelian ratio, were fertile and did not display any signs of growth 
retardation (data not shown). 
Figure 3.19 FGF21 deletion in CLPP deficient liver alters LONP1 and TFAM abundance. 
Western blot analysis of various proteins in liver tissue. CALNEXIN is used as loading control (n=3). 
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To investigate whether mitochondrial dysfunction due to CLPP deletion in liver is 
sufficient to alter whole body metabolism, body weight of ClppLKO and Clppfl/fl control 
mice was monitored. No significant difference in body weight was detected for males 
fed NCD until 15 weeks of age (Figure 3.20 B). Furthermore, glucose homeostasis of 
liver-specific Clpp mice was analyzed by glucose and insulin tolerance tests at 15 and 
16 weeks of age, respectively. Consistent with the unaltered body weight, the insulin 
sensitivity and glucose tolerance was not altered in ClppLKO mice as compared to 
control mice (Figure 3.20 C, D). 
 
.
 
 
3.3.2 Liver restricted loss of CLPP alters FAO enzyme levels and leads to 
moderate mitochondrial dysfunction 
Given the absence of a whole body phenotype of ClppLKO mice, it was investigated 
whether liver-specific loss of CLPP causes tissue-specific alterations at the molecular 
level. First, the expression profile of FAO enzymes was examined in liver and SkM 
tissue lysates, SkM serving as negative control. Identical to full body Clpp knockout 
Figure 3.20 Liver restricted loss of CLPP does not alter body weight and glucose homeostasis. 
(A) Western Blot analysis of CLPP levels in liver and SkM of control (Clppfl/fl) and ClppLKO mice. 
CALNEXIN serves as loading control (n=3). (B) Body weight of male control mice and ClppLKO mice (n=7) 
was monitored till 15 weeks of age on normal chow diet (NCD). (C) Insulin tolerance test was performed 
on male control and ClppLKO mice fed NCD (n=6). (D) Glucose tolerance test was performed after 6 h fast 
on male control and ClppLKO mice fed NCD (n=6). Data are presented as mean ± SD. GTT and ITT were 
performed together with Katharina Senft. 
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mice, the ClppLKO mice present decreased CPT2 and increased VLCAD levels in liver, 
while the levels in SkM were not changed for CPT2 and downregulated for VLCAD in 
the presence of CLPP (Figure 3.21 A), thus further supporting VLCAD as possible 
CLPP substrate. 
Next, mitochondrial complex levels were evaluated in liver of ClppLKO and control mice. 
Deletion of hepatic CLPP results in decreased levels of assembled respiratory 
supercomplexes, while monomers or dimers of CoIII and CoIV, CoII and CoV were not 
altered (Figure 3.21 B). Thus, it can be suggested that mostly CoI and CoI-enclosing 
supercomplexes are affected by the absence of CLPP. Although the liver is an 
important organ contributing to whole body energy expenditure and glucose 
homeostasis, ablation of CLPP in liver does not alter body weight and glucose 
homeostasis, despite moderate hepatic mitochondrial dysfunction. 
 
 
 
3.3.3 CLPP ablation in skeletal muscle and heart does not alter body weight 
and glucose homeostasis 
Whole body loss of CLPP causes a substantial alteration of whole body energy 
metabolism. To elucidate the contribution of muscle tissue to this phenotype, CLPP 
was selectively ablated in heart and SkM. Therefore, Clppfl/fl mice were mated with 
Figure 3.21 Hepatic deficiency of CLPP causes mitochondrial dysfunction and similar FAO profile 
as observed for Clpp-/- mice. 
(A) Western blot analysis of CPT2 and VLCAD in liver tissue lysates of control and ClppLKO mice (n=3).  
(B) BN-PAGE and subsequent Western blot analysis of mitochondrial respiratory chain supercomplexes of 
liver mitochondria from Clppfl/fl and ClppLKO mice (n=6). Antibodies against individual complex subunits 
(indicated in parenthesis) were used for the detection of assembled supercomplexes. 
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mice expressing Cre recombinase under control of the creatine kinase promoter 
(Ckmm-Cre). The promoter is fully active in skeletal muscle and heart after embryonic 
day 15.5 (E15.5) (Lyons et al., 1991). Cre expression induced a selective disruption of 
the Clpp gene in SkM and heart of ClppMKO mice as evidenced by Western blot 
analysis at 15 weeks of age (Figure 3.22 A). Liver extracts were used as negative 
control. In line with the liver-specific Clpp knockout mice, ClppMKO were also born in the 
expected Mendelian proportions without any visible defects and further ClppMKO were 
fertile. Again the body weight was followed for ClppMKO and control mice (Clppfl/fl) fed 
NCD, to investigate the impact of muscle-specific CLPP deficiency on whole body 
metabolism. Both genotypes exhibited a similar weight gain reaching approximately  
27 g body weight at the age of 15 weeks (Figure 3.22 B). To examine if the glucose 
homoeostasis is still enhanced, while CLPP is merely ablated in muscle tissue, glucose 
and insulin tolerance tests were conducted. However, insulin sensitivity and glucose 
tolerance in ClppMKO mice was indistinguishable from control animals (Figure 3.22 C, 
D). 
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3.3.4 Muscle restricted loss of CLPP induces FAO oxidation profile and causes 
mitochondrial dysfunction 
To complement the analysis of VLCAD and CPT2 protein abundance, SkM, heart and 
liver were analyzed in ClppMKO and control mice. Consistently, VLCAD levels were 
increased in the absence of CLPP in SkM and heart of ClppMKO mice and CPT2 was 
downregulated, while the abundance of both proteins was similar in liver (Figure 3.23 
A). If this finding has functional implications and leads to reduced fatty acid β-oxidation 
needs to be further addressed. 
CLPP ablation in liver resulted in specific decrease of mitochondrial supercomplexes, 
most likely due to decreased levels of CoI. Thus, it was analyzed whether muscle 
mitochondrial complexes are affected in a similar manner by loss of CLPP. 
Interestingly, in SkM of ClppMKO a decrease in supercomplex levels was only apparent 
when probing with a CoI specific antibody (NDUFA9) (Figure 3.23 B, left panel). 
Supercomplex levels were not changed when antibodies against CoIII (UQCRC1) or 
CoIV (COXI) were used for immunodetection (Figure 3.23 B, left panel). Instead, liver 
Figure 3.22 Skeletal muscle and heart restricted loss of CLPP does not alter body weight and 
glucose homeostasis. 
(A) Western Blot analysis of CLPP levels in SkM, heart and liver of control mice (Clppfl/fl) and ClppMKO 
mice. CALNEXIN serves as loading control (n=4). (B) Body weight of male control mice and ClppMKO mice  
(n=6-7) was monitored till 15 weeks of age on normal chow diet (NCD). (C) Insulin tolerance test was 
performed on male control and ClppMKO mice fed NCD (n=6). (D) Glucose tolerance test was performed 
after 6 h fast on male control and ClppMKO mice fed NCD (n=6). GTT and ITT were conducted together 
with Katharina Senft. 
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mitochondrial complex assembly and steady state levels were comparable between 
ClppMKO and control mice. These results favor the assumption that there are no cell 
autonomous effects, nonetheless, relative Fgf21 expression was determined in SkM 
and liver tissue. In line with the mitochondrial dysfunction, SkM of ClppMKO exhibit 
increased Fgf21 transcript levels as compared to Clppfl/fl mice (Figure 3.23 C). 
 
 
 
3.3.5 ClppMKO mice exhibit functional shivering activity 
Heat production is acquired by either shivering thermogenesis mediated by the SkM or 
non-shivering thermogenesis facilitated by BAT (Cannon and Nedergaard, 2010). 
Conventional whole body deletion of CLPP strongly impairs thermogenesis. Impaired 
Figure 3.23 Muscle deficiency of CLPP causes mitochondrial dysfunction and similar FAO profile 
as observed for Clpp-/- mice. 
(A) Western blot analysis of CPT2 and VLCAD in SkM, heart and liver tissue lysates of control and 
ClppMKO mice (n=3). (B) BN-PAGE and subsequent Western blot analysis of mitochondrial respiratory 
chain supercomplexes of SkM mitochondria from Clppfl/fl and ClppMKO mice (n=6). Antibodies against 
individual complex subunits (indicated in parenthesis) were used for the detection of assembled 
supercomplexes. (C) Fgf21 expression levels in SkM and liver of Clppfl/fl and ClppMKO mice (n=3-4). Data 
are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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BAT function has been shown for Clpp-/- mice, however, it is not known to which extent 
shivering thermogenesis is affected. Thus, ClppMKO mice were cold exposed to test 
whether loss of CLPP in muscle impairs shivering thermogenesis. The resting body 
temperature of control and ClppMKO mice was not different (t=0) and also upon cold 
exposure both genotypes were equally capable in maintaining body temperature during 
the 7 h cold exposure (Figure 3.24 A). Hence, ClppMKO mice display comparable 
shivering capacity and endurance than control mice. To exclude a compensatory 
increase of non-shivering thermogenesis in BAT of ClppMKO mice, UCP1 was analyzed 
in BAT tissue lysates. UCP1 levels were decreased in BAT lysates of ClppMKO mice, 
thus omitting increased non-shivering thermogenesis as a compensatory mechanism 
(Figure 3.24 B). The nature of decreased UCP1 expression needs to be further 
investigated, since PGC1α levels were not changed, indicating no increase or 
decrease in mitochondrial biogenesis and therefore most likely also no change in 
mitochondrial mass. 
Taken together, these data demonstrate, that tissue-specific loss of CLPP despite 
causing a tissue-restricted mild to moderate mitochondrial dysfunction, does not affect 
whole body metabolism. 
 
 
 
3.4 High fat feeding impairs hepatic mitochondrial translation in the 
absence of CLPP 
3.4.1 Clpp-/- mice maintain lean phenotype and enhanced glucose metabolism 
during HFD-feeding 
To examine how CLPP deficient mice are able to cope with metabolic stress, Clpp-/- 
mice and control mice were fed high fat diet (HFD) providing 60% calories from fat 
(lard) from 8 weeks of age for a period of 8 weeks. CLPP ablated mice gained 
Figure 3.24 Cold induced adaptive thermogenesis is not impaired in ClppMKO mice. 
(A) Body temperature of Clppfl/fl and ClppMKO exposed to 4°C for 7 h (n=3-4). (B) Western blot analysis of 
thermogenic proteins in BAT lysates of ClppMKO and control mice exposed to 4°C for 7 h (n=3). 
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significantly less weight in comparison to control mice irrespective of the gender 
(Figure 3.25 A, B). After 3 weeks on HFD the difference in body weight accounted for 
35% and increased to 45%-50% after 7 weeks on HFD. Therefore, all subsequent 
experiments were performed at the age of 15-16 weeks after 8 weeks on HFD. First, 
the effect of HFD-feeding on the enhanced glucose homeostasis of Clpp-/- was 
investigated. In accordance with the preserved lean phenotype, the enhanced insulin 
sensitivity and glucose tolerance was retained in CLPP deficient mice as compared to 
control. Blood glucose levels of control mice were only marginally reduced by insulin 
(Figure 2.25 C), pointing out an insulin resistant state. To link the enhanced glucose 
metabolism with insulin signaling, the levels of insulin-stimulated phosphorylation of 
AKT and GLUT1 was analyzed in liver tissue. No difference was observed in the 
insulin-stimulated AKT phosphorylation and GLUT1 levels between Clpp-/- and control 
mice. However, a strong increase was observed for Clpp-/- mice when comparing basal 
(NaCl injected) and stimulated pAKT levels (insulin injected) (Figure 3.25 E, F), 
whereas there was no difference for control mice. This finding supports the result of the 
ITT, confirming the HFD induced insulin resistant state of control mice, while Clpp-/- 
mice remain insulin sensitive. 
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To further corroborate the resistance to diet induced obesity of Clpp-/- mice serum 
parameters were analyzed. As it was revealed for the NCD, non-fasting and fasting 
blood glucose levels of Clpp-/- mice were also significantly lower during HFD-feeding. In 
addition, HFD exposure induced a strong increase in insulin and leptin in control mice, 
Figure 3.25 Loss of CLPP protects against HFD induced obesity. 
(A) Body weight of male control and Clpp-/- mice was monitored till 15 weeks of age fed HFD from 8 weeks 
of age. Arrow indicates start of HFD. (B) Body weight of female control and Clpp-/- mice was monitored till 
15 weeks of age fed high fat diet. (C) Insulin tolerance test was performed with 15-week-old control mice 
and Clpp-/- mice after 7 weeks on HFD. (D) Glucose tolerance test was performed after 6 h fast with  
16-week-old control mice and Clpp-/- mice after 8 weeks on HFD. (E) Western blot analysis of 
phosphorylated and total AKT in liver tissue lysates of control and Clpp-/- mice, which were fasted for 2 h 
and then insulin-stimulated for 30 min (-/+). CALNEXIN serves as loading control. (F) Quantification of 
Western blots shown in (E). Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired 
two-tailed t-test). GTT, ITT and Insulin signaling experiment were performed together with Dr. Alexandra 
Kukat. 
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whereas Clpp-/- mice displayed levels comparable to NCD conditions (Figure 3.26 B, 
C). Further, increased levels of ghrelin and glucagon were obtained for Clpp-/- mice, 
thus demonstrating an augmentation of the fasting-like phenotype previously observed 
during NCD feeding (Figure 3.26 D, E). In line with reduced insulin levels, GIP serum 
levels were also decreased in Clpp-/- mice although GLP-1 was not distinctive between 
control and CLPP deficient mice (Figure 3.26 F, G). Resistin is secreted from 
adipocytes and links obesity and insulin resistance (Steppan et al., 2001). In 
agreement with this, Clpp-/- mice exhibit lower levels of resistin compared to control 
mice fed HFD (Figure 3.26 H). Taken together, HFD-feeding affirms the fasting-like 
phenotype of Clpp-/- mice. 
 
 
 
 
Figure 3.26 Serum parameters of control and CLPP deficient mice fed HFD. 
(A) Fed and fasted blood glucose levels of control and Clpp-/- mice at 15 weeks of age after 7 weeks on 
HFD. (B-I) Analysis of serum metabolic markers in Clpp-/- and control at 16 weeks of age (B) Insulin  
(C) Leptin (D) Ghrelin (E) Glucagon (F) Glucose-dependent insulinotropic polypeptide (GIP) (G) Glucagon-
like peptide 1 (GLP-1) (H) Resistin (I) Plasminogen activator inhibitor-1 (PAI-1). Data are presented as  
mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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Since the uptake of excess nutrients leads to lipid accumulation not only in adipose 
tissue but also in liver, it was investigated whether loss of CLPP protects against HFD 
induced lipid accumulation. Whereas control mice fed HFD exhibit a clear hypertrophy 
of adipocytes of the EWAT, Clpp-/- mice failed to accumulate lipids relative to NCD fed  
Clpp-/- mice (Figure 3.27). In contrast, for the subcutaneous adipose depot no 
difference was observed and the lipid accumulation in BAT of Clpp-/- mice was 
deteriorated by HFD- feeding. For liver no significant difference was observed for the 
lipid accumulation based on the histological analysis (Figure 2.27). 
 
 
 
Considering the decreased FAO rate in liver of Clpp-/- mice fed NCD and the similar 
liver morphologies of control and Clpp-/- mice fed HFD, the question arose whether the 
FAO gene expression profile would have changed due to the change in diet. 
Interestingly, HFD-feeding increased CPT2 abundance in CLPP deficient liver to a 
similar level of control mice (Figure 3.28 A, B). As expected for a putative CLPP 
substrate, VLCAD expression was not changed by the HFD treatment and was 3-fold 
increased in Clpp-/- mice as previously revealed for the NCD. Thus, it can be concluded 
that due to the increased VLCAD protein levels in Clpp-/- mice, CPT2 is regulated 
dependent on the metabolic requirements. 
 
Figure 3.27 Clpp-/- mice are protected against HFD induced hypertrophy of EWAT. 
Histological analysis of EWAT, IWAT, BAT and liver tissue of control and Clpp-/- mice on HFD-feeding 
(n=4). Scale bar 50 µm. 
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3.4.2 Label-free quantitative proteomic profiling of liver reveals deregulated 
OXPHOS subunit levels due to HFD-feeding upon loss of CLPP 
Mass spectrometric analysis of liver tissue was performed to establish a 
comprehensive map of protein abundance to understand the impact of loss of CLPP 
during NCD or HFD-feeding. Using label-free quantitative proteomics it was possible to 
quantify a total of 1050 proteins of which 278 were annotated mitochondrial proteins. 
The approach applied (4h gradient) generally recovers between 4000 and 5000 
proteins. The low recovery observed here was due to low resolution of the mass 
spectrometric device and the requirement that peptides were quantified in at least three 
samples out of four (NCD) or five (HFD). Proteins were considered significantly 
deregulated for p-values <0.05 (-log p-value >1.3) and a false discovery rate (q-value) 
of 0.1. In liver of NCD fed Clpp-/- mice only 17 proteins were found to be differently 
abundant as compared to NCD fed control mice (Figure 3.29 A), which is in line with 
previous experiments, which showed that the phenotype of liver tissue was not much 
changed by loss of CLPP. Proteins, which were significantly changed in abundance, 
are involved in the following processes; protein folding, mitochondrial transcription and 
translation and TCA cycle. An increase in the mitochondrial chaperones TRAP1, 
Figure 3.28 CPT2 is upregulated upon HFD-feeding in Clpp-/- mice. 
(A) Western blot analysis of CPT2 and VLCAD in liver of control and Clpp-/- mice at 5 weeks of age, fed 
NCD or HFD (n=3). HSC70 serves as loading control. (B) Quantification of CPT2 and VLCAD Western 
blots shown in (A). Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed 
t-test). 
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mtHSP70 and GRPEL1 indicates a mildly disturbed mitochondrial proteome in liver of 
Clpp-/- mice. LRPRRC, EFG1 and OGDH are putative CLPP substrates involved in 
mitochondrial transcription, translation and TCA cycle and were elevated in the 
absence of CLPP, as we previously published for heart mitochondria (Szczepanowska 
et al., 2016). Loss of CLPP during HFD-feeding leads to more pronounced proteomic 
changes in the liver with a total of 128 proteins changed in relative abundance (Figure 
3.29 B). The most affected biological processes are identical to the NCD, however, in 
addition OXPHOS was strongly affected. Both nuclear- and mitochondrial-encoded 
respiratory chain subunits were upregulated or downregulated due to the loss of CLPP 
only during HFD-feeding with predominantly altered CoI subunits. Moreover, almost 
every enzyme of the TCA cycle was found to be increased or decreased in CLPP 
ablated liver confirming previous results (Fischer et al., 2015). Interestingly, 18 proteins 
of the large (60S) and small (40S) cytosolic ribosomal subunits were downregulated in 
liver of HFD fed Clpp-/- mice, most likely due to a secondary effect. Taken together, 
liver proteomic analysis revealed only minor changes of the liver proteome due to loss 
of CLPP during NCD conditions, which correlates with previous results, whereas HFD-
feeding in the absence of CLPP strongly affects OXPHOS subunits. 
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3.4.3 Loss of CLPP during HFD-feeding leads to strong decrease only in 
hepatic mitochondrial respiratory chain complexes 
Proteomic analysis disclosed changes in hepatic mitochondrial OXPHOS subunit levels 
in response to HFD-feeding in the absence of CLPP. To assess whether these 
changes impair mitochondrial function, assembly of mitochondrial complexes was 
investigated in liver mitochondria of NCD and HFD fed mice. BN-PAGE analysis 
demonstrates that lack of CLPP only had a minor effect on complex and supercomplex 
Figure 3.29 Quantitative assessment of liver proteomes of CLPP deficient mice fed NCD or HFD. 
Proteins were quantified by label-free proteomic analysis. (A-B) Volcano plots of differential abundance of 
liver proteins between Clpp-/- and Clpp+/+ NCD (A) and Clpp-/- and Clpp+/+ HFD (B) (n=4). Proteins are 
plotted according to statistical significance (−log10 p-value) and relative abundance (log2 fold change) 
(FDR<0.1). 
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levels under NCD, while having a profound effect on the levels of CoI, CoIII and CoIV 
comprising supercomplexes upon HFD (Figure 3.30 A). Notably, almost no difference 
was observed for CoIV monomers, CoIII and CoIV dimers, CoII and CoV complexes, 
suggesting CoI to be the primary cause for the decreased supercomplexes. Thus, loss 
of CLPP during HFD-feeding severely impairs OXPHOS integrity. 
A similar dietary intervention to HFD-feeding with a large proportion of dietary fat is the 
maternal lactation period during the first weeks after birth. Maternal milk contains 
roughly 29.8% fat compared to 34% crude fat in the HFD, that corresponds to 53% and 
60% calories provided from fat during lactation and HFD, respectively (Görs et al., 
2009). Thus, it was analyzed if maternal lactation has the same effect as HFD-feeding 
upon loss of CLPP in liver. To do so, liver mitochondria of 5-week-old CLPP deficient 
and control mice were used for the examination of complex levels. Mitochondrial 
supercomplex levels were decreased to the same extent as shown for liver 
mitochondria of HFD fed Clpp-/- mice (Figure 3.30 B). Thus, it can be concluded that 
loss of CLPP during metabolic challenging conditions like HFD-feeding or during 
lactation is detrimental for mitochondrial supercomplex abundance. Although, the 
levels of assembled complexes haven’t been analyzed in the liver it can be assumed 
that they would also be reduced during HFD-feeding as it was observed for loss of 
CLPP in heart mitochondria under NCD conditions (Szczepanowska et al., 2016). 
 
 
  
Figure 3.30 High dietary fat content causes mitochondrial dysfunction in liver. 
(A-B) BN-PAGE and subsequent Western blot analysis of mitochondrial supercomplexes of liver 
mitochondria from control and Clpp-/- mice fed either NCD or HFD (A) and 5-week-old Clpp-/- mice and 
controls (B) (n=3). Antibodies against individual complex subunits (indicated in parenthesis) were used for 
the detection of assembled complexes. 
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To distinguish whether an assembly defect or decreased abundance of individual 
complex subunits during metabolic stress conditions could account for the observed 
phenotype, steady state levels of several mitochondrial complex subunits were 
assessed. On NCD, CLPP deficient liver displayed decreased levels of mitochondrial 
complex subunits for two out five analyzed CoI subunits, ND1 (mitochondrial-encoded) 
and NDUFS2 (nuclear-encoded)(Figure 3.31 A, C). In addition, CoIII subunits 
(UQCRC1 and UQCRFS1) and the mitochondrial-encoded CoIV subunit COXI were 
decreased. In contrast, steady state levels of SDHA and ATP5A were increased in 
Clpp-/- liver mitochondria (Figure 3.31 A, C). Certainly, HFD-feeding had an even 
stronger influence on the level of complex subunits when CLPP was lost. The levels of 
ND1 and NDUFS2 were further reduced and in addition also the CoI subunits NDUFA9 
and NDUFB6 were decreased in the absence of CLPP (Figure 3.31 A, D). 
Furthermore, steady state levels of two CoIV subunits, COXII (mitochondrial-encoded) 
and COXIV (nuclear-encoded) were reduced in CLPP deficient liver mitochondria of 
HFD fed mice. Unlike on NCD, CoIV subunit COXI was not decreased in HFD CLPP 
deficient liver mitochondria. Similar to the HFD data, CoI mitochondrial subunits were 
strongly decreased in liver mitochondria isolated from 5-week-old Clpp-/- mice. Besides 
the CoI subunits, only the CoIII subunit UQCRFS1 was downregulated in CLPP 
deficient liver mitochondria at the age of 5 weeks (Figure 3.31 B, E). Hence, the 
decreased assembled supercomplexes during HFD-feeding and after lactation are 
resulting from diminished individual complex subunits, in particular of CoI. 
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Figure 3.31 Decreased steady state levels of mitochondrial and nuclear-encoded complex I
subunits in 5-week-old and HFD fed Clpp-/- mice. 
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Figure 3.31 Decreased steady state levels of mitochondrial and nuclear-encoded complex I 
subunits in 5-week-old and HFD fed Clpp-/- mice. 
(A) Western blot analysis of individual complex subunits in liver mitochondria of 15-week-old NCD and 
HFD diet fed control and Clpp-/- mice. Left panel - complex I subunits, right panel - other complex subunits  
(n=3-6). (B) Western blot analysis of individual complex subunits in liver mitochondria of 5-week-old 
control and Clpp-/- mice (n=3). VDAC serves as loading control. (C) Quantification of relative mitochondrial 
complex subunit levels in liver of control and Clpp-/- mice fed NCD. (D) Quantification of relative 
mitochondrial complex subunit levels in liver of control and Clpp-/- mice fed HFD. (E) Quantification of 
relative mitochondrial complex subunit levels in liver of control and Clpp-/- mice at 5 weeks of age. Data are 
presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
 
 
Having found this effect in liver, it was examined whether this response to HFD is 
conserved and is likewise present in SkM. Therefore, SkM muscle mitochondria from 
NCD and HFD fed Clpp-/- mice and control mice were analyzed for levels of respiratory 
supercomplexes and the levels of individual complex subunits. Strikingly, reduction of 
mitochondrial supercomplexes and complexes was not differently affected by either 
NCD or HFD-feeding upon loss of CLPP (Figure 3.32 A). The same could be observed 
for heart mitochondria (personal communication with Dr. Karolina Szczepanowska). To 
confirm this finding the levels of individual mitochondrial complex subunits were 
determined in SkM mitochondria. There was not a consistent tendency for the different 
complex subunits evident, since some subunits were decreased, whereas others were 
not changed (Figure 3.32 B, C). Hence, HFD-feeding does not affect SkM and heart 
mitochondrial complex levels upon loss of CLPP. Since SkM mitochondria do not 
display the differential response to HFD due to loss of CLPP, the further analysis 
focused on liver. 
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3.4.4 Decreased hepatic mitochondrial complex subunits in HFD fed Clpp-/- 
mice are not caused by increased turnover 
CLPP was previously shown to have a function in mitochondrial translation in heart 
(Szczepanowska et al., 2016). Therefore, the reduced levels of mitochondrial 
respiratory complex subunits in CLPP deficient liver could likewise result from impaired 
mitochondrial translation and a consequential imbalance of nuclear-encoded subunits. 
To exclude other mechanisms of being involved, it was first analyzed whether 
decreased complex subunits result from increased turnover by the protein quality 
control machinery. Since only few mitochondrial complex subunits are known targets of 
Figure 3.32 Complex composition is not affected by HFD-feeding in CLPP deficient SkM 
mitochondria. 
(A) Mitochondrial supercomplex levels in SkM mitochondria of control and Clpp-/- mice fed NCD or HFD 
assessed by BN-PAGE and subsequent Western blot analysis. Antibodies against individual complex 
subunits (indicated in parenthesis) were used for the detection of assembled complexes. (B) Western blot 
analysis and (C) relative quantification of individual mitochondrial respiratory complex subunits in SkM 
mitochondria (n=3). VDAC serves as loading control. Data are presented as mean ± SD (*P<0.05, 
**P<0.01, ***P<0.001; one-way ANOVA, Tukey’s post hoc test). 
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the m-AAA protease (Edgar et al., 2009; Hornig-Do et al., 2012), AFG3L2 and also 
LONP1 and mtHSP70 levels were examined in liver mitochondrial lysates. However, 
AFG3L2 was decreased in liver of Clpp-/- mice fed NCD compared to control mice and 
the levels were further decreased in Clpp-/- mice when fed HFD, whereas AFG3L2 
levels of control mice did not differ between NCD and HFD (Figure 3.33 A). No 
significant difference was observed for LONP1 between control and Clpp-/- mice fed 
either NCD or HFD, yet LONP1 levels increased for both genotypes on HFD as 
compared to NCD. For the mitochondrial chaperone mtHSP70 increased levels were 
observed in CLPP deficient liver mitochondria only on NCD, whereas no difference was 
observed for control and Clpp-/- mice on HFD (Figure 3.33 A). Since the proteomic 
analysis of liver tissue revealed an increase of mtHSP70 for Clpp-/- mice in both dietary 
conditions, there seems to be a biogenesis effect. Thus, the decreased levels of 
mitochondrial complex subunits are most likely not a result of increased turnover or 
impaired folding. 
To explore whether increased mitochondrial biogenesis could contribute to the 
reduction of mitochondrial complex subunits, the steady state levels of biogenesis-
related transcription factors and markers of mitochondrial mass were analyzed in liver 
tissue lysates. Both markers of mitochondrial content (VDAC and TOMM20) as well as 
transcription factors TFAM and PGC1α were significantly increased upon loss of CLPP 
during HFD-feeding in liver tissue as compared to HFD fed control mice (Figure 3.33 C, 
D), indicating an increased mitochondrial content in CLPP deficient liver during HFD-
feeding. This finding was confirmed by ultrastructural analysis of liver tissue from 
control and Clpp-/- mice. Mitochondrial morphology and number were not different 
between control and Clpp-/- mice on NCD. A strong difference in mitochondrial number 
was apparent for HFD fed control and Clpp-/- mice (Figure 3.33 G). Thus, it is possible 
that due to the increased mitochondrial biogenesis/mass the mitochondrial protein 
synthesis is not able to meet the requirements. Hence, loss of CLPP during metabolic 
challenging conditions like HFD induces mitochondrial biogenesis to compensate the 
energy deficiency due to the mitochondrial dysfunction. 
Mitochondrial dynamics are implicated to play a role in adaptions to different energy 
states. Mitochondrial fusion is supposed to function as a repair mechanism, by allowing 
content mixing and preventing mitophagy (Gomes et al., 2011). Thus, it was analyzed 
whether altered mitochondrial fusion is contributing to the observed phenotype. No 
significant differences were observed for the abundance of OPA1, MFN1 and MFN2 in 
between control and CLPP depleted liver mitochondria of NCD or HFD fed mice 
(Figure 3.33 E, F). Notably, all fusion proteins were increased in HFD fed control and 
Clpp-/- mice, indicating an increased need for fusion mediated quality control.  
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Taken together, these data demonstrate that decreased mitochondrial complex 
subunits in Clpp-/- mice upon HFD-feeding are not resulting from increased turnover, 
however, are possibly influenced by increased biogenesis. 
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Figure 3.33 Decreased mitochondrial complex subunits in liver do not result from increased 
turnover or altered fusion events rather from increased biogenesis. 
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Figure 3.33 Decreased mitochondrial complex subunits in liver do not result from increased 
turnover or altered fusion events rather from increased biogenesis. 
(A) Western blot analysis and (B) relative quantification of mitochondrial proteases and mtHSP70 in liver 
mitochondrial lysates of control and CLPP deficient mice fed NCD or HFD (n=3). VDAC is used as loading 
control. (C) Western blot analysis and (D) relative quantification of mitochondrial proteins indicative for 
mitochondrial biogenesis in liver extracts of control and Clpp-/- mice (n=6). CALNEXIN is used as loading 
control. Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; one-way ANOVA, Tukey’s 
post hoc test). (E) Western blot analysis of mitochondrial fusion proteins in isolated liver mitochondria of 
control and CLPP deficient mice fed NCD or HFD (n=3). VDAC serves as loading control. (F) 
Quantification of relative protein levels of blots shown in (E). (G) Transmission electron micrographs of 
liver tissue of control and Clpp-/- mice fed NCD or HFD (Scale bar 0.5 µm) (n=3). 
 
3.4.5 Loss of CLPP causes increased mitochondrial mRNA levels and reduced 
de novo protein synthesis with an aggravating effect of HFD 
To decipher whether mitochondrial protein synthesis is accounting for the decreased 
levels of mitochondrial-encoded complex subunits in liver of Clpp-/- mice during HDF-
feeding, first mitochondrial transcription was assessed by determining levels of 
mitochondrial rRNAs and mRNAs using Northern blot. In agreement with previously 
reported increased mitochondrial mRNAs and rRNAs in CLPP deficient hearts 
(Szczepanowska et al., 2016), an increased level of ND1 was observed for NCD CLPP 
deficient liver and HFD was found to even have an additive effect on ND1 mRNA 
levels. Moreover, 16S rRNA was mildly increased in the absence of CLPP during NCD 
and HDF-feeding, whereas the levels of 12S rRNA were not different between both 
genotypes and diets (Figure 3.34 A, B). Proteomic data revealed increased levels of 
LRPPRC in liver of NCD and HFD fed Clpp-/- mice, which relates to the increased 
steady state levels of the mitochondrial mRNA, since LRPPRC is required for 
mitochondrial mRNA stability (Ruzzenente et al., 2012). Although de novo 
mitochondrial transcription was not assessed, it can be assumed not to be impaired but 
rather enhanced similar to the heart (Szczepanowska et al., 2016). 
Since not only mitochondrial-encoded complex subunits were decreased in HFD fed 
Clpp-/- mice, relative transcript levels of nuclear-encoded complex subunits were 
determined by qPCR. None of the analyzed mitochondrial complex subunits differed in 
their relative expression between control and Clpp-/- mice fed either NCD or HFD 
(Figure 3.34 C). Hence, mitochondrial und nuclear transcripts of mitochondrial complex 
subunits are not changed or increased by the loss of CLPP. 
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To test whether a dietary intervention like HDF-feeding could have an impact on the 
hepatic mitochondrial translation upon loss of CLPP, de novo protein synthesis and 
degradation were analyzed in isolated liver mitochondria of NCD and HFD fed mice. 
During an in organello translation assay newly synthesized mitochondrial proteins were 
radiolabeled with 35S-methionine (pulse) and their degradation was followed over time 
(chase). The protein synthesis was only mildly reduced in CLPP deficient mice fed 
NCD, whereas mitochondrial translation was significantly reduced by 40% in liver of 
CLPP deficient mice fed HFD (Figure 3.35 A, B). While the dietary conditions had a 
strong impact on the overall protein synthesis in CLPP deficient mitochondria, no 
difference was observed for the turnover of mitochondrial proteins (Figure 3.35 A, B). 
Thus, it can be concluded that metabolic stress as induced by HDF-feeding impairs 
protein translation in the absence of CLPP. Therefore, it seems reasonable to conclude 
that due to the decreased availability of mitochondrial-encoded complex subunits, the 
levels of nuclear-encoded subunits are adapted since proteins from both origins need 
to be assembled in correct stoichiometry (Edgar et al. 2009). 
 
Figure 3.34 Mitochondrial transcript levels are increased in liver of CLPP deficient mice. 
(A) Northern blot analysis and (B) and relative quantification of mitochondrial transcript levels in liver of 
control and CLPP deficient mice (n=3-4). (C) Relative expression levels of nuclear-encoded mitochondrial 
complex subunits in liver of control and Clpp-/- mice (n=4-5). Data are presented as mean ± SD (*P<0.05, 
**P<0.01, ***P<0.001; one-way ANOVA, Tukey’s post hoc test). 
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Figure 3.35 High fat feeding exacerbates the mitochondrial translation defect in liver in the absence 
of CLPP. 
(A) Result of the in organello translation analysis of liver mitochondria of CLPP deficient mice fed either 
NCD or HFD. Proteins were isolated after pulse labeling with 35S-methionine for 1 h to assess de novo 
mitochondrial protein synthesis or after 3 h cold chase to analyze mitochondrial protein turnover. Position 
of individual proteins is indicated on the left and right. Coomassie brilliant blue stained gel serves as 
loading control. (n=3) (B) Relative mitochondrial protein synthesis and turnover rate. (*P<0.05, **P<0.01, 
***P<0.001; one-way ANOVA, Tukey’s post hoc test). In organello translation analysis was performed 
together with Dr. Alexandra Kukat. 
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To further investigate whether the lactation period during the first three weeks of life is 
sufficient to impact mitochondrial translation in the absence of CLPP to the same 
extent than HFD, de novo protein synthesis was assessed in liver mitochondria of  
5-week-old CLPP deficient and control mice. To note, pups rely for the first 15 days 
fully on the maternal lactation, afterwards they begin to ingest also solid food, while the 
nursing still continues. Upon 21 days they are weaned and feed on the NCD (Silver, 
1995). Interestingly, the protein synthesis in liver mitochondria from 5-week-old Clpp-/- 
mice was strongly reduced as compared to control mice, whereas the turnover of 
mitochondrial proteins was not different (Figure 3.36 A, B). The translation reduction in 
5-week-old Clpp-/- mice was comparable to HFD fed CLPP deficient mice. 
 
 
Figure 3.36 Mitochondrial translation defect in 5-week-old CLPP deficient liver is comparable to 
HFD fed Clpp-/- mice. 
(A) Result of the in organello translation analysis of liver mitochondria of 5-week-old CLPP deficient mice. 
Proteins were isolated after pulse labeling with 35S-methionine for 1 h to assess de novo mitochondrial 
protein synthesis or after 3 h cold chase to analyze mitochondrial protein turnover. Position of individual 
proteins is indicated on the left and right. Coomassie brilliant blue stained gel serves as loading control 
(n=3). Data are presented as mean ± SD (*P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). 
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3.4.6 Loss of CLPP does not impair hepatic mitoribosome assembly 
To further address the observed translation defect in HFD CLPP deficient liver, first the 
abundance of mitochondrial ribosomal proteins was analyzed. No significant 
differences were observed for the steady state levels of mitoribosomal proteins of the 
small (MRPS18B, MRPS35) and large (MRPL37) ribosomal subunits between control 
and CLPP deficient mice fed NCD or HFD (Figure 3.37 A, B). This is in line with 
comparable levels of 12S and slightly increased levels of 16S rRNA, indicating no 
increase in ribosomal biogenesis despite the strong translation defect.  To examine 
which step of hepatic mitochondrial translation might be affected, the assembly of 
mitoribosomes was assessed next. Mitochondrial lysates were subjected to sucrose 
gradient centrifugation for the separation of the 28S (small ribosomal subunit), 39S 
(large ribosomal subunit) and the fully assembled mitoribosome 55S (monosomes). As 
expected, MRPS35 and MRPS18B components of the small ribosome were present in 
the 28S and 55S fractions and MRPL37 a constituent of the large ribosome was 
located in the 39S and 55S fractions (Figure 3.37 C). Strikingly, there was no 
difference in the abundance of the small and large ribosomes and fully assembled 
mitoribosomes between control and CLPP deficient liver mitochondria, neither on NCD 
nor on HFD (Figure 3.37 C). In conclusion, CLPP deficiency in the liver does not affect 
mitoribosome assembly, indicating that the translation defect is not caused by defective 
mitoribosome assembly. This is in contrast to the phenotype observed in heart of CLPP 
deficient mice (Szczepanowska et al., 2016). In heart loss of CLPP was shown to 
cause accumulation of the 28S ribosome and to decrease mitoribosome assembly, due 
to enhanced association of the CLPP substrate ERAL1 with the small ribosomal 
subunit. The absence of the ribosomal phenotype in liver indicates a strong tissue 
specificity
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3.4.7 Hepatic translation defect of CLPP deficient liver mitochondria is not 
caused by an increased association of ERAL1 with the 28S ribosomal 
subunit 
In heart of CLPP deficient mice ERAL1 was demonstrated to associate with the 28S 
subunit due to insufficient removal by CLPP and thereby impair mitoribosome 
assembly (Szczepanowska et al., 2016). Although no assembly defect of 
mitoribosomes was detected for CLPP deficient liver of mice fed NCD or HFD (Figure 
3.37 C), an increased association of ERAL1 with the 28S subunit could still affect the 
small ribosomal subunit assembly. Therefore, the migration of the CLPP substrates 
CLPX, EFG1 and ERAL1 with the 28S and 39S ribosomal subunits and 55S 
mitoribosomes were analyzed by sucrose gradient centrifugation followed by Western 
Figure 3.37 Loss of CLPP does not affect mitoribosomal protein levels of the small and large 
subunit and mitoribosome assembly in liver. 
(A) Western blot analysis of mitochondrial ribosomal proteins in liver. VDAC serves as loading control. 
(n=3) (B) Quantification of Western blots shown in (A). (C) Analysis of mitoribosomal assembly by sucrose 
gradient density sedimentation in liver mitochondria of NCD and HFD fed control (n=3) and Clpp-/- mice 
(n=3). The migration of small (28S) and large (39S) ribosomal subunits and monosomes (55S) was 
assessed by Western blot using antibodies against MRPS35, MRPS18B and MRPL37. Data are presented 
as mean ± SD. Sucrose gradient analysis was performed by Dr. Karolina Szczepanowska. 
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blot analysis with the respective antibodies. The migration of ribosomal subunits and 
mitoribosomes were determined as formerly done by following the migration of 
MRPS35 and MRPL37 for simplicity reasons blots are not shown. In the absence of 
CLPP, CLPX was found to associate with the 28S subunit in NCD conditions, whereas 
this association was not observed for HFD CLPP ablated mitochondria (Figure 3.39). 
Whether this effect is dependent on diet or is due to experimental variation needs to be 
determined with additional repetitions of the experiment. EFG1 was only found in the 
free fractions and not associated with any ribosomal subunits, despite its higher 
abundance in the absence of CLPP, which is in contrast to previous studies reporting 
EFG1 to associate with the 28S subunit. This discrepancy might be explained by 
different experimental settings. For ERAL1, a mildly increased association with the 28S 
subunit was observed in the absence of CLPP for mice fed NCD and HFD (Figure 
3.39), although this interaction was weak, indicating that this mechanism is conserved 
between heart and liver. 
Taken together, a mildly increased association of ERAL1 with 28S in the absence of 
CLPP was found in liver of NCD and HFD fed mice and it might be the cause for the 
mild decrease in mitochondrial translation in liver of NCD fed mice. Since this 
association is comparable for NCD and HFD, the strong translation defect in CLPP 
deficient liver of HFD fed mice is caused by distinct factors. 
 
 
 
Figure 3.38 Mild comigration of the CLPP substrate ERAL1 with the small ribosomal subunit in liver 
irrespective of diet. 
Sucrose gradient density sedimentation analysis of CLPX, EFG1 and ERAL1 in liver mitochondria of NCD 
and HFD fed control (n=3) and Clpp-/- mice (n=3). The migration of the small (28S) and large (39S) 
ribosomal subunits and monosomes (55S) is indicated. Sucrose gradient analysis was performed by Dr. 
Karolina Szczepanowska. 
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Since loss of CLPP in liver had a different impact on mitoribosome assembly than in 
heart, protein expression of important parameters involved in this process was 
compared between heart and liver of control and Clpp-/- mice fed NCD. To control for 
differences in mitochondrial mass, the analysis was performed in isolated 
mitochondria. Interestingly, the basal levels of CLPP differed between control heart and 
liver and was 2-fold greater in liver. The identified causative factor of the heart 
mitochondrial translation defect ERAL1 was 8-fold increased in CLPP deficient heart 
mitochondria, whereas in liver the difference was only 3-fold between control and  
Clpp-/- mice, owing to the fact that the basal expression in liver was greater than in 
heart. Another CLPP substrate EFG1 was increased to the same extent in CLPP 
ablated mitochondria from heart and liver. In addition, analysis of MRPS35 revealed 
the previously mentioned increase in small ribosomal subunits in heart of Clpp-/- mice 
and no significant difference in liver, however, the basal levels of MRPS35 was greater 
in liver. In contrast, VDAC was increased in heart as compared to liver in control and 
Clpp-/- mice, emphasizing the general tissue-specific traits of mitochondria (Figure 3.38 
A). Taken together, tissue-specific differences in the levels of ERAL1 and ribosomal 
protein in heart and liver might account for the observed differences in mitochondrial 
translation and mitoribosome assembly in the absence of CLPP on NCD. 
In line with these observations, no significant difference in ERAL1 levels was observed 
in liver of NCD and HFD Clpp-/- mice (Figure 3.38 C, D). Accordingly, basal CLPP 
expression was not altered between control mice fed NCD or HFD. Furthermore, CLPX 
was upregulated to the same extent in Clpp-/- mice fed NCD or HFD. CLPX was shown 
to be itself a substrate of the ClpXP protease (Graham et al., 2013). Thus, differences 
in hepatic mitochondrial translation between NCD and HFD fed Clpp-/- mice cannot be 
traced back to ERAL1. 
Next, mitochondrial translation factors were analyzed to screen for possible differences 
in protein abundance between NCD and HFD Clpp-/- mitochondria that could account 
for the altered mitochondrial protein synthesis. First the translation initiation factors 
MTIF2 and MTIF3 were analyzed. The levels of MTIF2 were not changed between 
control and Clpp-/- mice fed NCD or HFD, yet its expression was induced by HDF-
feeding. MTIF3 levels were decreased in CLPP deficient liver mitochondria irrespective 
of diet and MTIF3 expression was again induced upon HFD in control mice. The CLPP 
substrate EFG1 has been shown by proteomic analysis to be increased in the absence 
of CLPP on NCD and HFD and this was confirmed by Western blot analysis (Figure 
3.38 E, F). Strikingly, no significant difference was observed for EFTU between control 
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and Clpp-/- mice on NCD, however, on HFD EFTU levels were elevated for control 
mice, whereas they were decreased in CLPP deficient mitochondria (Figure 3.38 E, F). 
EFTU is an elongation factor responsible for the delivery of aminoacyl-tRNAs to the 
ribosome, thus reduced levels of EFTU in liver of HFD fed Clpp-/- mice could slow down 
mitochondrial translation. These data indicate that HDF-feeding stimulates expression 
of mitochondrial translation factors in wildtype mice and proposes EFTU as a factor 
facilitating the translation defect in liver of HFD fed Clpp-/- mice. Correct ratios of 
translation factors have been shown to be essential for the mitochondrial translation 
process and ratios were further suggested to differ between different tissues (Coenen 
et al., 2004), which could explain the observed tissue-specific differences between 
heart, SkM and liver. Taken together, mitochondrial translation in liver is not regulated 
through the same mechanism as in heart and CLPP is specifically required for hepatic 
mitochondrial translation during metabolic stress conditions like HDF-feeding or 
lactation. 
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Figure 3.39 Difference in hepatic mitochondrial translation of NCD and HFD fed CLPP deficient 
mice might be affected by altered ratios of mitochondrial translation factors. 
(A) Western blot analysis and (B) relative quantification of CLPP substrates and mitoribosomal protein in 
heart and liver mitochondria of control and CLPP deficient mice.  MNSOD is used as loading control.  
(C) Protein levels of mitochondrial translation factors were assessed by Western blot analysis in liver 
mitochondria of control and Clpp-/- mice fed NCD or HFD. VDAC serves as loading control. (D) 
Quantification of Western blots shown in (C). (E) Western blot analysis ERAL1, CLPP and CLPX in liver 
mitochondria of control and Clpp-/- mice. VDAC is used as loading control. Data are presented as mean  
± SD (*P<0.05, **P<0.01, ***P<0.001; one-way ANOVA, Tukey’s post hoc test). 
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4 Discussion 
 
The study of mitochondrial function has received broad interest in the last decades due 
to the large impact of mitochondrial dysfunction on the ageing process and human 
diseases. Mitochondria are the central core for energy production in the cell and many 
metabolic pathways converge in them at different levels. Defects in mitochondrial 
function could therefore affect several parts of the metabolic network and have broad 
cellular and physiological consequences. This points to the critical role of mitochondria 
for cellular homeostasis and explains why metabolic defects underlie a broad range of 
human diseases. The emergence of metabolic disorders, likely due to changes in 
lifestyle has further focused on studies of metabolism and its regulation. 
Mitochondrial function and form is closely connected to the metabolic state and vice 
versa (Liesa and Shirihai, 2013). Therefore, it is essential to study how mitochondria 
regulate and maintain their function to understand defects observed in several 
metabolic diseases. Many components of the mitochondrial quality control machinery 
have been identified so far, however, the physiological function of several of these 
proteins, including mitochondrial proteases remains largely unknown. 
This study aimed at deciphering the role of the mitochondrial matrix protease CLPP in 
mammalian metabolism. For this purpose different mouse models lacking CLPP were 
generated. First, a whole body CLPP deficient mouse model was analyzed to 
determine CLPP function under basal conditions and during high metabolic stress by 
feeding high fat diet. Second, CLPP function was investigated in distinct highly 
metabolically active tissues to determine the impact of disturbed mitochondrial 
proteostasis in individual organs on whole body metabolism. Finally, it was investigated 
whether the mitokine FGF21 is an essential metabolic mediator of the phenotype and 
the metabolic adaptions observed in CLPP deficient mice. 
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4.1 Loss of CLPP alters whole body metabolism 
This study demonstrates that loss of CLPP under normal dietary condition has different 
tissue-specific consequences with an overall favorable metabolic phenotype. In 
humans, mutations in Clpp cause Perrault Syndrome, which is characterized by growth 
retardation, sensorineural hearing loss and ovarian failure (Jenkinson et al., 2013). 
CLPP deficient mice represent a faithful model of the Perrault syndrome displaying 
reduced growth and body weight, sterility and deafness (Gispert et al., 2013). Growth 
defects are a common feature of mitochondrial mutants, suggesting a similar 
underlying mechanism (Leong et al., 2012; Levéen et al., 2011; Wells et al., 2012). In 
many studies the growth defect was triggered by alterations in the GH/IGF1 axis. In 
growth restricted UCP1 transgenic mice, for example, decreased IGF1 levels were 
determined in serum (Keipert et al., 2014). Interestingly, we did not observe a decrease 
in Igf1 transcript levels in liver, thus serum analysis might be another possibility to 
ascertain whether the GH/IGF1 axis is determining the growth restriction in the 
absence of CLPP. 
Remarkably, in our study loss of CLPP does not have an impact on longevity, which is 
in contrast to another study performed in a different Clpp knockout mouse model. Here, 
an increased postnatal mortality was reported (Gispert et al., 2013), however, other 
observed phenotypes for both mouse models are similar. Possible reasons that might 
account for the discrepancy could be the different techniques used to generate the 
CLPP deficient mice (gene trapping or gene targeting) or differences in the hygienic 
status of the animal facilities. Moreover, the influence of CLPP absence on lifespan is 
also species dependent, since loss of CLPP in the fungus P. anserina leads to an 
increased lifespan (Fischer et al., 2015). 
 
On the metabolic level, the loss of CLPP leads to enhanced glucose metabolism, as 
evidenced by increased insulin stimulated glucose disposal, reduced basal blood 
glucose levels and decreased hepatic and muscular glycogen stores. An increased 
glucose uptake can be facilitated by either increased protein expression of GLUT1 or 
GLUT4 and an enhanced stress related translocation of the latter one. In SkM and 
EWAT increased levels of the insulin dependent GLUT4 was observed. This relates to 
an increased activation of the metabolic regulator AMPK in SkM. AMPK is suggested 
to enhance glucose uptake by facilitating GLUT4 translocation (Fulco and Sartorelli, 
2008). Its activation by phosphorylation at the Threonine residue 172 is mediated by 
upstream kinases and an allosteric interaction with AMP, indicating an increased 
AMP/ATP ratio in CLPP deficient SkM. 
In general an enhanced glucose metabolism is commonly seen in mouse models with 
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OXPHOS dysfunction (Diaz et al., 2008a; Levéen et al., 2011; Wredenberg et al., 
2006). A metabolic switch to increased glycolysis might be an alternative source of 
ATP, thereby reducing glycogen stores. Glycogen synthesis might be additionally 
decreased due to hormonal influence of increased glucagon levels, as it was shown for 
Clpp-/- mice. 
Several groups have implicated mitochondrial dysfunction in the etiology of type 2 
diabetes as a cause of insulin resistance (Kim et al., 2000; Petersen et al., 2003; Ritov 
et al., 2004), which is in contrast to results obtained in this study. Different metabolic 
impacts of mitochondrial stress or dysfunction might be dependent on the degree and 
the localization of the mitochondrial defect. An interesting example is the deletion of 
TFAM specifically in β-cells or skeletal muscle. In beta-cells TFAM deletion leads to 
impaired mitochondrial function (Silva et al., 2000), deficient insulin secretion and 
glucose intolerance, whereas skeletal muscle-specific deletion of TFAM causes 
enhanced glucose tolerance (Wredenberg et al., 2006). The importance of the degree 
of mitochondrial dysfunction becomes evident by comparing homozygous and 
heterozygous PolG mutator mice. These mice accumulate somatic mitochondrial 
mtDNA mutations due to a proofreading-deficient polymerase gamma, leading to 
respiratory chain dysfunction and a premature ageing phenotype. Homozygous mice 
display resting hypoglycemia and enhanced glucose tolerance, whereas heterozygous 
mice are glucose intolerant and exhibit an obesity phenotype (Saleem et al., 2015; 
Wanagat and Hevener, 2016). Our model depicts a global deletion of CLPP with 
varying degrees of mitochondrial dysfunction in different tissues, yet glucose 
metabolism is not impaired but rather enhanced, questioning the causal role for 
OXPHOS dysfunction and insulin resistance. 
Another interesting finding of this study is that loss of CLPP increases energy 
expenditure. The total energy expenditure is composed of the basal metabolic rate, 
cold-induced thermogenesis (at non thermoneutrality), thermic effect of food and 
physical activity (Speakman, 2013). The physical activity is decreased in CLPP mice, 
most likely due to reduced OXPHOS function and resulting energy deficiency in SkM. 
Since the food intake was not changed in CLPP mice it can be assumed that the 
thermic effect of food is neglectable, indicating that an increased thermogenesis or an 
increased basal metabolic rate could account for the increased energy expenditure in 
CLPP deficient mice. A possible contributing factor to enhanced energy expenditure is 
increased uncoupling of the mitochondrial electron transfer system from the ATP 
synthesis by UCP1. Unexpectedly, the loss of CLPP in BAT resulted in the dissociation 
of lipid storage from lipid use, despite comparable levels of UCP1 in male mice, leading 
to whitening of BAT. In contrast, EWAT exhibited a reduced mass and a transcript 
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profile associated with browning, suggesting an enhanced energy expenditure of 
EWAT. The reduction of CLPP deficient EWAT mass was due to a decrease in 
adipocyte number rather than adipocyte size. Similarly, a mouse model of Costeff 
syndrome OPA3L122P displays whitening of BAT, browning of EWAT and no effect on 
IWAT, proposing a similar tissue-specific response to the mitochondrial perturbation 
(Wells et al., 2012). The function of OPA3 has not been fully elucidated; it was reported 
to induce mitochondrial fragmentation and mutations in the OPA3 gene have been 
linked to this metabolic syndrome. 
Moreover, whitening of BAT was also observed in mouse models of FAO deficient 
adipose tissue (Lee et al., 2015) and a globally impaired supercomplex assembly due 
to lack of COX7RP (Ikeda et al., 2013), indicating that FAO as well supercomplex 
assembly is required for BAT homeostasis, both being affected or impaired in the 
absence of CLPP. The inability of CLPP deficient mice to maintain body temperature 
upon cold exposure, demonstrates a requirement of CLPP function specifically during 
metabolic stress conditions. During acute cold exposure there is an increased energy 
supply to BAT mitochondria with enhanced glucose uptake and increased FAO. 
Although under physiological conditions the FAO in CLPP ablated BAT was not 
affected, it can be speculated that in combination with the cold-stress induced 
OXPHOS dysfunction, the FAO was not functioning to the fullest capacity leading to 
the severe hypothermia. Additionally, the ability of UCP1 induction upon cold exposure 
was decreased by CLPP ablation.  
The β-adrenergic stimulation upon cold exposure was reported to increase lipolysis 
(Chondronikola et al., 2016). Thus, the gender-specific phenotypes discovered in 
female Clpp-/- mice, increased lipolysis and decreased UCP1 levels in BAT, might be 
intimately linked. The decreased UCP1 abundance might cause a reduced body 
temperature and thereby induce β-adrenergic signaling leading to the activation of 
lipolysis. However, to affirm this hypothesis the body temperature of female Clpp-/- mice 
needs to be determined. 
 
Unlike in C.elegans, where ClpXP was shown to degrade only misfolded proteins and 
thereby take part in the UPRmt, a recent study in P.anserina suggested the involvement 
of CLPP in energy metabolism (Fischer et al., 2015; Haynes et al., 2007, 2011). Based 
on a CLPP substrate-trapping assay, using a catalytically inactive human CLPP 
version, many potential substrates have been identified in various metabolic pathways, 
including fatty acid metabolism (Fischer et al., 2015). Correspondingly, in this study 
VLCAD, which is involved in FAO of long chain fatty acids, is proposed as novel 
substrate of mammalian CLPP, further supporting a role for CLPP in lipid metabolism. 
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As one would assume for a potential substrate, the steady state levels of VLCAD were 
increased in the absence of CLPP, however, FAO rates were decreased in liver and 
SkM of Clpp-/- mice on NCD. This decrease in FAO can be attributed to the reduced 
levels of CPT2, which is required for the uptake of long chain fatty acids, suggesting a 
countervailing response to limit fatty acid oxidation as a protective measure. 
Interestingly, CPT2 abundance was dependent on the dietary supply of lipids, since 
HDF-feeding induced CPT2 expression. A similar adaption was reported for VLCAD 
depleted mice (Zhang et al., 2010). These mice are protected against HFD induced 
obesity due to a compensatory increase in LCAD in certain tissues, an enzyme with 
overlapping fatty acid chain length specificity. Tissue-specific adaptations in response 
to FAO disorders are most likely dependent on their reliance on FAO. Impaired FAO in 
liver due to loss of CPT2 leads to hepatosteatosis upon fasting (Lee et al., 2016a) and 
loss of CPT2 in adipose tissue triggers lipid accumulation in BAT, whereas WAT is 
unaffected by loss of CPT2 and is even protected from HFD induced oxidative stress 
and inflammation (Lee et al., 2015, 2016b). These observations support our result of 
the absence of compensatory CPT2 downregulation in WAT of Clpp-/- mice. 
A question that remains unanswered is how CPT2 expression is regulated in response 
to the increased VLCAD stability upon loss of CLPP. Transcriptional regulation of the 
Cpt2 gene can be excluded, since transcript levels were not changed and additionally 
Pparα levels were not altered. PPARα is an important transcriptional regulator of genes 
involved in fatty acid oxidation, including Cpt2 (Barrero et al., 2003; Rakhshandehroo 
et al., 2009). Hence, either mRNA stability of Cpt2 might be decreased or the turnover 
of the CPT2 protein increased. 
Taken together, the presented data indicate that in the absence of CLPP, VLCAD is 
stabilized most likely due to decreased turnover, which leads to different compensatory 
regulations of CPT2 thereby reducing FAO under NCD conditions or increasing it under 
HFD conditions. Thus, the reduced body fat may be a result of robust carbohydrate 
usage that reduces fatty acid synthesis, since increased fatty acid oxidation can be 
excluded under NCD conditions. However, under HFD conditions FAO is most likely 
increased in Clpp-/- mice. A limiting factor for mitochondrial FAO is the recovery of the 
cofactor NAD+, which is required by the 3-hydroxyacyl-CoA dehydrogenase. Especially, 
mitochondrial OXPHOS dysfunctions were reported to limit FAO due to the inability to 
recover NAD+ from NADH and thereby favoring glycolysis (Levéen et al., 2011).  The 
profound decrease in CoI in CLPP deficient liver upon HDF-feeding might also imply an 
inhibition of FAO due to reduced recovery of NAD+. However, unpublished data from 
our lab reveal the presence of a functional N-module with NADH oxidative activity that 
is probably not associated with CoI in mitochondria lacking CLPP, suggesting a potent 
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NAD+ recovery in the absence of CLPP. Thus, FAO might be increased in conditions of 
high dietary burden upon loss of CLPP and contributes to the resistance of HFD 
induced obesity. 
 
4.2 FGF21 is not a metabolic regulator of the CLPP phenotype 
The fibroblast growth factor 21 (FGF21) is an endocrine hormone induced and 
secreted upon starvation from the liver to elicit adaptive responses in glucose and lipid 
metabolism (Potthoff et al., 2009). Its beneficial metabolic actions raised the interest in 
FGF21 as possible anti-diabetic drug candidate (Kharitonenkov and Adams, 2014). 
Recently, FGF21 was also shown to be induced and secreted from heart and SkM in 
response to different kinds of mitochondrial perturbations and integrated stress 
response activation (Dogan et al., 2014; Keipert et al., 2014; Tyynismaa et al., 2010; 
Vandanmagsar et al., 2016), suggesting an adaptive mitochondrial stress-related 
starvation response. In line with these reports, a general induction of Fgf21 was 
observed in all analyzed tissues of CLPP ablated mice and an increase in FGF21 
serum levels. Interestingly, the degree of mitochondrial dysfunction in the different 
tissues correlates with the levels of Fgf21 expression. An increase in Fgf21 expression 
by age with increasing levels of mitochondrial dysfunction has been previously reported 
for the ‘deletor mouse’. This mouse model expresses a mutant mitochondrial helicase 
Twinkle, leading to the accumulation of mtDNA deletions, which mimics late-onset 
mitochondrial myopathy (Tyynismaa et al., 2010). 
Since liver mitochondria are only very mildly affected by the absence of CLPP under 
NCD conditions, one could argue that the increase in hepatic Fgf21 expression is 
induced by the fasting-like phenotype of CLPP deficient mice. However, in CLPP 
deficient liver no increase in Pparα was detected, the transcription factor found to 
induce Fgf21 upon starvation (Inagaki et al., 2007). ATF4 is another transcription factor 
known to induce Fgf21, yet no concurrent increase in expression was detected in the 
analyzed tissues in the absence of CLPP. Due to the concordant increase of Atf5 in all 
CLPP deficient tissues with increased Fgf21 expression, ATF5 is suggested as an 
additional transcriptional regulator of Fgf21 expression. Further investigations are 
required to understand whether ATF5 is involved in the transcriptional activation of 
Fgf21. 
 
As the proposed function of FGF21 suggests, systemic metabolic adaptations were 
observed in CLPP deficient animals, including reduced body weight and fat mass as 
well as growth retardation and increased insulin sensitivity. Many previous studies 
speculated on the beneficial functions of FGF21, however, only very few studies 
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provide proof of principle experiments using genetic ablation of FGF21 to show its 
causal role. In contrast to a previous study on muscle autophagy deficient mice (Kim et 
al., 2013), our study on Clpp/Fgf21 DKO mice clearly shows that the mitochondrial 
stress induced leanness and reduced body fat content is independent of FGF21. 
Notably, autophagy is involved in many cellular processes and the metabolic response 
induced by the obstruction of autophagy might not ascend from mitochondrial stress, 
but rather from a generally impaired cellular homeostasis demanding FGF21 action. 
In accordance with our results, the depletion of FGF21 in a mouse model with 
increased mitochondrial uncoupling in SkM did not lead to the attenuation of the 
decreased body weight, reduced fat mass and reduced body length (Ost et al., 2016). 
This study further presented that the glycolytic control in UCP1 transgenic mice was 
independent of FGF21. In addition, they demonstrate that the browning of WAT was 
clearly dependent on FGF21 (Ost et al., 2016). Currently, we are analyzing the 
browning of WAT in our DKO mice, however, this could indicate that the browning of 
WAT is not contributing significantly to the whole body energy expenditure in CLPP 
depleted mice. This assumption awaits further experimental evidence. Impaired FAO in 
SkM was also shown to induce FGF21 with metabolic adaptions similar to the Clpp-/- 
mice (Vandanmagsar et al., 2016).  Likewise to our results, the growth defect and fat 
mass were not corrected by the absence of FGF21, whereas the decreased body 
weight and the increased glucose uptake were attenuated by the lack of FGF21 in their 
model (Vandanmagsar et al., 2016). The preceding observations, together with our 
data, demonstrate that growth defects induced by mitochondrial dysfunction are the 
only consistent phenotype not to be rescued by Fgf21 knockout. Hence, they seem not 
to be mediated by FGF21 induced growth hormone insensitivity, as suggested for 
Fgf21 knockout mice (Inagaki et al., 2008). Moreover, whether or not FGF21 is 
involved in metabolic adaptions like changes in body weight or fat mass, browning of 
white adipose tissue and adjustment in insulin sensitivity depends on the primary 
affected mitochondrial/cellular process responsible for the FGF21 induction. Another 
explanation for different outcomes with regard to the mitigation of metabolic 
phenotypes in the absence of FGF21 in mitochondrial mutant mice is the possibility of 
a compensatory substitution of FGF21 by other myokines/mitokines.  
Therefore, FGF21 could be used as indicator of mitochondrial dysfunction in Clpp-/- 
mice, however, the adaptive metabolic responses due to the absence of CLPP are 
mostly occurring independent of FGF21. 
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4.3 Tissue-specific CLPP deletion does not have systemic implications 
The whole body ablation of CLPP has a profound metabolic phenotype as evidenced in 
this and previous studies (Gispert et al., 2013). However, the systemic consequences 
of CLPP deficiency in distinct tissues are not known. Therefore, we generated liver- 
and SkM/heart- specific Clpp knockout mouse models. Liver and muscle are both 
important tissues involved in the regulation of whole body metabolism by regulating 
glucose and lipid metabolism. Nonetheless, loss of CLPP in either tissue has no 
significant impact on the whole body metabolism. Both models present a normal body 
weight development and no difference in the glucose metabolism at the age of  
15 weeks, indicating that loss of CLPP in distinct tissues does not elicit systemic 
alterations as early as for the full body knockout. The complete loss of CLPP was 
confirmed at 15 weeks of age, however, depending on the turnover of the protein, the 
complete loss might be achieved rather late, thus delaying the phenotype 
development. For example MTERF3 was still detectable in heart at 12 weeks of age 
upon Ckmm-Cre deletion and fully absent only at 16 weeks of age (Park et al., 2007). 
Recently, CLPP has been ascribed to have a role in mitochondrial translation 
(Szczepanowska et al., 2016). In the tissue-specific Clpp knockout mice, the translation 
defect manifests in decreased supercomplex levels. Interestingly, the decrease in 
supercomplex levels in the tissue-specific CLPP mice is more pronounced than in the 
whole body CLPP deficient mice in the respective tissues of the same age, indicating 
that different adaptive responses might be activated depending on a restricted or 
systemic mitochondrial defect. 
These observations are different from other studies using Ckmm-Cre mediated deletion 
of mitochondrial transcription/translation genes like Tfam (Hansson et al., 2004), Tfb1m 
(Metodiev et al., 2009), Mterf4  (Cámara et al., 2011). The systemic effects of these 
mitochondrial perturbations are detectable as early as 2 weeks of age for Tfam,  
15 weeks for Tfb1m and 5 weeks of age for Mterf4. The different phenotypes of these 
mice as compared to the ClppMKO mice can be explained by the much more severe 
mitochondrial dysfunction of these mutants, owing to the fact that those are essential 
genes as their full body deletion is lethal. All mouse models displayed a severe 
cardiomyopathy, whereas SkM was only mildly affected. Moreover, TFAM has also 
been deleted exclusively in SkM using the Mlc1f-Cre recombinase (Wredenberg et al., 
2002, 2006). Interestingly, these mice are healthy till 4 months of age and display an 
increased glucose tolerance only upon two 2 months of age. 
 
The role of hepatic mitochondrial dysfunction did not receive as much attention as the 
heart or brain, most likely because most mitochondrial pathologies are related to these 
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energy demanding tissues. To date, no Afp-Cre mediated hepatic mitochondrial mouse 
model has been published to our knowledge. Another common liver-specific Cre line is 
exploiting the albumin promoter (Alb-Cre), which was reported to result in incomplete 
recombination (Diaz et al., 2008b). Nevertheless, studies with moderate and severe 
OXPHOS dysfunction in liver induced by depletion of the AIF (Pospisilik et al., 2007) or 
COX10 (Diaz et al., 2008b) with the Alb-Cre are in part supporting and in part 
contrasting our results. Similar to loss of CLPP, AIF depletion mostly affects CoI and 
these mice also exhibit an unchanged body weight yet increased insulin sensitivity. 
Thus, depending on the degree of mitochondrial dysfunction, the tissue is able to cope 
with the defect before systemic alterations are visible. To determine how liver or SkM 
are able to cope with CLPP deficiency a longer follow-up of these mice is required. 
Furthermore, it would be interesting to determine whether tissue-specific CLPP 
deletion is sufficient to protect against HFD induced obesity. 
 
4.4 CLPP is required for hepatic mitochondrial translation in metabolic 
stress conditions  
The current study shows that ubiquitous loss of CLPP protects against HFD induced 
obesity and insulin resistance. Another key finding is that in the absence of CLPP, 
dietary food with high fat content has a negative impact on mitochondrial translation 
explicitly in liver. HFD-feeding was demonstrated to decrease hepatic mitochondrial 
translation, which resulted in decreased supercomplex levels in CLPP deficient liver 
mitochondria. Moreover, the observed translation defect was distinct from the former 
translation mechanism described for CLPP deficient hearts (Szczepanowska et al., 
2016). 
Our results are consistent with HFD studies performed in other mitochondrial mutants, 
which are also protected against diet induced obesity (Kim et al., 2013; Quintens et al., 
2013; Vernochet et al., 2012; Zhang et al., 2010). The protection from diet induced 
obesity in Clpp-/- mice is linked to the enhancement of a fasting-like phenotype as 
described for the NCD that is evidenced by reduced blood glucose levels and favorable 
hormone levels (reduced leptin and insulin levels, increased glucagon and ghrelin 
levels). Evidence for enhanced lipid catabolism or decreased lipid synthesis are 
reduced EWAT hypertrophy and generally reduced body fat content despite the 
increased dietary fat content. 
Results of HFD studies are hard to compare and interpret due to different experimental 
schemes, different diet compositions and sources of fat, lard (saturated fatty acids) vs. 
fish oil (poly-unsaturated fatty acids). In this study, HFD rich in lard was used 
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containing mainly saturated fatty acids, which is known to induce obesity related 
complications like diabetes and inflammation (Buettner et al., 2006). In control mice 
insulin-mediated AKT phosphorylation is blunted after 7 weeks on HFD, leading to 
insulin resistance, whereas loss of CLPP is protective. 
On the molecular level, loss of CLPP during HDF-feeding leads to a severe OXPHOS 
defect exclusively in liver (not in SkM and heart), as revealed by reduced CoI 
containing supercomplexes and reduced steady state levels of complex subunits. This 
finding is on the one hand in line with data obtained for heart mitochondria (NCD) 
(Szczepanowska et al., 2016) and on the other hand contradicting them, since the 
deregulated OXPHOS subunits in liver were only observed for HFD, whereas on NCD 
loss of CLPP had no effect on hepatic complexes yet in heart complex levels are 
decreased, indicating tissue-specific functions or requirements for CLPP during 
different metabolic burdens. 
The question arises why predominantly CoI is affected in Clpp-/- mice and also in many 
other mitochondrial mutants or mitochondrial pathologies. One can only speculate on 
the mechanism: firstly the majority of mitochondrial-encoded subunits are CoI subunits; 
secondly CoI contains more subunits and redox groups than the other complexes; 
thirdly there might be distinct requirements for turnover due to different susceptibilities 
to cellular insults or environmental factors (Mimaki et al., 2012). 
This is along the line with the tissue specificity observed for mitochondrial diseases and 
also for the absence of CLPP. The mitochondrial dysfunction observed for heart and 
SkM deficient in CLPP is affected to the same extent by NCD or HDF-feeding, 
however, in liver only on HFD mitochondrial dysfunction is evident. Proposed 
mechanisms are tissue-specific differences in mitochondrial proteome composition and 
quantities that lead to different capacities to remodel mitochondrial complexes, different 
energy demands or the reliance on glycolysis or fatty acid oxidation as primary source 
of ATP (Mootha et al., 2003; Pagliarini et al., 2008; Rossignol et al., 1999). Hence, 
CLPP might be required in liver for the maintenance of OXPHOS and mitochondrial 
translation only during condition of metabolic stress. 
Interestingly, hepatic respiratory complex levels in control mice are not altered upon  
8 weeks HDF-feeding, however, a loss of mitochondrial mass becomes apparent, 
indicating that HFD does not induce mitochondrial dysfunction per se, yet energy 
production/expenditure might be limited due to reduced mitochondrial number. 
The hepatic mitochondrial dysfunction in Clpp-/- mice triggered a compensatory 
activation in biogenesis, accompanied by an increase in mitochondrial transcripts as 
compensation for the decreased mitochondrial translation. This is in accordance with 
other mouse models of impaired protein synthesis like Mterf3, Mterf4, Nsun4 (Cámara 
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et al., 2011; Metodiev et al., 2014; Park et al., 2007) and results obtained for CLPP 
deficient heart, despite the tissue-specific susceptibility to the HFD (Szczepanowska et 
al., 2016). 
The striking decrease in hepatic mitochondrial translation in the absence of CLPP upon 
high dietary lipid content either after HFD or lactation, suggests a novel role for CLPP 
in conditions of high metabolic stress in liver. The translation defect in CLPP deficient 
liver seems to be distinctive from the mechanism recently described in heart, where an 
increased association of ERAL1 to the small ribosomal subunit leads to an impaired 
mitoribosome assembly (Szczepanowska et al., 2016). Here, no evidence was found 
for an impaired mitoribosome assembly, additionally the steady state levels of 
mitoribosomal proteins, as well as the small and large subunit levels were unchanged. 
Most importantly, the association of ERAL1 with the small ribosomal subunit was not 
different on NCD or HFD in the absence of CLPP, implying an alternative mechanism 
for the translation defect in liver. 
The ratio of mitochondrial translation factors was reported to be very essential and 
although excess of EFG1 or EFG2 has no effect on mitochondrial translation, excess of 
EFTU or EFTS impairs it (Coenen et al., 2004), suggesting that also a decrease in 
EFTU could reduce translation velocity. This assumption is strengthened by the finding 
that knockdown of EFTU decreases tumor cell growth by reducing mitochondrial-
encoded complex subunits (Škrtić et al., 2011). In CLPP deficient liver, decreased 
levels of MTIF3 and increased levels of EFG1 were detected on NCD and HFD, 
whereas EFTU was only decreased on HFD. Furthermore, a recent study 
demonstrated that CLPP slows down translation velocity (Dominic Seiferling, PhD 
thesis). In combination with the imbalance in translation factors particularly in CLPP 
deficient liver on HFD, this might be a factor contributing to the translation defect. 
 
So far there are no reports on defective mitochondrial translation due to high loads of 
dietary lipids. The observation that hepatic mitochondrial translation is impaired to the 
same extent in liver of HFD fed Clpp-/- mice and in young Clpp-/- mice, which have 
already been without lactation for 2 weeks at the time of analysis, suggested a more 
enduring alteration of CLPP deficient liver mitochondria like changes in the lipid 
composition of the mitochondrial membrane. Depletion of the PGS1 gene in 
S.cerevisiae results in a decrease of phosphatidylglycerol the precursor of cardiolipin 
and cardiolipin itself and was accompanied by a selective decrease in mitochondrial 
translation products (Chang et al., 1998; Ostrander et al., 2001). Interestingly, CLPP 
might be involved in the turnover of SLP-2, a protein implicated in the regulation of 
cardiolipin synthesis, since it was enriched in label-free quantification and CLPP 
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trapping experiments  (unpublished data from Dr. Karolina Szczepanowska) (Christie 
et al., 2011). However, whether loss of CLPP has an impact on cardiolipin content or 
remodeling and this might in turn affect mitochondrial translation needs to be 
experimentally addressed. 
Taken together, loss of CLPP protects against HFD induced obesity and insulin 
resistance. Moreover, CLPP function is required for hepatic mitochondrial translation in 
conditions with high lipid burden. 
 
4.5 Summary 
Our results demonstrate that ubiquitous deletion of CLPP results in a lean phenotype 
with enhanced glucose metabolism, owing to increased energy expenditure in part by 
WAT browning, despite decreased physical activity. Moreover, CLPP was shown to be 
involved in fatty acid oxidation by the regulation of its putative substrate VLCAD. In 
addition, CLPP has a critical role in BAT homeostasis and thermogenesis. 
Furthermore, FGF21 was shown to be induced by the mild to moderate mitochondrial 
dysfunction caused by the loss of CLPP, yet FGF21 is not mediating the metabolic 
changes observed in Clpp-/- mice. 
The tissue-specific depletion of CLPP revealed a dispensable role for CLPP with 
regard to whole body metabolism, although tissue restricted mitochondrial dysfunction 
was present. Finally, ablation of CLPP protects against HFD induced obesity and 
insulin resistance and it was shown for the first time that hepatic mitochondrial 
translation is compromised by metabolic stress in the absence of CLPP. 
Therefore, this study is contributing to the basic understanding of the CLPP protease 
function and its regulated metabolic pathways, which may help to understand 
pathologies with deregulated CLPP expression. 
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